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ABSTRACT

Quantitation of Bovine Serum Albumin in Cow's-Milk-Based
Infant Fonnulas and Removal of Bovine Serum Albumin
from Cow's Milk and Whey Protein Isolates
by
Patricia Z. Marincic, Doctor of Philosophy
Utah State University, 1997
Major Professor: Dr. Deloy Hendricks
Department: Nutrition and Food Science
Early intrcxiuction of cow's-milk-based infant fonnulas, in particular the ABBOS
epitope of bovine serum albumin (BSA), has been implicated as an autoimmune trigger in
the pathogenesis of insulin dependent diabetes mellitus (IDDM) . A direct enzyme-linked
immunosorbant assay (ELISA), using polyclonal anti-BSA antibodies, was developed to
determine the BSA content of cow's milk and 15 infant fonnulas. Powdered high-whey
(60% ) formulas averaged 41 mg BSA/ 100 ml; 2% milk contained 52 mg BSA/ 100 ml; and
the high-casein fonnulas averaged 13 mg/ 100 ml . BSA content of powdered polymenc
formulas and cow's milk varied directly with the whey protein concentration (correlation
coefficient= 0 .8445, Q = 0.008) . BSA was not detected in any hydrolyzed powdered
formula or commercially sterile liquid preparation regardless of protein composition. The
absence of BSA was confinned by polyacrylamide gel electrophoresis. It is unlikely that
the ABB OS epitope is present in the formulas testing negative for BSA due to enzymatic
hydrolysis and heat denaturation of these formula preparations.
A laboratory technology was developed that could be upgraded to produce BSA
free protein bases used in the manufacture of infant formula. Affinity chromatography,
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using paramagnetic beads with an immobilized antibody against BSA, was applied to
extract BSA from cow's milk and whey isolates. Monoclonal and polyclonal antibodyact1vated beads were used to capture BSA from samples. The capture efficiency in milk
was 11 % and 19% for polyclonal beads, and 59% for monoclonal beads. Capture
efficiency of monoclonal beads of 91 % was significantly greater in both acid and sweet
whey compared to the polyclonal beads exhibiting a capture efficiency 31 % and 24% in
acid and sweet whey, respectively. Capture efficiency of monoclonal and polyclonal
beads did not differ significantly in milk, acid whey, or sweet whey. Removal of BSA
from a known sample of 25ng of BSA treated with polyclonal beads was 70% effective
with a capture efficiency of 35%. A net reduction of 99.9% of the BSA could be expected
by coupling immunocapture with molecular sieving. Immunocapture was most effective
in removing BSA when only small amounts were present in the sample.
(251 pages)
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CHAPTER I
INTRODUCTION
Insulin dependent diabetes mellitus (IDDM) is a chronic autoimmune di sease that
results in destruction of the insulin-producing beta-cells of the islets of Langerhans of the
pancreas in genetically susceptible individuals. While 25% of the population carries genetic
markers of IDDM, only 5% of those with genetic predisposition will develop IDDM
-2

(American Academy of Pediatrics, 1994). Since genetic predisposition alone does not
confer progression to clinical disease, recent research has focused on identifying specific
environmental determinants that may also be involved in the immunopathogenesis of
IDDM.
The environmental contribution of infant feeding practices was brought to the
forefront of diabetes research by Barsch-Johnson and colleagues (1984), who reported
epidemiological evidence that a decrease in the incidence of breast-feeding in Scandinavia
since World War II has been paralleled by an increase in the incidence of IDDM. Infants
who are not breast fed or who receive supplemental breast milk substitutes are exposed to
cow's-milk-based infant formula and other potential dietary antigens at an early age. Risk
of !DOM has been shown to be two-fold higher in infants who receive dairy products prior
to 2 months of age (Yirtanen et al ., 1993) and proportional to the total amount of cow's
milk protein in the diet (Cerrato, 1993). These observations have led to the current
hypothesis that cow's milk may precipitate IDDM (Drash, 1990; Gerstein , 1994;
Karjalainen, Martin, et al., 1992; Kostraba et al., 1993 ; Yirtanen et al. , 1992).
The whey protein, bovine serum albumin (BSA), in particular, the ABBOS epitope
(pre-BSA position 153-169), is thought to cross react with a protein on the surface of the
beta-cell and trigger an autoimmune response that progressively leads to !DOM (Cheung,
Karjalainen, Vandermeulen , Singal , & Dosch, 1994). Exposure of infants to cow's milk

and infant formula, prior to "gut closure," which occurs between 3 and 12 months of age
(McCarren, 1992), may be a contributing factor in the pathogenesis of IDDM. The amount
of BSA required to elicit the autoimmune response has not been established.
Cow's-milk-based infant formulas vary in their casein-to-whey ratio, degree of
thermal processing, and extent of enzymatic hydrolysis. Each of these factors is likely to
affect total BSA content and residual antigenicity. Epidemiological studies, to date , which
have attempted to establish the impact of infant feeding practices and early exposure to
cow's-milk-proteins (e.g., BSA) in the pathogenesis of IDDM, have failed to consider the
potential heterogeneity of infant formula. Reports in the literature of the BSA content of
cow's milk vary by four-fold (Robin, Turgeon, & Paquin, 1993 ; Swaisgood, 1982;
Whitney, 1988). Although BSA has been detected in a number of infant formulas, the
quantitative BSA content of commercial infant formulas has not been well defined. There
is no method that has been employed for consistent and sensitive quantitation of BSA in
cow's milk and infant formula. The relative contribution of BSA to the infant's diet from
cow's milk and cow's-milk-based infant formulas is unknown.
The described research was undertaken to provide a comprehensive quantitative
assessment of BSA content of cow's milk and cow's-milk-based infant formulas. Both
direct and indirect enzyme linked immunosorbant assays (ELISA) were evaluated as a
method for quantitating BSA. A sensitive, direct ELISA was developed to specifically
detect and quantitate the amount of BSA present in cow's milk and infant formula
preparations. The information obtained provides a consistent, relative quantitative measure
of the contribution of cow's milk and cow's-milk-based infant formula to the BSA antigen
load in the diet of infants.
The objective of the second component of the described work was to produce a
BSA-free polymeric protein base. Current technology to decrease antigen load in infant
formulas involves extensive enzymatic hydrolysis. This affects all proteins in the
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preparation, is costly, and decreases nutritional quality and palatability. Of the major milk
proteins, BSA has been shown to be the most resistant to enzymatic hydrolysis by trypsin
and' other proteases (Jost, Monte, & Pahud, 19'f57). An immunomagnetic capture system
was developed and utilized to selectively extract BSA from cow's milk and whey protein
isolates that are used in the manufacture of commercial infant formula
Assessment of the BSA content of cow's milk and commercial infant formula
preparations will provide critical information to assist professionals and public health
agencies in making sound nutritional recommendations to help reduce the incidence of
IDDM in those infants not exclusively breast-fed for the first year of life. The American
Academy of Pediatrics ( 1994) "strongly encourages" farnilies with a history of IDDM to
adopt the practice of breast-feeding and avoid cow's milk and products containing intact
cow's-milk-protein during the first year of life. Since routine screening to detect the
"diabetic genes" is not practical at this time as a component of public health policy, it may
be appropriate for all infants to avoid BSA . Development of technology to commercially

produce an affordable BSA-free breast-milk substitute for use in feeding all infants not
exclusively breast-fed may prophylactically help to reduce the incidence of IDDM. The
results of the research reported within this dissertation provide vital information that infant
formula is not heterogeneous in terms of its BSA content. This information can be used
to further evaluate infant feeding practices and the contribution of BSA to the
immunopathogenesis of IDDM.
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CHAPTER II
LITERATURE REVIEW

Insulin dependent diabetes mellitus (IDDM), Type I, or Type l has historically
been referred to as juvenile diabetes since it manifests itself in early childhcxxi and peaks in
adolescence. Research over the past 20 years has clearly demonstrated that IDDM is an
autoimmune disorder with a genetic bias (Alberti, 1993). There is mounting evidence to
suggest that a number of environmental factors influence the expression and progression of
the autoimmune disease process that ultimately results in pancreatic beta-cell failure and
insulin deficiency.
The following literature review provides a summary of the scope and incidence of
IDDM. The major genetic determinants and autoimmune abnormalities associated with
IDDM are addressed. An overview of the principal environmental influences thought to
contribute to the etiology of IDDM are discussed with emphasis on infant feeding practices.
A critical, in-depth review of the literature is provided on the potential protective effects of
breast-feeding and the role of exogenous cow's milk proteins, including bovine serum
albumin (BSA), in the immunopathogenesis of IDDM. Current recommendations for
infant feeding practices will be evaluated in light of the composition of commercially
available infant formulas and their potential contribution to the risk of IDDM.
OVERVIEW OF INSULIN DEPENDENT
DIABETES MELLITUS
Incidence
In Northern Europe and the United States, IDDM is one of the most prevalent and
costly severe chronic diseases of childhcxxi (LaPorte, Matsushima, & Chang, 1995;
Libman, Songer, & LaPorte, 1993; Rewers, LaPorte; King, & Tupmilehto, 1988).
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The annual incidence of !DOM in the United States is 12 to 14 cases per 100,000 (Atkinson
& Maclaren, 1994). Approximately 30,000 new cases of !DOM are diagnosed annually in

the United States (LaPorte et al ., 1995). Of the total number of new cases, it is estimated
that over 13,171 individuals, age 0 to 19, will develop diabetes each year in the United
States and that 123,032 currently have the disease (Libman et al., 1993). When considering
cases of !DOM in both children age 0 to 19 and those either diagnosed in or progressing to
adulthood, it is estimated that over 1.4 million Americans suffer from !DOM (Cerrato,
1993).
The age-specific incidence of !DOM is similar worldwide. The disease is rare prior
to 9 months, has a peak incidence between 5 and 15 years of age, and declines thereafter
(David, Leslie, & Elliott, 1994). Approximately 20 to 25% of new cases of IDDM are
diagnosed in children less than 5 years old (Thai & Eisenbarth, 1993; Tuomilehto et al .,
1995) . The incidence of IDDM becomes two-fold and three-fold higher in the 5- to 9year and 10- to 14-year age brackets, respectively, than in the 0 to 4 age group (Rewers et al.,
1988). Incidence peaks are notable in both sexes during puberty (Dahlquist et al ., 1985).
Minor differences in the incidence of !DOM by gender have been reported in several
studies. Overall a slight male excess in disease incidence has been seen in Europe, which
was particularly apparent in the areas with the highest incidence of disease. In contrast, a
female excess has been seen in areas of low disease incidence (Green , Gale, & Patterson,
1992) . Similarly, a slight excess of boys with !DOM was reported in Australia (Glatthaar
et al., 1988). There appears to be a tendency for increased prevalence in males in countries
of high risk and females in non-Caucasian populations of low risk (Rewers et al., 1988).
The significance of these observations has not been established.
A 50-fold geographical vanation exists between high risk countries such as Finland

and low risk areas of China and Japan (LaPorte et al., 1995). The international variability
in the incidence of !DOM is shown in Figure 1. A high incidence of IDDM is found in
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Figure l. International variability in the incidence of insulin dependent diabetes
mellitus. Adapted from LaPorte, Matsushima, and Chang (1995) .

indi viduals of Northern European descent, with the greatest frequency of occurrence
reported in Finland of 40 cases per 100,000 diagnosed each year (Atkinson & Maclaren ,
1994). While not as high as Finland, the Swedes report an incidence of 23 .6 cases per
100,000, which shows an increasing incidence similar to that reported in other European
countries (Dahlquist et al. , 1985). A high incidence of IDDM has also been observed in the
Liguria and Sardinia regions of Italy (Mazzella et al. , 1994). The incidence of IDDM is as
low as 1to2 cases per 100,000 in Japan (Atkinson & Maclaren, 1994; Rewers et al.,
1988) . Most active registries from Asian countries including China, Japan, and Korea
report low incidence rates of less than 3 cases per 100,000 (LaPorte et al., 1995) . A
similar pattern is reported in Central and South America including Cuba, Chile, Mexico,
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and Peru; full ascertainment from diabetes registries 1s questioned (LaPorte et al., 1995).
The geographic influence does not appear to simply reflect a north-south gradient
previously reported in Europe and throughout the world (Mazzella et al., 1994).
Racial and genetic influences are apparent. Diabetes has not been detected in the
Aborigine population of Australia despite a prevalence in the Australian population of 12.3
per 100,000 (Glatthaar et al., 1988). Within the United States large racial and ethnic
variation in IDDM incidence exists. An incidence of 3.3 per 100,000 is reported in the
. San Diego registry for African Americans compared to 20.6 per 100,000 for Whites in the
Rochester, Minnesota registry. The incidence is higher in Hispanics of Puerto Rican
descent than Mexican Americans. The incidence of IDDM in Mexico, itself, is 0.4 per
100,000 (Rewers et al., 1988). Approximately 40% of the variation in incidence of IDDM

in the United States can be attributed to ethnic diversity (LaPorte et al., 1995).
Reports of a rising incidence of IDDM in the United States and Europe coupled to
rapid rises during selective years in isolated areas pose some concern over an epidemic of
IDDM (LaPorte et al., 1995; Libman et al., 1993). The incidence of IDDM has increased
50% over the past 20 years in Northern Europe (Schober, Schneider, Waldhor, &
Tuomilehto, 1995). There has been a significant and consistent nse in IDDM since records
have been available beginning in 1953. The incidence of IDDM in Finland has risen
consistently since World War II, with the highest incidence reported in 1986. Between
1965 and 1992 the incidence of IDDM rose by 94% with an average annual increase of
2 .8%. Of note, yearly fluctuations suggest epidemic peaks (Tuomliehto et al., 1995). The

pattern of IDDM in Finland, Poland, and Italy points to a temporal variation consistent
with a pandemic of IDDM resembling an infectious disease (Rewers et al., 1988).

A

recent study in Austria showed a pattern of rising incidence of the disease similar to that of
the Northern European countries (Schober & Schneider, 1995).
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The trend toward a rising incidence of IDDM could be attributed to improved
diabetic registries (MacLaren & Atkinson, 1992). Others have suggested that a genetic bias
exists that favors transmission of human leukocyte antigen (HLA) haplotypes that are
diabetogenic . This genetic bias results in an increase in the pool of genetically susceptible
individuals. Factors that could impact the size of the genetic pool include good survival of
young-onset IDDM, an increased number of offspring of parents with !DOM, decreased
perinatal mortality in diabetic pregnancies, and an increased number of woman with !DOM
bearing children (Tuomilehto et al., 1995). In addition, an array of environmental
determinants is currently being explored for their potential contribution to the etiology of
IDDM given both the rising incidence and reports of disease peaks that are suggestive of an
epidemic.
Pathophysiology
!DOM results from the autoimmune destruction of the insulin-producing beta-cells
of the islets of Langerhans of the pancreas. It is generally accepted that some combination
of genetic and environmental factors trigger an autoimmune sequence of events that
ultimately lead to pancreatic beta-cell failure. The destructive autoimmune attack involves
both cellular (T-cell) and humoral (8-cell) immune responses, cytokine release , and likely
free radical accumulation (American Academy of Pediatrics, 1994). Nitric oxide may
mediate the final toxic event. Histological abnormalities reveal islets lacking beta-cell s,
exocrine atrophy, and mild interstitial fibrosis (Atkinson & MacLaren, 1994) . Insulinitis is
a term used to describe the chronic inflammatory infiltrate of the islet cell. The infiltrate
consists of CD8+ and CD4+ cells, B-lymphocytes, macrophages, and natural killer cells
(Atkinson & MacLaren, 1994). Patients usually present with overt pronounced symptoms
of hyperglycemia and ketosis resulting from a total lack of insulin production. This occurs
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late in the pathogenesis of IDDM. The requirement for insulin to sustain life is a hallmark
of the disease.
IDDM has a long prediabetic phase in which genetic , environmental, and
autoimmune factors work in concert to trigger and sustain a process that results in
destruction of the pancreatic beta-cells. Events leading to IDDM suggest a chronic
autoimmune process that exists for years prior to onset of clinical disease (Atkinson &
MacLaren, 1994). Humoral immune changes, increased fasting pro-insulin levels , decline
in insulin secretion, and impaired glucose tolerance have been detected as much as 12 years
prior to onset of clinical disease and provides evidence of a long diabetic prodrome (David
et al., 1994).
Eisenbarth ( 1986) has ranked the progression of IDDM in six stages. Stage I is
genetic predisposition. A hypothetical triggering event characterizes Stage II, which leads
to active autoimmunity (Stage III) . Initially, there is normal insulin secretion despite an
active autoimmune process. Stage IV is characterized by progressive loss of glucosestimulated insulin secretion in the presence of normal blood glucose. Gross abnormalities
in insulin response to intravenous glucose have been observed prior to the onset of
hyperglycemia. These findings are common in the later stages of the diabetic prodrome
(Bingley, Bonifacio, & Gale, 1993) . Marked loss of first-phase insulin secretion precedes
the development of hyperglycemia in all subgroups of patients studied (Bingley et al.,
1993 ; Eisenbarth, 1986; Thai & Eisenbarth, 1993) . The selective loss of response to
intravenous glucose likely parallels the reduction in beta-cell mass . Stage Vis characterized
by overt diabetes with hyperglycemia. Hyperglycemia induced by stress and asymptomatic
glucosuria are early clinical observations of impaired glucose tolerance in children (Thai &
Eisenbarth, 1993). Presence of C-peptide retlects minimal residual insulin secretion.
Finally, complete beta-cell failure occurs (Stage VI). Fewer than 10% of beta-cells remain
2 to 4 months after initiation of insulin therapy (Bach, 1994).
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Loss of first phase insulin response to intravenous glucose appears to represent the
"point of no return" in which progression to clinical IDDM within 3 years is imminent.
This change occurs in the last stages of the diabetic prodrome with loss of 80 to 90% of
beta-cell function (Atkinson & Maclaren, 1994; Tam et al., 1988). An inductive event at
an early age is associated with more pronounced immunity to beta-cells (Atkinson &
Maclaren, 1994). The variable age of disease presentation has been proposed to rellect
different rates of disease progression (David et al., 1994).
Metabolically active beta-cells appear to be particularly subject to autoimmune attack
and may be involved in the pathogenesis of IDDM. The incidence of IDDM in childhood is
low in early infancy and peaks during puberty (Atkinson & Maclaren, 1994). The peak is
reported to occur around 11 or 12 years of age. Increased metabolic demands on the betacell in puberty may exacerbate the pathogenesis of the disease (Atkinson & MacLaren,
1994) . An increased need for insulin occurs during the pubertal growth spurt (Mazzella et

al., 1994). It is generally accepted that puberty 1s associated with decreased insulin
sensitivity. The relative insulin resistance is likely due to elevated levels of growth
hormone that are known to induce insulin resistance. The resulting increased work load on
the beta-cell may accelerate existing beta-cell destruction ( Dahlquist, 1994) or increase
substrate for autoimmune attack. A growth delay that occurs many months prior to clinical
diagnosis has been attributed to subtle changes m glucose tolerance , insulin production,
and sex hormone levels (David et al., 1994) and is a common early symptom of clinical
di sease.
!DOM is sometimes classified into two subgroups, epidemic and non-epidemic.
Epidemic IDDM is characterized by seasonal incident peaks with short duration of symptoms. Rapid progress of the disease often follows an acute infection. Non-epidemic
disease is spread throughout the year, has a more gradual onset of symptoms, and rarely
follows an infection (Samuelsson, Johansson , & Ludvigsson, 1993).
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hyperplasia, hirsutism, decreased hematocrit, and decreased creatinine clearance. Less
common but more severe side effects of high dose long-term use include lymphoma and
irreversible renal damage (Eisenbarth, 1986).
Exogenous insulin therapy has been utilized in an attempt to delay or prevent the
onset of clinical IDDM. Prophylactic exogenous insulin has been administered to induce
beta-cell "rest" (Scott & Marliss, 1991 ). Decreasing the metabolic activity of the beta-cells
is thought to result in a decrease in the immunogenic target antigens (Atkinson &
. Maclaren, 1994) making islet cells less susceptible to immunologically mediated
destruction or the direct effects of anti-insulin autoimmunity (Eisenbarth et al., 1994).
Insulin administration may, therefore, induce tolerance to the beta-cells. In addition,
intravenous insulin has been shown to enhance endogenous insulin production and may
work by decreasing beta-cell damage caused by hyperglycemia. Insulin prophylaxis may
decrease insulinitis, beta-cell damage, and the development of overt diabetes (Scott &
Marliss, 1991).
High dose niacin has received attention as another possible mediator of remission to
IDDM . High dose nicatinamide may induce remission in newly diagnosed patients with
IDDM and delay disease onset in antibody positive non-diabetic children (Alberti, 1993).
Nicatinamide has been demonstrated to prevent and cure spontaneous diabetes in non-obese
diabetic mice, but not in the spontaneously diabetic biobreed rat (Hermitte, Allan-Gepner,
Payan, Mehelleb, & Vialettes, 1995). The proposed mechanism of action of nicatinamide
is that it works in the pancreatic beta-cell by increasing the nicatinamide adenine
dinucleotide pool required for poly (ADP-ribosyl) action and inhibiting the action of
molecular poly (ADP-ribose) polymerase implicated in DNA repair (Alberti, 1993; Kolb,
1989). Nicatinamide may decrease progression of IDDM in individuals with high islet cell
antibody titres and poor first phase insulin response. Nicatinamide may maintain insulin
secretion in nev.dy diagnosed diabetics ; however, results have been inconsistent (Dorman,
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McCarthy, O'Leary, & Koehler, 1995). The beneficial effects of niacin in the prevention
of IDDM may not be seen when treatment follows substantial beta-cell loss evidenced by
extremely impaired first-phase insulin response (Scott & Marliss, 1991).
Other experimental strategies aimed at delaying or preventing the onset of clinical
I DOM have been evaluated in animal models. Administration of the islet cell anti gen
glutamic acid decarboxylase may increase tolerance to glutamic acid decarboxylase
antibodies implicated in the pathogenesis of IDDM. High vitamin E intake and essential
fatty acid deficiency have also been shown to decrease the incidence of IDDM in the
diabetogenic biobreed rat (Hermitte et al., 1995). This could be related to the role of
essential fatty acids in eicosanoid synthesis, inhibition of lipo-oxygenase by vitamin E, and
the role of eicosanoids in mediating immune responses. Under preliminary experimental
conditions, bacille Calmette-Guerin shows promise for inducing remission by generating
regulatory cytok.ines, which may limit destruction of the islet cells (Atkinson & Maclaren ,
1994).
While much of the research in prevention of !DOM has focused on non-diabetic
siblings of those with !DOM, familial !DOM accounts for only a small fraction of cases.
Sporadic occurrence accounts for 85-90% of cases of newly diagnosed !DOM (Alberti,
1993) . In order to detect prediabetes, population screening would be necessary. This
would be costly and complicated. Genetic markers are of limited use in predicting those
who will develop !DOM. Islet cell antibodies appear to be one of the best long-term
predictors of IDDM; however, random population screening would be expected to pick
up only 1 diabetic in 4000 individuals screened in the general population (Tarn et al .,
1988). Accurate identification of those at risk is needed.
The preventative strategies outlined above would need to be life-long and, at
present, often come along too late because the disease has well progressed prior to
diagnosis. At diagnosis, typically 90% of the beta-cells have already been destroyed with
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few insulin-producing cells left to salvage (Cerrato, 1993). With apparent lack of primary
prevention it would be beneficial if the disease process could be arrested, by secondary
prevention strategies, when most beta-cells remain functional and normal glucose tolerance
prevails (Tam et al., 1988). Given the long prediabetic penod prior to development of
clinical symptoms of IDDM, the possibility of identifying individuals at increased risk and
implementing prevention strategies before appreciable beta-cell damage occurs looks
promising.
Treatment
IDDM is a chronic illness that requires ongoing medical care, nutrition therapy, and
patient education to prevent acute decompensation due to diabetic ketoacidosis and reduce
risk of chronic disease complications (American Diabetes Association, 1997). Treatment is
aimed at lowering blood glucose levels to normal or near normal, improving the lipid
profile, and normalizing metabolic status. The Diabetes Control and Complications Trial
(DCCT ; 1993) demonstrated conclusively that patients with IDDM can reduce risk of
development or progression of retinopathy, neuropathy, and nephropathy by 50% to 75%
with implementation of intensive treatment regimens. Intensive management includes:
(a) aggressive insulin management with pump therapy or multiple daily injections, as
needed ; (b) nutrition intervention; (c) frequent blood glucose monitoring (e.g. , preprandial
and bedtime glucose, routine Hgb A 1C); (d) regular exercise; and (e) patient education.
Intensive management of IDDM is recommended and encouraged for all patients with
IDDM. Despite this, the risks of devastating complications remains high (LaPorte et al.,
1995).
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Complications

In the pre-insulin era, prior to 1921, diabetic coma predominated as the cause of
death, and life expectancy was usually less than one year following the onset of clinical
symptoms. Insulin injections prevent death, but fail to preclude loss of sight, limbs, and
kidney function associated with progressive degenerative microvascular disease and
macrovascular complications, which may lead to premature death (Dosch, 1993 ; Rewers
et al., 1988). The majority of deaths in individuals with IDDM now occur in middle and
late adulthood (Portuese & Orchard, 1995). In the middle years, renal disease is the
predominant cause of death. After 30 years, two thirds of IDDM deaths result from
cardiovascular disease, which is further corriplicated by the presence of renal involvement
(Portuese & Orchard, 1995).
Acute complications resulting from elevated peaks and low troughs in blood sugar
still challenge the daily management of IDDM for many individuals . Poorly controlled
diabetes, characterized by a glycosylated hemoglobin greater than or equal to 11 % during
the first 4 years of follow-up, was significantly (Q < 0.001) more likely to result in
development of complications such as m1croalbuminuria, proliferative retinopathy, distal
symmetrical polyneuropathy, nephropathy and renal failure (Lloyd, Becker, Ellis , &
Orchard, 1996) . The DCCT ( 1993) has reported marked reduction in early complications
with intensive treatment of IDDM. Howe ver, intensive treatment is not without risk.
Weight gain and severe hypoglycemia are the most commonly reported problematic side
effects of aggressive management of IDDM (Lloyd et al. , 1996).
Mortality rates for individuals with IDDM remain high. Over 90% will develop
disabling complications including heart disease, stroke, kidney failure, gangrene , and
blindness (Strand, 1994). Childhood onset IDDM has a mortality rate 20 times higher
than seen in age-matched controls (Portuese & Orchard, 1995). Greater than 15% \viii die
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before age 40 (Portuese & Orchard, 1995) . Although greatly improved by insulin and
intensive management, the long-term prognosis for individuals with IDDM remains poor.
Cost
In U.S. dollars the average cost to treat diabetes for someone diagnosed at age
7 through age 40 is $50,000. Cost after age 40 increase as complications progress
(LaPort et al., 1995; Rewers et al., 1988). It has been estimated that the lifetime
cost of an individual contracting IDDM in childhood may reach one million U.S.
dollars (Akerblom, Dosch, et al., 1993).
Summary
The high incidence of IDDM in the northern tiers of the world, in particular
northern Europe, makes it the number one chronic disease of childhood in these regions .
IDDM is an autoimmune disease with a long latent period in which gradual destruction of
the pancreatic beta-cells leads to absolute insulin deficiency and hyperglycemia. IDDM has
serious implications in terms of life-long need for intensive disease management,
debilitating life-threatening complications, and overall cost of the disease to the indi vidual
and health-care system. In the absence of primary prevention and only marginally
effective secondary prevention, it is clear that further understanding of the complex
interactions of genetic predisposition, autoimmunity, and environmental determinants is
needed.
GENETIC DETERMINANTS OF INSULIN DEPENDENT
DIABEfES MELLITUS
Autoimmune destruction of the insulin-prcxiucing pancreatic beta-cells appears to
occur only in those indi viduals with specific genetic markers of disease risk. Genetic
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predisposition to IDDM has been mapped to 20 different chromosomal regions (Atkinson
& MacLaren, 1994). Approximately 25% of the population carries at least one genetic
marker of IDDM (Rennie, 1992). However, fewer than 5% of those possessing the
identified "diabetes genes" will develop IDDM (Norris & Pietropaolo, 1994). While
genetic predisposition appears to be required for development of IDDM, genetic influence
alone does not confer overt clinical disease.
Familial Patterns of Disease Expression
The population risk of developing IDDM is 0.4% in the United States (Todd,
1990). Familial risk is considerably higher than the overall population risk. The incidence

of IDDM in children is significantly higher when IDDM is present in relatives
(i.e., parents, grandparents, parental siblings, cousins, and siblings ; .Q < 0.05; Blom,
Dahlquist, Nystrom, Sandstrom, & Wall , 1989). Risk for first degree relatives varies
with the number of shared human leukocyte antigen (HLA) haplotypes with the proband.
The reported risk is 10 to 16%, 2 to 9% , and less than 1% for those sharing two, one , and
zero haplotypes, respectively (Deschamps , Bevessi , Khalil, Robert, & Hors, 1991 ; Tarn et
al., 1988) . Taken together, a sibling is 15 to 20 times more likely to develop IDDM before
age 20 than an 1nd1vidual in the background population (Bingley et al., 1993). Ten to 12%
of duldren newly diagnosed with IDDM have a first-degree relative with the disease
(father, mother, or sibling; Bruining et al., 1989) .
The incidence of IDDM is three-fold higher in offspring of fathers with IDDM
than affected mothers (Warren , Krolewski, Gottlieb, & Kahn, 1984). The risk to
offspring of a diabetic father developing IDDM is 4 to 6% compared to 2 to 3% for
offspring of a diabetic mother. Age of diagnosis of clinical disease is correlated with the
age of diagnosis of a diabetic father or sibling (.Q < 0.005) . These observations were not
seen in offspring of mothers with IDDM (Metcalfe & Baum, 1992).

18

Although IDDM is not inherited, the increased familial incidence of the disease
clearly reflects a genetic bias. Shared environment risk for North American Caucasians
ranges from l to 15% for first-degree relatives compared to less than l % of indi\'iduals
without relatives with IDDM (Dorman et al., 1995). Despite familial association , the \'ast
majority of patients do not have a family member with IDDM and present with what has
been referred to as "sporadic" IDDM (8ruining et al., 1989). These individuals do,
however, posses an array of genetic markers consistent with predisposition to !DOM.
Genetic Markers of Disease Risk
The genetic predominance associated with a predisposition to IDDM has been
mapped to the major histocompatibility complex (MHC) on chromosome 6 (Deschamps et
al ., 1991; Dosch, Karjalainen, Markowski, Martin, & Robinson, 1992; Thai & Eisenbarth,
1993). MHC class molecules are located in the region of genes coding for highly
polymorphic immune-system-recognition molecules termed human leukocyte antigen
(HLA; Atkinson & MacLaren, 1994). These gene regions function to regulate immune
recognition and response (Dosch et al. , 1992).
MHC class I genes (HLA - A, 8, and C) encode a-chains, which combine with
B-2-microglobulin to form transmembrane molecules (antigens) . These are expressed on
the surface of most nucleated cells and are responsible for cytotoxic T-cell activity
(Deschamps et al., 1991). HLA class I molecules direct antigenic peptides to cog+
(c;.totoxic and suppressor) T-lymphocytes (Atkinson & MacLaren, 1994).
Class II molecules are primarily expressed on cells of the immune system such as
8-lymphocytes, activated T-cells, macrophages, monocytes, dendritic cells, and thymic
cor.tical epithelium (Scott, 1994). Class II molecules present antigens to the T-cell receptor
on T-helper cells (Bach , 1994; Lemmark, 1994 ). MHC class II molecules encode
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complement components (Bf, C2, C4A, and C48), 21-hydrox.lylase, tumor necrosis
factors, and heat shock proteins (Deschamps et al., 1991). MHC class II molecules control
CD4+ helper T-lymphocytes, which have been strongly implicated in the pathogenesis of
!DOM (Todd, 1990). Foreign antigens are processed by these cells, bound to class II
molecules. HLA class II proteins, HLA-DP, DQ, and DR, present antigenic peptides to
CD4+ (helper and inducer) T-lymphocytes (Atkinson & MacLaren, 1994) . Recognition of
the HLA-peptide complex produces signals leading to the activation ofT-helper cells and
initiation of the immune response (Deschamps et al. , 1991).
The peptide-binding groove of class II molecules is influenced by amino acid sidechains located within the groove. These amino acid side-chains likely contribute to the
properties of class II molecules (Lernmark, 1994). The characteristics of the binding
groove direct the ability of class II molecules to bind antigenic peptides. The ability to
accept or reject an antigen may have significant implications in the susceptibility to IDDM
and the contribution of specific exogenous antigens to disease pathogenesis.
Specific subclasses of HLA-DQ and HLA-DR class II proteins exhibit
characteristics associated with increased risk or confer protection from IDDM. IDDM has
been strongly associated with the class II alleles DR3 and DR4 (Alberti, 1993). DR3 or
DR4 is present m approximately 90% of patients with IDDM compared to 40% of the nondiabetic population (Todd, 1990). DR3 positive individuals show slower disease
progression in the presence of islet cell antibodies (Deschamps et al., 1991) . DR4 alleles
are associated with increased insulin autoantibodies (Thai & Eisenbarth, 1993). Susceptibility appears stronger in the 04 subregion compared to 03 (Deschamps et al., 1991) .
Progression to IDDM has been reported to be 3 to 4% with HLA-DR3 or DR4 alone and
16% for HLA DR3/DR4 heterozygotes. The presence of islet cell antibodies in the latter
group has been associated with a 70% progression rate to overt clinical disease within 5
years. Those with both DR3 and DR4 haplotypes present with more severe disease and
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Individuals homozygous for both DQB l *non-Asp-57 and DQA l * Arg-52 alleles have a
high risk of IDDM, which can explain 62% of the incidence of IDDM in high-risk
individuals (Deschamps et al., 1991; Dorman et al., 1995). The presence of aspartate at
position 57 decreases susceptibility but does not appear to confer absolute protection
(Todd, 1990). These findings point to a specific molecular basis of the genetic
predisposition to IDDM.
Non-MHC genetic determinants have also been linked to IDDM. The insulin gene
is associated with IDDM, particularly in HLA DR4 positive subjects (Bach, 1994; Todd ,
1990) . Susceptibility to IDDM has also been associated with genes coding for the
transporter involved in antigen presentation (TAP), the TAP peptide transporter. In a
recent review, TAP transport was reported to be defective in patients with IDDM (Atkinson
& MacLaren, 1994). There are at least 10 other non-MHC predisposition loci (Bach,

1994). These other genes may be invol ved by coding for immunoregulatory cells such as
cytokine genes and genes controlling beta-cell sensitivity to immune recognition (Bach,
1994).
Genetic Markers Conferring Disease Protection
In addition to the presence of aspartate at position 57 of the DQB chain, other MHC
determinants are thought to provide disease resistance . Resistance to IDDM appears to be
conferred by certain alleles of DQA 1 and DQB 1 (Todd, 1990). On the DQA l locus,
replacement of the usual A2 allele with the A3 allele has been observed in diabetics. These
findings suggest that the A2 allele confers resistance to IDDM (Todd, 1990). Additionall y,
the DQB 1*0602 haplotype has been reported to provide strong protection from diabetes m
both familial and population based studies (Thai & Eisenbarth, 1993). DQ6, formed by the
a-chain DQB 1*0602 and the a-chain of DQA 1*0102, appears to provide dominant
protection. These determinants are present in 30% of the Swedish population despite an

otherwise high risk of !DOM (Lemmark, 1994). DQB l *030 l (OQ7) also appears to
afford protection (Lernmark, 1994). DQ haplotypes may be primarily protective.
The DR2 (0Rwl5) haplotypes are inversely associated with !DOM in all races
(Deschamps et al. , 1991). This suggests that the DR2(DRw15) haplotype provides disease
resistance (Todd, 1990). Protection against !DOM appears to be provided by DR2 and the
T AP2*0201 allele which ccxies for a transporter of antigenic peptides to MHC class I
molecules (Bach, 1994). Defective peptide transport and capture of peptides by protective
. HLA molecules could prevent binding to predisposing HLA molecules, effective
presentation to T-cells, and immunological tolerance (Bach, 1994). Lack of DR2
protection would leave one subject to autoimmunity triggered by an environmental antigen.
Use of Genetic Markers to Predict Risk of Insulin
Dependent Diabetes Mellitus
Genetic resolution of MHC-IDDM association is complicated by disease
heterogeneity in terms of age of onset and ethnic variables (Bach, 1994). Several genes
determine predisposition to !DOM; howe ver, nongenetic factors contribute equally to
disease development (Deschamps et al. , 1991). The positi ve predictive value of HLA
genotyping is low and would provide a number of false positives if used to screen
population groups (Lemmark, 1994). While HLA DR3 and DR4are present in more than
90% of European patients with !DOM, they have a poor predicti ve value gi ven that 40 to
55% of the background population share these markers (Tarn et al., 1988). Genetic
population screening for IDDM risk is considered to be impractical , if not impossible.
Genetic screening would pick up the 6% of the population heterozygous for HLA DR3 and
DR4. Based on the current incidence of IDDM, 97.5% of this 6% would never develop
overt clinical disease (Tuomilehto & Wolf, 1987). Additional determinants of risk and
progression to clinical IDDM are needed.
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AUTOIMMUNE PATHOGENESIS OF INSULIN DEPENDENT
DIABETES MELLITUS

A long, latent period of subclinical autoimmunity exists in which selecti\·e
destruction of the insulin producing pancreatic beta-cells precedes the development of
IDDM (Norris et al., 1996). It is generally accepted that the initiation of autoimmumty
begins in early childhood or infancy given that approximately 20 to 25% of cases of
I DOM are diagnosed prior to age 5 (Thai & Eisenbarth, 1993; Toumilehto et al., 1995) .
Sera conversion to beta-cell autoimmunity after age 5 is rare (Norris et al. , 1996). It 1s
now widely accepted that immunological and metabolic alterations occur long before
symptomatic hyperglycemia (Thai & Eisenbarth, 1993). The autoimmune processes
leading to beta-cell destruction are triggered by poorly understood factors . These
immunological abnormalities occur in genetically predisposed individuals of whom only a
small fraction will progress to clinical disease (Bruining et al., 1989).

Environmental

factors are likely to play a role in triggering and sustaining the complex autoimmune
response, which eventually leads to beta-cell failure and insulin deficiency.
Tolerance
The mam function of the immune system is to protect the host from foreign
pathogens. In this capacity, the ability to discriminate self from nonself is critical (Cordle,
1994). An important feature of the normal healthy immune system is that B-cells and

T-cells are physiologically tolerant to most self-antigens so that there is no pathological
autoimmune response (Bach, 1994). The autoimmune pathogenesis of IDDM may evolve
from acquired processes that overcome anergy or suppression resulting in IDDM (Rossini,
Greiner, Friedman, & Mordes, 1993 ). The breakdown of self-tolerance that characterizes
autoimmune diseases may occur through three major mechanisms: insufficient intrathymic
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negative selection, bypass of penpheral anergy, or defective suppression (Bach , 1994).
These three cntical processes likely work in concert to prevent autoimmunity (Rossini et
al. , 1993 ). Breakdown of T-cell anergy could occur by deviant expression of MHC
molecules and molecular mimicry (Bach, 1994). Defective suppressorT-cell function,
which may be related to an imbalance in TH l(fH2, likely allows amplification of the
autoimmune response that eventually destroys the beta-cells (Bach, 1994). The exact
mechanisms underlying the autoimmune pathogenesis of IDDM are still unknown but likely
involve loss of self-tolerance to islet antigens (Bach, 1994). Environmental insults may
interfere with the regulatory balance and preclude self-tolerance.
Immune System Abnormalities
IDDM is associated with HLA genes known to be expressed in individuals with
most other autoimmune diseases. Patients with IDDM suffer from other autoimmune
diseases (e.g., rheumatoid arthritis, myasthenia gravis, pernicious anemia, and thyroiditis ;
Rossini et al. , 1993 ). In addition, mononuclear cell infiltration of target tissues invol ved in
disease pathogenesis is a common association of IDDM with other autoimmune di seases,
most notably thyroiditis (Bach, 1994).
The immunopathogenesis of IDDM is characterized by infiltration of the islets of
Langerhans by mononuclear cells and is termed insulinitis (Bach, 1994). Insulinitis is an
inflammatory infiltrate which is confined to the islets. These infiltrates contain
lymphocytes that express either CD8+ (suppressor/inducer) or CD4+ (helper/i nducer)
surface markers and MHC class II antigens. Increased expression of MHC class I
molecules suggests lymphokine activity (e.g., gamma-interferon) by infiltrating cells
(Rossini et al., 1993). IDDM is characterized by predominantly CD4+ pol yclonal
insulinitis (Miyazaki et al. , 1995). Macrophages are seen in earl y pancreatic infiltrates.
These are an important source of cytokines, which have been detected in inflamed islet

25

cells. Cytokines may mediate pancreatic beta-cell destruction and lysis (Todd, 1990). In
the non-obese diabetic (NOD) mouse, insulinitis has been shown to be present well before
the presentation of clinical diabetes. Insulinitis was seen in 50% of the mice at 40 days and
70% of the mice at 90 days. In humans, circulating monocytes are activated in newly
diagnosed diabetics, both peripherally and at the local site of inflammation in the pancreas.
Monocyte proliferauon appears to reflect ongoing pathogenic immunological destruction of
the pancreas (Josefsen, Nielsen, Lorentzen, Damsbo, & Buschard, 1994) . Insulinitis
appears to be required for progression to frank clinical diabetes, but insufficient by itself to
produce overt disease (Miyazaki et al ., 1995).
The destruction of beta-cells is mediated by T-lymphocytes (Dotta, Anastasi,
Tiberti, & Di Mario, 1994). T-cells are predominantly, if not exclusively, involved in
creating islet cell lesions that lead to beta-cell atrophy. This appears to follow a stage of
reversible inflammation (Bach, 1994). T-lymphocytes are required for initiation of both
cell mediated and humoral immune responses. The presence of both CD4+ and CD8+
T-cells has been demonstrated to be necessary for beta-cell destruction (Todd, 1990).
T-lymphocytes bind and react to only those antigens that associate with its autologous,
specific MHC molecules (Dosch et al., 1992). In addition , increased circulating
B-lymphocytes (CDS+) are seen in IDDM and are characteristic of other autoimmune
diseases (Atkinson & Maclaren , 1994; Bach, 1994). The events that trigger the activation
of auto-reactive lymphocytes in IDDM remain elusive (Krakowski et al ., 1995).
Other nonspecific abnormalities in the immune system of individuals with IDDM
include increased levels of T-cells expressing the interleukin-2 receptor (Rossini et al.,
1993), lymphocytopenia, increased natural killer cell activity, and thymic abnormalities
(Bach , 1994) . Interleukin-I inhibits insulin secretion and is cytotoxic at high
concentrations (Atkinson & Maclaren, 1994). lnterleukin-lB has been identified as a
major beta-cell cytotoxic effector molecule (Fourth International Onnela Workshop, 1990).
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lnterleukin-6 is a powerful stimulator of the immune response and may contribute to both
beta-cell destruction and insulinitis (Atkinson & Maclaren, 1994). Production of alphainterferon 1s induced by viruses. Alpha-interferon stimulates the expression of HLA
molecules and 1s chemotaxic to other lymphocytes. Patients dying of ketoac1dosis exhibit
high levels of alpha-interferon (Atkinson & Maclaren, 1994). Toxic free oxygen radicals
(e .g., superoxide) and nitric oxide, produced during the abnormal autoimmune response ,
may be the final mediators of the cytotoxic destruction of the insulin producing pancreatic
beta-cells (Atkinson & Maclaren, 1994; Fourth International Onnela Workshop, 1990).
Au toan ti bodies
Autoantibodies are found against a wide array of membrane and cytoplasmic
constituents of beta-cells including insulin, proinsulin, and glutamic acid decarboxylase
(GAD ; Alberti, 1993; Bach, 1994). Other potential autoantigens include peripherin
(a neurone cytoskeleton molecule) carboxypeptidase H, heat shock protein 65, 37kD
protein, 38kD protein, 52kD antigen, the polar antigen, GT3 ganglioside, and other islet
cell antibody-reacti ve gangliosides (GM2-l ; Bach, 1994; Dotta et al ., 1994).
Autoantibodies have been detected against each of the following antigens in patients with
!DOM: pancreatic sialoglycoconjugate, insulin, glutamic acid decarboxylase, bovine serum
albumin, carboxypeptidase H, pancreatic sulfatide, lymphocyte surface, pancreatic
cytokeratin, thymic hormone , HLA-DQ molecules , beta-cell glucose transporter, and a
number of islet cell proteins (37- or 40kD , 38-kD, 52-kD, and 69kD proteins ; Atkinson &
Maclaren, 1994; Rossini et al., 1993). Monocytes taken from patients with IDDM show
proliferation upon exposure to most of these antigens (Atkinson & Maclaren, 1994).
Cellular staining of islet cell antibodies and insulin autoantibodies suggest multiple
autoantigens (Reddy, Bibby, & Elliott, 1987) . Islet cell antigens may be directly involved
in the pathogenesis of IDDM or may function as targets for antibodies involved in
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immunity to beta-cells and, therefore, do not directly contribute to disease development
(Atkinson & Maclaren, 1994; Dotta et al., 1994). Of note, insulin autoanti bodies and islet
cell antibodies are absent in 15 to 20% of patients with recent onset diabetes (Bach, 1994).

Insulin Autoantibodies
To date, insulin is the only established beta-cell specific autoantigen in IDDM
(Dotta et al., 1994). Insulin autoantibodies demonstrate both islet cell and beta-cell
specific autoimmunity. Elevated insulin autoantibodies have been shown to be positively
associated with DR4 genes and some DQA 1 alleles. These observations clearly reflect the
role of genetic influence in diabetic autoimmunity. Antibodies to insulin have been detected
prior to other autoantibodies in prediabetes and have also been shown to correlate with age
of onset of clinical disease (Eisenbarth et al., 1994). The highest frequency of insulin
autoantibodies ( 100%) has been observed in children diagnosed before the age of 5. High
titres of insulin autoantibodies may reflect the virulence of the autoimmune process and
concordant level of beta-cell destruction (Thai & Eisenbarth, 1993). Insulin autoantibodies
have been reported to be present in 50% of newly diagnosed cases of IDDM and are a
highly predictive marker of disease risk (Atkinson & Maclaren, 1994). However, insulin
autoantibodies appear to have little prognostic significance in the absence of islet cell
anubodies (Bingley et al., 1993). Where both insulin and islet cell cytoplasmic
autoantibodies are detected, there is a high risk of progression to clinical IDDM (Atkinson
& Maclaren, 1994; Thai & Eisenbarth , 1993) .

Islet Cell Antibodies
The presence of islet cell antibodies (ICAs) in newly diagnosed diabetics, which are
absent or are detected in very low titres in the reference population, is a distinguishing
characteristic of IDDM (Lipton & LaPorte, 1989). Islet cell antibodies bind primarily to the
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cytoplasm of beta-cells, but can bind to the cytoplasm of other islet endocrine cells (Bach.
1994) . Islet cell antibodies may help to idenufy molecules that can be a target of T-cells.

T-cell autoantigens may have a pathogenic role in IDDM caused by a cell-mediated autoimmune response (Dotta et al., 1994). The presence of islet cell antibodies has been used
as a marker of beta-cell damage and time course to progression to overt clinical IDDM.
Impaired first phase insulin response to intravenous glucose has been observed around the
time of presentation of detectable islet cell antibodies (Tuom1lehto & Wolf, 1987). Islet
cell surface antibodies may affect glucose stimulated insulin release (Lemmark, 1994). It is
not clear whether islet cell antibodies play a direct role in disease process or serve as
markers of tissue damage initiated by other etiological factors (Dorman et al., 1995).
The presence of islet cell antibodies prior to overt clinical symptoms of IDDM
supports the long diabetic prodrome of disease pathogenesis. In the non-obese diabetic
mouse, islet cell antibodies were detected well before the presentation of clinical diabetes.
Islet cell antibodies were present in 40% at day 40 and 54% at day 90. The concordance
rate was 50% at 90 days (Reddy et al ., 1987). Islet-cell cytoplasmic autoantibodies have
been reported to be detected at high levels

in

70 to 80% of newly diagnosed patients with

IDDM , 3 to 4 % in non-diabetic relatives, and onl y 0.5% in the general population
(Atkinson & MacLaren, 1994) . Islet cell antibodies have been detected in non-diabetic
siblings of those suffering from IDDM many years prior to the development of clinical
symptoms in the sibling of the diabetic proband (Alberti, 1993). In a cohort of 4 ,015 nondiabet1c relatives, 67.5% of those with positi ve islet cell antibody titres progressed to
!DOM within 10 years (Riley et al. , 1990). Similarl y, Thai and Eisenbarth ( 1993)
reported that greater than 50% of relatives exhibiting high islet cell antibody titres
developed symptoms of clinical disease within 5 years. In a 10-year foll ow-up study of
islet cell antibodies and development of IDDM in childhood, 4 of 8 subjects with islet cell
antibodies progressed to overt clinical diabetes. Of the 4,806 children ages 5 to 19 who
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tested negative for islet cell antibodies, 99.9% did not develop !DOM over the 10-year
study period (Bruining et al., 1989) .
The occurrence of islet cell antibodies in the general population of children is
restncted to those who are genetically susceptible to !DOM (Tuomilehto & Wolf, 1987).
High antibody titres to islet cells increase the risk of developing diabetes to 50%. Presence
of two or more antibodies confirm a 90% risk of progression to clinical diabetes (Alberti,
1993). Complement fixing or high titre islet cell antibodies have been cited as predictable

markers of impending !DOM. Fifty-four percent of subjects positive for complement
fixing islet cell antibodies on three or more occasions were noted to develop frank IDDM .
Approximately 76% of those positive for complement fixing islet cell antibodies can be
expected to eventually develop IDDM (Tarn et al., 1988).
The highest antibody titres are seen at the onset of clinical IDDM. In fact, these
antibodies occur years before the onset of clinical diagnosis. Following disease
establishment, islet cell antibodies drop markedly (Lipton & LaPorte, 1989). Islet cell
antibodies have been shown to be present in approximately 80% of patients newly
diagnosed with IDDM, but were observed to show a progressive decline in the time leading
up to diagnosis (Tarn et al., 1988). These may fall below the level of detection or below
the baseline of nondiabetic controls w1th10 2 to 10 years of diagnosis in a large percentage
of patients (Lipton & LaPorte, 1989). Once !DOM is established, consistent with marked
beta-cell destruction, islet cell antibody levels decrease as no antigen remains to support the
immune response .
Use of Insulin Autoantibodies and Islet Cell Antibodies As
Predictive Markers of Insulin Dependent Diabetes Mellitus
Islet-cell cytoplasmic autoantibodies and insulin autoantibodies have been used as
metabolic markers to predict susceptibility to IDDM and pathogenesis of the disease .
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Presence of islet cell antibodies are a potent indicator of risk for IDDM, at least in high risk
individuals (Bingley et al., 1993; Lipton & LaPorte, 1989). Most cases of !DOM will
de\'elop in the islet cell antibody posnive subgroup of first-degree relatives. It is likely that
60 to 70% of the islet cell antibody positive group will require insulin within 10 years with
risk directly proportional to antibody titre (Bingley et al., 1993). However, n is not
inevnable that the remainder will develop clinical disease (Bingley et al., 1993 ; Lipton &
LaPorte, 1989). Islet cell antibodies alone have limited prognostic value in the general
population. While it can be expected that 2.8% of school-age children will be positive for
islet cell antibodies, progression to diabetes within 5 years would be expected to be seen in
only 2 to 3% of the 2.8% positive for islet cell antibodies (Bingley et al., 1993). In islet
cell antibody positive relatives, the presence of both elevated titres of insulin autoant1bodies
and loss of first phase insulin response is strongly predictive of rapid progression to
clinical IDDM . Progression is seen within 3 to 4 years in 90% of these individuals
(Bingley et al., 1993). In relatives positive for insulin autoantibodies, nsk of developing
IDDM becomes much higher in those also positive for islet cell anubodies (63% vs. 9%) .
With insulin autoantibody titres greater than 150nU/ml , 100% of relatives of a diabetic
proband have been shown to advance to IDDM within 5 years (Dotta et al., 1994). Taken
together, islet cell antibodies and insulin autoantibodies appear to be the best predictive
markers of IDDM in high risk relatives (Bach, 1994).
While there is clearly an interrelationship between genetics, autoimmunity, and
!DOM, only about 10% of the population have close relatives with IDDM. Lack of
inexpensive, specific, and sensitive markers of IDDM is a limitation to early identification
of all individuals at risk. To date, MHC typing is less powerful as an IDDM predictor
than the presence of islet cell antibodies, complement fixing autoantibodies , insulin
autoantibodies, or loss of first-phase insulin response (Scott & Marliss, 1991).
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Immunological markers of IDDM, in combination with genetic screening, are currently
limited to relatives of probands and to research settings. These markers can be utilized to
detect individuals with early autoimmune lesions of IDDM and target evaluation of
secondary preventative strategies.
Interaction Between Genetic Markers of Insulin Dependent
Diabetes Mellitus and Autoimmunity
It is well accepted that there is a link between markers of the HLA-region of
chromosome 6 and destruction of the pancreatic insulin producing beta-cells associated
with IDDM (Wilkin & Amtitage, 1986). The hallmark of genetic susceptibility to !DOM
resides in an inherit defect in the ability to establish tolerance to beta-cell autoantigens
(Atkinson & Maclaren, 1994). MHC class II molecules bind peptide fragments from
foreign proteins and present these antigens to CD4+ helper/inducer T-cells. Defects in
MHC class I proteins, which nomtally present fragments of endogenous proteins to the
immune system, may result in impaired development and maintenance of nomtal selftolerance and lead to diabetic autoimmunitv (Rossini et al., 1993).
The ability of the antigen presenting cells (APCs) to bind and present antigens to the
immune system is detemtined by HLA genes (McCarren, 1992). The proposed mechanism
by which HLA-DR and DQ impact expression of IDDM is by affecting the degree of
immune responsiveness to an autoantigen . Alternatively, these genes may present the
antigen in a manner that does not promote nomtal tolerance (Atkinson & Maclaren , 1994).
Interaction between the HLA molecule, the antigenic peptide, and the T-lymphocyte
receptor causes lymphocyte proliferation, a process common to all immune responses
(Atkinson & Maclaren, 1994).
Antigenic epitopes ranging from 13-25 residues are most likely to bind to MHC
class II molecules (Papadopoulos, 1993). It appears that B-chain residue 57, which
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occupies an outward facing cleft in the molecule, may be involved with antigen binding
(Rossini et al., 1993). In "protective" MHC class II molecules, aspartate holds the number
57 position. In "susceptibility" molecules, arginine holds this position (Papadopoulos,
1993). Conformation and expression of DQ molecules impacts autoantigen binding
(Todd, 1990). The variability in the size or shape of the antigen binding sites (cleft) of
DQ molecules affects the ability of antigen-presenting cells to bind specific islet-cell
autoantigens and establish immunological tolerance (Maclaren & Atkinson, 1992;
. Todd, 1990).
Genetic derangements that impact immune recognition and responsiveness are
clearly involved in the pathogenesis of IDDM. It is generally accepted that genetic
predisposition is , in fact, required to yield the abnormal autoimmune response (Bach,
1994). Diabetic autoimmunity is likely triggered by an exogenous environmental insult.
In genetically susceptible individuals, this results in failure to establish self-tolerance and a
deranged immune response that ultimately leads to the destruction of the insulin-producing
pancreatic beta-cells.
Environmental Antigens in the Autoimmune Pathogenesis of
Insulin Dependent Diabetes Mellitus
Research into the etiology and pathogenesis of IDDM has recently focused on the
potential involvement of environmental antigens that may trigger the autoimmune process
that leads to beta-cell failure and insulin deficiency in genetically susceptible individuals.
Antigenicity is defined as the capacity of molecules (antigens) to interact with
immunologically-specific antibodies. The antibody-antigen interaction is determined by the
three-dimensional chemical structure of a relati vely small segment of the molecules that
contacts the antibody during binding (Cordle, Duska-McEwen, Janas, Malone, & Hirsch,
1994) . An epitope is the three-dimensional site on an antigen to which an antibody will
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bind (Siemensma, Weijer, & Bak, 1993). Antigen presentation is derived from antigen
dose, route, and frequency of administration that ultimately leads to successful initiation of
immunity (Cordle, 1994). White blood cells, known as antigen presenting cells (APC),
engulf a foreign cell, digest it, and present fragments of the dead cell on the surface of the
antigen presenting cell. This presentation of foreign matter to the immune system is
followed by a T-cell-mediated response to the antigen and the synthesis of antibodies by the
8-cells (McCarren, 1992). The ability to recognize a specific antigenic structure of proteins
is genetically determined (Cordle, 1994).
Immunogenicity is the capability of molecules (immunogens) to elicit the production
of specific antibodies and/or initiate specific cellular immune responses. Immunogenicity is
effected by molecular weight, chemical complexity, "foreignness," dose, and mode of
exposure (Cordle et al., 1994). Strong immunogens have multiple binding sites (Cordle,
1994). A number of potential dietary antigens have been identified that may be involved in
the immunopathogenesis of IDDM. It is unlikely that only a single initiating antigen leads
to islet cell damage (Dotta et al., 1994).
Several hypotheses have been put forward that describe potential interactions
between genetic predisposition, environmental factors, and the immunopathogenesis of
IDDM. Environmental factors such as food antigens and viruses may cause expression of
an abnormal beta-cell surface protein. For instance, the beta-cell protein, p69, which is a
recognized autoimmune target in !DOM, presents itself on the surface of the islet cells
following stress and infection (Mccarren, 1992) . Expression of beta-cell p69 is mediated
by gamma-interferon. The presence of p69 causes failure of the immune system to
recogruze the beta-cell as self or causes structural changes in the cell that impact insulin
production (Rossini et al., 1993). Antibodies to p69 have been detected in 70% of newly
diagnosed diabetics and 9% of first-degree relatives (Datta et al., 1994). An alternative
hypothesis proposed by Thai and Eisenbarth ( 1993) suggests that the autoimmune
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derangements are initiated by somatic mutations similar to those seen in some genetic
malignancies.
The immature immune system is capable of establishing the immune memory that
sustains the diabetic autoimmune process culminating in the demise of the msulinproducing beta-cells (Dosch et al., 1992). The early and defective immunological response
involves antigenic or molecular mimicry in which a specific MHC structure has the ability
to bind to an antigen that is similar but not identical to some self-protein. Autoantibody
production and abnormal T-cell suppressor function follow (Rossini et al., 1993).
Molecular mimicry is a faulty process of immune recognition. The immune system
sensitized to one protein, an antigen, sees the second similar protein as foreign and mounts
an immune attack against the analogous protein, regardless of its endogenous host origin.
The autoimmune response causes destruction of the tissues that express the self-protein
(Dosch et al., 1992). In this case, it is the insulin producing pancreatic beta-cells.
Atkinson and MacLaren ( 1994) have recently proposed two elaborate
immunological models for the pathogenesis of IDDM. Autoimmunity to beta-cells may be
caused by an 1mmunological response to a viral protein which shares an amino acid
sequence with a beta-cell protein. This results in the production of cytotoxic CD8+
lymphocytes that react with the analogous self-protein on the pancreatic beta-cells
(Atkinson & Maclaren, 1994). The second proposed mechanism involves exposure to an
environmental insult. This in tum may generate cytokines and other mediators of the
inflammatory response. These immune components induce expression of adhesion
molecules in the vascular epithelium of islet cells. Enhanced adhesion and extravasation of
circulating leukocytes, infiltrating macrophages, and lymphocytes result in beta-cell
damage (Atkinson & MacLaren, 1994). In either case, the process would be perpetuated
by release of inflammatory cytokines from the damaged islet cells leading to overexpression of HLA class I molecules on beta cells. Further destruction of islets could be
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mediated by antibody-dependent cellular cytotoxicity, delayed hypersensitivity, compliment activation, and elevated levels of C)lokines (Atkinson & Maclaren, 1994) .

Summary of the Autoimmune Pathogenesis of !DOM
!DOM is a chronic disease of insulin deficiency following a long diabetic prodromc
in which multiple autoimmune abnormalities eventually lead to beta-cell failure . Failure to
establish normal immune tolerance, production of autoantibodies against a number of betacell autoantigens and insulin, and a battery of other immunological insults mediated by Tlymphocytes and other immune regulators are characteristic features of the autoimmune
pathogenesis of IDDM. Immunological intervention for IDDM will depend on early
prediction, immunosuppression, and induction of immunological tolerance to self and
mimicry antigens (Bach, 1994).
ENVIRONMENT AL INFLUENCES OF DISEASE EXPRESSION
The rising incidence of IDDM

in

Europe roughly reflects a two-fold increase in the

number of reported cases in the past 20 years. This observation points to invol ve ment of
an environmental determinant in the etiology of !DOM (Green et al., 1992). A sharp peak
in the incidence is consistent with a sudden outbreak of !DOM, considered to be indicative
of an epidemic, lending support to the recognition of environmental factors as additional
causative agents (Schober et al. , 1995) . There has been a rapid rise in the incidence o f
!DOM in several Scandinavian countnes with pronounced geographical variation in
reported cases, despite a population that is genetically homogenous (Blom et al ., 1989) .

.

The major geographicil variations in the worldwide incidence of IDDM are reported to be
as high as 36- to 50-fold from region to region, with certain populations showing
significant changes in incidence over time (Diabetes Epidemiology Research International ,
1987). Migrants have been shown to take on the risk equivalent to their new country
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(Diabetes Epidemiology Research International, 1987). Pronounced differences in
incidence rates between genetically similar populations, geographical location, and
nuctuat1ons over time point to the role of environmental factors. These environmental
insults may directly damage the beta-cells or are involved in a complex autoimmune
mechanism leading to beta-cell destruction.
Human leukocyte antigen (HLA) genes confer susceptibility but are not determining
factors in that the majority of individuals possessing these "diabetes genes" do not develop
!DOM (David et al., 1994). Over 95% of the population with high-risk histocompatibility
antigens evade diabetes (Diabetes Epidemiology Research International, 1987). Additional
support for the involvement of environmental events as a component of the complex
pathogenesis of diabetes is provided by studies in twins. Concordance of !DOM in
homozygotic twins has been reported to range from 35% to 50% (Atkinson & Maclaren,
1994; David et al., 1994; Tattershaw & Pike, 1972; Todd, 1990). Approximately 90% of

siblings with identical histocompatibility antigens do not develop diabetes (Diabetes
Epidemiology Research International, 1987; Todd, 1990)). The average risk to siblings for
developing diabetes is only 6% (Todd, 1990). Over 90% of children newly diagnosed
with IDOM do not have a first-degree relative with the disease (LaPorte et al., 1995).
Environmental factors likely modulate the expression of predisposing or protective
genes. The modulation hypothesis would suggest that the environmental factors are only
important in the population at genetic risk with multiple and chronic exposure exerting
positive and negative effects (Bach, 1994). Environmental factors may break tolerance to
pancreatic beta-cell antigens and precipitate the onset of the autoimmune process leading to
!DOM in genetically susceptible individuals (Baxter & Cooke , 1992). Environmental
insults are likely to exert their effect early in life, in utero or during infancy (Kyvik, Green,
Svendsen, & Mortensen, 1992). Environmental factors may operate over this relativel y
narrow window of early childhood inducing an autoimmune process that eventuall y
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destroys the insulin-producing beta-cells. A long prodrome precedes the onset of clinical
symptoms (David et al., 1994; Scott, 1994). Evidence to support an early environmental
event is provided in the observation that 25% of IDDM is diagnosed prior to age 5. The
decrease in incidence with incre_asing age is likely attributed to a decreased environmental
effect. Later environmental events such as viruses and stress could precipitate disease
presentation but not initiate disease process (David et al ., 1994).
Primary worldwide detenninants of IDDM are environmental, not purely
· immunogenic (Diabetes Epidemiology Research International, 1987). Investigators from
this project have estimated that at least 60% of IDDM worldwide, and conceivably up to
95%, is environmentally detennined and, therefore, is potentially avoidable. These
environmental factors, if identified, are likely to be more effective and less risky in
preventing IDDM than current immunological approaches (Diabetes Epidemiology
Research International, 1987).
Demographic Patterns of Disease Prevalence
Geographical Variation
The geographic variation in incidence of IDDM in childhood is unique among
chronic diseases . Reported incidence of !DOM based on geographic variation has been
shown to correlate with the average yearly temperature of the environment, distance from
the equator, prevalence of certain viruses, diet , life-style patterns, as well as ethnic
characteristics of the population at risk (Diabetes Epidemiology Research International ,
1988). Distribution of HLA-OQB non-Asp-47 and HLA-DQa Arg-52 alleles may, in part,
explain the geographical variation in incidence of IDDM (Scott, 1994). Once genetic
susceptibility is taken into account, there is a marked decrease in the impact of geographic
differences on the incidence of IDDM (Scott & Marliss , 1991).
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containing fish and many fresh fruits compared to the New Zealand diet where breastfeeding is less likely or of shorter duration, and the child is weaned to a diet high in animal
proteins and vegetables (Scott & Marliss, 1991). Risk of IDDM closely parallels that of the
host country rather than the pattern of risk of the country of native origin. The differences
between ethnic groups may reflect socioeconomic status and life-style patterns in addition
to genetic determmants of IDDM (Diabetes Epidemiology Research International , 1988).
Seasonal Variation
Onset of diabetes has been shown to be related to season (Mazzella et al., 1994).
An increased number of cases are reported in the winter months, which could plausibly be
related to the known increase in viral infections observed during this period. Seasonal
variation in incidence rates, with peak incidence in autumn and winter months, has been
reported in Sweden (Dahlquist et al., 1985; LaPorte et al., 1995). Seasonal variation in the
United States is small but tends to take the pattern observed worldwide. A general decline
in registered cases of IDDM occurs in the summer months (LaPorte et al., 1995) . The
seasonal pattern of cases of IDDM in the Marche region of Italy parallels other
Mediterranean countries, again, with a greater frequency of cases diagnosed during the
winter months (Cherubini et al., 1994). A colder environment has been indicated as a risk
factor for IDDM due to increased need for insulin (Mazzella et al., 1994). Increased work
load on the pancreatic beta-cell may increase vulnerability to lymphokines and accelerate
beta-cell destruction (Dahlquist, 1994).
Psychological and Social Factors
The Swedish Childhood Diabetes Study examined social and perinatal determinants
of IDDM (Blom et al. , 1989). Most notable was a significant increase in the incidence of
IDDM with increasing age of the mother over 35 years. There was a slight inverse

correlation with educational level of the mother. Other social factors that have been
identified at greater frequency in !DOM compared to the background population include
overcrowding, environmental depnvation, unemployment, and lack of home or car
ownership (Dorman et al., 1995).
Severe psychological stress has profound effects on the immune system and may
predispose to !DOM (Rossini et al., 1993). Accute stress has been shown to accelerate the
onset of !DOM in non-obese diabetic mice (Bach, 1994). Physical, psychological, and
social stress may influence onset of !DOM in humans, as well. In a case control study
investigating multiple environmental risk factors, the most significant finding was the
increased risk associated with social and psychological dysfunction in children and to a
lesser extent, a physical or socially stressful event within 12 months preceding onset of
clinical disease symptoms (Siemiatycki, Colle, Campbell, De War, & Belmonte, 1989).
Life events such as accidents, pregnancy, and other personal problems frequently occurred
within a year prior to diagnosis of !DOM (Dorman et al., 1995). In a Hungarian study ,
questionanaires were sent by mail to diabetic farnilies to gain knowledge of family
characteristics, social status, feta! and perinatal events, breast-feeding practices, infectious
diseases, and stressful life events (Soltesz, Jeges , Dahlquist, & the Hungarian Childhood
Diabetes Epidemiology Study Group, 1994). A higher number of diabetic children , in
particular, those diagnosed between 10 and 14 years of age, reported a higher number of
stressful life events(£= 0.016, odds ratio= 3.9) . This reflected the greatest association
with !DOM for any of the parameters studied.
Severe psychological stress increases insulin requirements due to increased cortisol
and catacholamine release. The antagonistic effects of these hormones on insulin appear
to accelerate or precipitate the onset of clinical disease symptoms (Blom et al., 1989;
Dahlquist, 1994). In addition, increased glucose levels in response to stress may increase
the metabolic activity of pancreatic beta cells and, therefore, make the beta-cell more
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Several mechanisms have been proposed that address the pathological role of
viruses in IDDM. Viruses may exert direct cytol}tic effects on the pancreatic beta-cells
(Bach , 1994) or may exert their effects indirectly by altering normal immune tolerance and
competence (Rossini et al., 1993). Viruses are associated 1,vith elevated lymphokines. The
lymphokines, in tum, may cause an inflammatory response that is damaging the pancreatic
beta-cells (Dahlquist, 1994). Defects in immune tolerance could occur in combination with
a T-cell immune reaction to viral neoantigens on the cell surface. Viral induced T-cell
. activation may be necessary for development of diabetes, at least in some cases (Bach,
1994). The beta-cell protein p69, a known autoantigen, is detected on the surface of the
beta-cell during times of stress such as a viral infection (McCarren, 1992). Molecular
mimicry following a viral insult could occur where a nontolerized exogenous antigen crossreacts with a tolerized antigen and breaks tolerance (Bach, 1994). Alternately, Dosch
( 1993) suggested that repeated viral infections eventually take their tole on the beta-cells.
The combination of genetic, immunological, and multiple environmental events could
explain why an insult in infancy results in the manifestation of clinical diabetes at different
ages indifferent children.
Coxsackie virus, which has been associated with increased prevalence of IDDM,
appears to exert its effects by the process of molecular mimicry described above.
Co xsackie virus (PC-2 protein) has regions homologous to glutamic acid decarboxylase, a
known beta-cell autoantigen (Bach , 1994). An immune system primed to attack Coxsackie
virus may attack the glutamic acid decarboxylase beta-cell protein (Mccarren, 1992;
Rossini et al., 1993). In addition, interaction between genetic predisposition and
environment has been demonstrated by an increase in the prevalence of Coxsackie 8 virus
in DR3 positive versus DR3 negative patients with IDDM (Dorman et al., 1995).
Similarly, cytomegalovirus may lead to expression of viral or host antigens on the beta-cell
surface, resulting in the production of islet cell antibodies, or antibodies to cytomegalovirus

43
may recognize both host and viral antigens by the process of molecular mimicry (Donnan
et al., 1995). Congenital cytomegalovirus is associated with the development of !DOM,
usually by age 15 (Dahlquist, 1994).
Congenital rubella has a 13 to 40% prevalence of !DOM (Blom et al., 1989). The
highest frequency of IDDM associated with congenital rubella is seen in those that are also
HLA-DR3 and/or DR4 positive (Dorman et al., 1995). Rubella is known to multiply in the
pancreas and cause lesions to the beta-cells (Tuomilehto & Wolf, 1987). A temporal
relationship also exists between mumps and the development of IDDM. In a population of
diabetics, over 50% were exposed to the mumps virus within 4 years preceding the
diagnosis of IDDM (Dorman et al., 1995). ·An aggressive immunization program against
rubella and mumps, the MMR (measles, mumps, and rubella) vaccine currently used in the
United States, was implemented in Finland in 1982. Some have postulated that the
continued rising incidence of IDDM, despite successful public health programs promoting
breast-feeding, may be caused by the very immunization program targeted to reduce the
risk of !DOM.
Viral infections may also serve a protective role. Viruses could promote the
production of immunosuppress1ve cytokines (Bach, 1994). Todd (1990) has reported that
infection and the resulting stimulation of the immune system may reduce susceptibility to
!DOM in some cases. While the north-south gradient may expose to predisposing viral
infections in the northern sector, increased incidence of Hepatitis A and cytomegalovirus in
the southern tiers may be protective. This 1s supported by a similar north-south gradient
observed for multiple sclerosis, another T-cell-mediated autoimmune disease. The
mycobacteria Bacillus-Calmette-Guerin has been used as a vaccine in rodent models and
has shown some therapeutic promise in preventing IDDM (Bach, 1994).
Currently, no concrete evidence exists for a direct pathogenic role of a virus in
IDDM (Bach, 1994). There is only limited evidence associating viral infection or exposure
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with the presence of islet cell antibodies (Lipton & LaPorte, 1989). Despite this , the viral
contribution to IDDM remains central to pathogenesis of the disease (Bach, 1994).

Nutritional Factors
The role of diet has been both controversial and difficult to evaluate. The long
latent penod prior to the onset of clinical disease symptoms makes it difficult to determine
which dietary components may be diabetogenic (Scott, 1994). A single nutrient approach
to studying the effects of diet on IDDM, particularly in epidemiological studies, may be too
simplistic (Scott, 1994). Dietary factors may serve as catalysts for mduction of !DOM
(Coleman, Kuzava, & Leiter, 1990).
Diet has been demonstrated to modify the incidence of diabetes, and impact age of
onset of IDDM and the degree of associated insulinitis in experimental animal studies
(Hoorfar, Bushard, & Dagnaes-Hansen, 1993). As much as 85% of diabetes in the
spontaneously diabetic biobreed rat appears to be dependent on dietary exposures (Scott,
1994). Ell ion and Martin ( 1984) were the first to demonstrate that dietary proteins, in
particular wheat and milk proteins, fed during the weaning period could impact progression
to diabetes in biobreed rats. The incidence of IDDM in rats fed a synthetic diet containing
hydrolyzed proteins was significantly lower than in rats fed a diet supplemented with gluten
or milk ( 15%, 35% , and 52% incidence of IDDM, respectively). Intact protein was
concluded to be necessary for full expression of genetic susceptibility to !DOM in the
biobreed rat (Elliott & Martin, 1984). In non-obese diabetic mice, the window of
vulnerability to diabetogenic dietary constituents occurs between weaning and 70 days of
age (Hoorfar et al., 1992). The impact of nutritional factors may be limited to a relatively
narrow, early phase of the postnatal period.
These observations have been applied to numerous human epidemiological,
experimental, and case control studies that have attempted to evaluate the role of infant
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protein intake was previously low (Tuomilehto & Wolf, 1987). The protective effect of
feeding a casein hydrolysate in the prevention of IDDM in the biobreed rat and non-obese
diabetic mouse would appear to be the lack of intact protein and, therefore , diabetogenic
antigens (Elliott, Reddy , Bibby, & Kida, 1988; Hoorfar et al. , 1993).
A great deal of research has been directed toward reaching an understanding of the
role of various cow's milk proteins in the pathogenesis of IDDM. At least some milk
proteins appear to function as diabetogenic antigens. The role of specific milk proteins in
the pathogenesis of IDDM is discussed under the section entitled "Infant Feeding Practices:
Breast-feeding and Early Intrcxluction of Cow's-Milk-Based Infant Formula in the
Pathogenesis of Insulin Dependent Diabetes Mellitus."
Wheat
Animal studies have shown that cereal-based rcxlent diets are the most diabetogenic
(Hoorfar et al ., 1992; Scott & Marliss, 1991). Preliminary findings from Austrailia
suggest that high consumption of cereals is associated with increased risk of IDDM
(Virtanen & Aro, 1994). Long-term ad libitum feeding of wheat flour has consistently
been associated with a diabetes incidence of 40 to 65% in the biobreed rat and non-obese
diabetic mouse strains (Elliott & Martin, 1984; Hoorfar et al., 1993; Scott et al., 1989).
Foods rich in carbohydrate are typically rich in wheat gliadin. The increased incidence of
IDDM observed in children with higher carbohydrate intakes may support the hypothesis
that wheat gliadin is harmful to the beta-cell (Dahlquist et al ., 1990). Celiac disease and
IDDM have been shown to coexist. Both diseases are associated with HLA DR3 and DQ.
The potential impact of the gliadin fraction of gluten, which is responsible for celiac
disease, in the pathogenesis of IDDM was first proposed by Scott and colleagues ( 1989).
Provision of wheat gluten to biobreed rats resulted in a significantly greater incidence of
IDDM than in the casein-fed control group. In children diagnosed with IDDM, over half
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had increased levels of lgG anti-gliadin antibodies despite the absence of clinical symptoms
of celiac disease (Scott et al ., 1989) .

Expenmental animal studies have linked soy feeding to !DOM. Long-tenn ad

Ii bi tum feeding with soy bean meal m non-obese diabetic mice has been associated with a
relatively high incidence of diabetes (45%) (Hoorfar et al., 1993). In the biobreed rat, soy
administration resulted in at least a 50% incidence of !DOM with up to an 80% frequency
of insulinitis (Scott, 1994).
Soy formulas are commonly used in children with allergies to intact cow's milk
protein with or without alterations in gastrointestinal function. Approximately 8 to 25% of
children with hypersensitivity to cow's-milk-based proteins are allergic to soy prcxiucts
(Kleinman, Bahna, Powell, & Sampson, 1991). Viral infections may precipitate the use of
soy formulas due to alterations in the mucosa! lining and absorption (Fort et al., 1986).
Children given soy milk may exhibit increased gut permeability to antigens due to
preexisting viral infection, diarrhea, lactose intolerance, or milk allergy. Soy protein is at
least as antigenic as milk protein and should be used with caution as prophylaxis against
possible dietary antigen/antibody-related disease (Eastham, Luchauco, Grady, & Walker,
1978) . These factors may contribute to an autoimmune response to a foreign protein, such
as bovine serum albumin, implicated in the pathogenesis of !DOM. Diabetic children have
been reported to be twice as likely to have received soy formula in infancy as compared to
control children (Fort et al., 1986). Soy formula is clearly not a viable alternative to
polymeric cow's-milk-based infant formulas
for prophylaxis against IDDM.
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Fat
Dietary lipids have long been recognized as potent immune system regulators. Cell
membrane composition can be altered by the degree of saturation of dietary fats potentially
resulting in changes in membrane Ouidity and function . Effects of varying the
polyunsaturated to saturated fat ratio (P/S) of the diet include altered membrane
phospholipid content, B-lymphocytes, resistance to tolerance, suppressor activity , and
T-cell dependent immune responses (Scott & Marliss, 1991). Omega-3 polyunsaturated
fatty acids are potent immunosuppressants. They function as a competitive inhibitor for
cyclo-oxygenase, resulting in a decrease in thromboxane synthesis. Supplementation of
diets with omega-3 polyunsaturated fatty acids has been shown to suppress the synthesis of
several cytokines (interleukin-la, interleukin-lB, and tumor necrosis factor) . InterleukinlB has been reported to be toxic to beta-cells (Rossini et al., 1993). In addition , studies
using fish oil supplements have shown a reduction in the production of monokines,
including interleukin-I and tumor necrosis factor (Scott & Marliss, 1991). Diets low in
essential fatty acids and protein may be protective against IDDM by interfering with the
anti-islet immune response (Bach, 1994).
Nitroso Compounds
Exposure to dietary nitrates, nitrites, and nitrosamines may increase the risk of
developing IDDM (Blom et al., 1989; Tuomilehto et al., 1995). Streptozocin (STZ) and
the rodenticide Vacor, both N-nitroso compounds, are experimental diabetogenic agents
(Siemiatycki et al., 1989). Streptozocin is thought to act as a hapten in vivo, resulting in
T-cell activation, lymphokine secretion, and subtoxic effects potentially exerted directly on
the beta-cell (Scott & Marliss, 1991). N-nitrosothiazolidine (NTHZ) and 3-nitrosothiazolidine-4-carboxylic acid (NTCA) have been shown to increase plasma glucose levels
in mice following a single injection under experimental conditions (Scott, 1994). Alloxan
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can also induce IDDM (Bach, 1994). Nitrosamine compounds are toxic to beta-cells
(Dahlquist, 1994) and have been associated with a higher risk of IDDM in several studies
(Virtanen & Aro, 1994).
These findings have raised some questions as to the diabetogenicity of cured meat
prcxiucts. In the Icelandic population, increased incidence of IDDM in boys born in
October may be correlated with periconceptuaJ intake of smoked cured mutton during the
Christmas holidays. This hypothesis proposes that periconceptual intake of nitrates may
impact the beta-cells in utero with a long latency pericxi of approximately 15 years pnor to
expression of overt clinical disease (Tuomilehto & Wolf, 1987). In Finnish children a
high dietary intake of nitrite, but not nitrate, was associated with greater risk of developing
IDDM (Virtanen & Aro, 1994). The incidence of IDDM has been correlated with the nitrate
content of drinking water (Dahlquist, 1994). A dose response relationship has also been
observed between frequency of intake offocxis containing nitrosamine and the risk of
children developing IDDM (Dahlquist et al., 1990). Historically there has been a low
prevalence of IDDM in primitive societies that do not use fcxxi preservation such as
nitrosamines (David et al., 1994); however, the results have been mixed. A case control
study of environmental risk factors for IDDM showed no increased risk associated with
intake of meats preserved with nitrates (Siemiatycki et al., 1989).
VitaminC
While there has been some concern that degraded vitamin C may accelerate beta-cell
damage, the antioxidant effects of vitamin C may, in fact, be protective. Ascorbic acid may
scavenge free radicals that have been implicated in beta-cell damage (Glatthaar et al., 1988).
Free radical scavengers could partially suppress the cytotoxic activity of macrophages
toward islet cells (Scott & Marliss, 1991 ). Descriptive epidemiology of the childhood
diabetic population in Australia showed that the greatest difference between cases and
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controls was the more frequently reported intake of vitamin C in controls (Glalthaar et al. ,
1988). Others have reported no significant differences in vitamin C intake in diabetic
children compared to controls (Dahlquist et al., 1990).

Summary of the Role of Environment in the Etiology of !DOM
The large variation in the incidence of !DOM among population groups with similar
genetic charactenstics points to the influence of environmental factors which initiate and
sustain the diabetic autoimmunity or confer protection from the disease. The search to
identify etiological environmental factors contributing to !DOM contmues. Clearly stress ,
viruses, and nutritional practices play a role in the pathogenesis of IDDM. The potential for
interaction of several environmental factors with genetic predeterminants of risk cannot be
overlooked in the attempt to unravel the complex autoimmune pathogenesis of !DOM.
INFANT FEEDING PRACTICES: BREAST-FEEDING AND
EARLY INTRODUCTION OF COW'S-MILK-BASED
INFANT FORMULA IN THE PATHOGENESIS OF
INSULIN DEPENDENT DIABETES NtELLITUS
Infant feeding practices resulting in early exposure to a number of food antigens has
been a major area offocus of research in the pathogenesis of IDDM over the past 20 years.
The proposed theory suggests that exposure to environmental events occurs over a limited
period in early childhood. The variable age of presentation of !DOM reflects different rates
of disease progression rather than different ages of critical environmental exposure (David
et al., 1994). Sensitization to a dietary antigen could occur either prior to gut closure
and/or following an acute gastrointestinal infection.
Cow's milk carries the reputation of being one of the most allergenic foods given to
infants . Unfortunatelv, cow's-milk-based infant formulas are often introduced early in !ife
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as an alternative to breast-feeding. While cow's-milk-based formulas are the mainstay o f
nutrition for bonle-fed infants and provide supplemental feedings for infants not
exclusively breast-fed, early exposure to dietary antigens remains an area of concern.
Specific milk proteins, in particular bovine serum albumin (BSA), have been implicated in
the pathogenesis of IDDM.
The impact of breast-feeding, duration of breast-feeding, and early introduction o f
cow's-milk-based infant formulas on the pathogenesis of IDDM will be reviewed in detail
in the following sections. An in-depth review of the literature supporting and refuting the
role of BSA in the pathogenesis of IDDM is provided. Specific attention is given to the
mechanism by which BSA contributes to IDDM and its interaction with predisposing
genetic characteristics in the autoimmune pathogenesis of IDDM.
Physiology of the Gastrointestinal Tract in Infancy
The gastrointestinal tract is not fully developed at birth even in term infants.
Age dependent changes in gut permeability to macromolecules (e.g., cow's milk proteins) ,
maturation of gastrointestinal proteases, slow maturation of the intestinal barrier, and gutbased tolerance to foreign proteins occur over the first year of life (Akerblom, Savilahti , et
al., 1993 ). Notable immaturity of the gastrointestinal tract is observed with increasing
prematurity.
Digestion and absorption of dietary protein occur in three phases. The initial phase ,
which occurs in the stomach and gut lumen, involves breakdown of intact protein to free
amino acids and short peptides. The second phase occurs at the brush border of the
enterocyte where brush border peptidases attack peptides. Free amino acids and peptides
are transported into the mucosa! cell by four major ammo acid transporters and more than
one peptide transporter. The final stage occurs in the cytoplasm of the enterocyte where
di peptides and tripeptides are broken down to free amino acids by cytoplasmic enzymes.
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IgA locally in the small intestine. Circulating antibodies to ingested food proteins can be
detected in almost all infants during the first 3 months of life due to a systemic
1mmunological response to proteins absorbed from the small intestine (Eastham et al.,
1978). Normally the immune system learns to tolerate foreign proteins that enter the body

through the gastrointestinal tract or mounts only a mild ineffect1ve assault against them
(Rennie, 1992). This is reported to be of little pathological significance (Eastham et al. ,
1978). Slow maturation of the intestinal immunological barrier against dietary

macromolecules, in particular potential antigens, occurs in infancy (Akerblom, Savtlahti, et
al., 1993; Fourth International Onnela Workshop, 1990). In addition, development of host
non-immunologic and immunologic defense mechanisms further protects against uptake of
antigenic macromolecules (Fourth International Onnela Workshop, 1990).
Gas troen teri tis
Functional and structural alterations in the mucosa[ barrier may occur due to
malnutrition, acute gastroenteritis, cow's milk allergy, and enzyme deficiencies and result
in increased absorption of macromolecules (Fourth International Onnela Workshop, 1990).
Gut permeability can be increased temporarily due to diarrhea (Akerblom, Savilahti, et al.,
1993). Transient changes in the gut mucous associated with episodes of gastroenteritis

permit passage of intact dietary proteins that may function as antigens raising antibodies to
a number of dietary constituents. Acute gastroenteritis in children less than 3 years of age
results in increased protein absorption, which may trigger food allergy, in particular,
allergy to cow's milk proteins. Human a-lactalbumin serum concentrations in children
during the acute phase of rotaviral gastroenteritis have been shown to be similar to those of
healthy children, but rise significantly ( Q < 0.001) during the 5- to 8-week period of
convalescence (Holm, Andersson, Gothfors, & Lindberg, 1992). Damage to the intestinal
epithelium by infections (e.g. , retroviral insults) may lead to an excess passage of intact
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cow's milk protein into the blood stream and increase antibody production in response to
BSA (Norris & Pietropaola, 1994). Siemiatycki and colleagues ( 1989) have reported a
higher incidence of recent gastrointestinal infections in newly diagnosed cases of IDDM.
Cow's Milk Allergy
An apparent feature of gastrointestinal syndromes accompanied by diarrhea dunng
the first year of life is a considerable overlap between characteristics, symptoms, findings,
and etiology. Nonspecific vomiting, colic, and diarrhea can occur in infants without
immune-mediated reactions to dietary antigens and are thought to occur due to increased
intestinal permeability. Gastrointestinal blood loss, protein losing nephropathy,
enterocolitis, colitis, and malabsorptive syndrome result from allergic reactions to dietary
antigens that occur in infancy. Each of these symptoms has been at one time attributed to
intake of cow's milk protein (Kleinman et al., 1991).
Cow's milk allergy is estimated to affect 0.4% to 7.5% of all infants (Bahma, l 9f!>7 ;
Kleinman et al., 1991). Infants present with malabsorptive syndrome characteriszed by
protracted diarrhea, carbohydrate and fat malabsorption , small intestine villous atrophy ,
and patchy enteropathy (Kleinman et al ., 1991). Enterocolitis is usually seen in infants
between the ages of 1 week and 3 months. Infants present with occult blood, leukocytes,
and eostnophils in stool specimens. This 1s accompanied by carbohydrate intolerance and
watery diarrhea. Peripheral polymorphonuclear leukocytosis is often seen. This results
commonly from immune-mediated allergic reaction to cow's milk, but has been observed
with other intact protein antigens (Kleinman et al., 1991) . Elemental , hydrolyzed formulas
are indicated for use in both the management of malabsorption and to reduce exposure to
intact antigenic proteins. However, it appears that some residual antigenicity remains even
after extensive fragmentation of the protein (Seban, Konijn, & Freier, 1977). Despite these
findings showing increased antigen permeability with diarrhea and milk allergy, a positive
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history of allergy or gastroenteritis has not been reported to be associated \\<ith elevated
antibody titres to cow's milk proteins in diabetics, sibling-controls, or population controls
(Virtanen et al., 1994).

Lactose Intolerance
Chronic diarrhea and alterations in the gastrointestinal mucosa resulting in lactase
deficiency may alter gut penneability to peptides. While lactose intolerance has not been
directly linked to the pathogenesis of !DOM, it is interesting to note a fairly high incidence
of late onset lactose intolerance is observed in Finnish children, a population previously
noted to have the highest worldwide incidence of !DOM. Prevalence of lactose intolerance
of late-onset is reported to be 4% in 7- to 11-year-olds, 9% in 12- to 15-year-olds, and
15% in 16- to 20-year-olds (Fourth International Onnela Workshop, 1990). In
populations where genetic lactose intolerance is prevalent (e.g., Japanese, Australian
Aborigines, and Native Americans), milk consumption is avoided, and the incidence of
!DOM is far less than would be expected by genetic profile and the presence of lactose
intolerance (Strand, 1994). However, in Finland and other areas where milk consumption
is high and lactose intolerance has been reported, evaluation of the prevalence of lactose
intolerance m diabetic children compared to non-diabetic children may be warranted.
Summarv of the Phvsiologv of the Gastrointestinal Tract in lnfancv
Antigen penneability appears to occur in infancy prior to gut closure, following an
episode of acute gastroenteritis or due to gastrointestinal damage associated with milk
allergy or intolerance. · Decreased mucosa! lgA and immaturity of the immunological
tolerance mechanism may result in an immunological response to a foreign dietary antigen.
Abnormal immunological responses to the exogenous antigen could trigger diabetic
autoimmunity and subsequent pancreatic beta-cell destruction leading to insulin deficiency.
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the duration of breast-feeding and the age of introduction of supplementary formula
feedings increased between 1972 and 1982. Breast-feeding practices were shown to
correlate inversely with the incidence of IDDM. In addition, international patterns of
breast-feeding prevalence at 3 months of age are inversely related to the prevalence of
IDDM between countries(£= -0.53; g < 0 .05).
Case-Control Studies
Case-control data lend support to cross-sectional national comparison studies that
suggest a relationship between breast-feeding practices and prevalence of IDDM. Children
who developed diabetes have been reported to be completely or partially breast-fed for a
significantly shorter period of time than their healthy siblings and the background
population. In addition , fewer diabetic children had ever received breast milk (BorschJohnson et al., 1984). Similarly, Metcalfe and Baum ( 1992) reported a significant
difference(£< 0.01) in breast-feeding incidence and duration between a large sample of
index cases of IDDM compared to the reference population obtained from breast-feeding
statislics in the British Isles. In comparison , a descriptive epidemiological report of IDDM
in Australian children revealed that only a marginally significant excess of diabetic children
had not been breast-fed at all or failed to be breast-fed beyond 1 week. However, there is a
relatively low frequency of breast-feeding in the Australian population as compared to the
Scandinavian population (Glanhaar et al., 1988). Similarly, Samuelsson and colleagues
( 1993) report a marginal role, if any , of breast-feeding in the prevention of IDDM, again in
a population with low breast-feeding rates. The relationship of infant feeding practices to
childhood diabetes suggest that a longer duration of breast-feeding is associated with a
lower risk for developing diabetes (Verge, Howard, Irwig, Simpson, & Silink, 1992).
Breast-feeding duration of less than 3 months has been associated with an increased
risk of IDDM in a number of retrospective, case-control studies. A negative relationship
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has been reported between ~reast-feeding at 3 months of age and risk of developing IDDM
(Q < 0.05; Scott, 1990; Verge et al., 1992; V1rtanen, Rasanen , Aro, Lindstrom , Sippola, et

al., 1991 ; Virtanen, Rasanen, Aro, Lindstrom, Tuomilehto, et al., 1991; Virtanen et al.,
1992). Risk of developing diabetes was reported to be reduced in children who \Vere

breast-fed during infancy for at least the first 2 to 3 months (odds ratio 0 .60 and 0.63
respectively) (Virtanen, et al., 1992). In Finnish children presenting with overt clinical
diabetes prior to age 7, a significantly smaller portion of diabetic children were breast-fed
compared to control children at each interval evaluated: 3 months (75% vs. 89%, Q < 0.04)
and 4 months (43% vs. 61 %, Q < 0.04). Given the infant feeding practices of Finnish
children and the incidence of diabetes diagnosed prior to age 7, it would appear that the
proportion of children exclusively breast-fed is limited and may be an associated factor of
disease risk (Virtanen, Rasanen, Aro, Lindstrom, Sippola, et al ., 1991; Virtanen,
Rasanen, Aro, Lindstrom, Tuomilehto, et al ., 1991). In addition, exclusive breast feeding
for 3 months or more has been demonstrated to have a significant protective effect against
the development of IDDM (Verge et al., 1992), while breast-feeding of less than 3 months
has been cited as a risk factor for IDDM (Blom et al., 1989).
In populations having a higher frequency and duration of breast-feeding, the
impact of a longer duration of breast-feeding on IDDM could be evaluated. In a
retrospective case-control study of 268 children selected from the Colorado IDDM Registry
and the Barbara Davis Center for Childhood Diabetes, a significantly smaller portion of
children with diabetes (30%) had been breast-fed. In addition, the group that was breastfed for a shorter duration also had an increased incidence of IDDM. A greater decrease in
this risk of IDDM was seen in those infants breast-fed for 12 months or more (Mayer et al.,
1988). The incidence and duration of breast-feeding was higher in this population than

other populations reporting both association and Jack of correlation between breast-feeding
and incidence of IDDM.
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Early exposure to cow's milk

in

the diet and/or short duration of breast-feeding may

lead to increased risk of development of IDDM (Verge et al., 1992). Blom and colleagues
( 1989) evaluated the effect of both partial and exclusive breast-feeding and the associated
risk of !DOM. Even though, breast-feeding of less than 3 months was cited as a risk
factor for developing !DOM, no significant differences in the time of introduction of infant
formula \Vas noted between diabetic and non-diabetic children. Here , breast-feeding
appeared to have a protective effect independent of age of introduction of cow's-milkbased infant formula
It appears that the benefits of breast-feeding in the prevention of IDDM may be
more strongly related to diabetes that develops early in childhood. In a multivariate
analysis of children by age-group, breast-feeding duration of less than 3 months was a
significant risk determinant for diabetes in the 0 to 4 age group (Dahlquist et al ., 1991).
The impact of short duration of breast-feeding did not carry over to the older age brackets.
Similar findings were reported by Blom and colleagues ( 1989). In children 0 to 6 years of
age, the duration of breast-feeding was significantly shorter for the diabetic children
compared to controls (Q = 0.03). The median duration of breast-feeding for diabetic
children was 5 months, l month shorter than the control children. The impact of breastfeeding was not significant in the 7 to 14 year age group (Blom et al., 1989). In children
\vi th !DOM, diabetes developed at a later age in those that were breast-fed as infants
compared to those receiving breast-milk substitutes.
Meta-analysis of Breast-Feeding and Incidence
of Insulin Dependent Diabetes Mellitus
Meta-analysis can be used to combine the results of clinical trials and observational
studies and obtain a summary risk estimate suitable for discussions of causality and
development of health policy (Kostraba, 1994). In a recent meta-analysis by Gerstein
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( 1994), decreased incidence and duration of breast-feeding was consistently related to
!DOM in ecological and time-series studies in which the prevalence of !DOM was
compared to the rate of breast-feeding in different populations over a specified penod of
time . Case-control studies, in which neonatal feeding histories of patients with !DOM were
compared to control subjects, showed that patients with diabetes were more likely to have
been breast-fed in infancy for an interval of less than 3 months. A weak, but significant
association between infant feeding practices and the risk of IDDM was reported (odds ratio
1.5) (Gerstein, 1994). In a separate meta-analysis, reviewing similar studies, the amount
of IDDM that could be explained by breast-feeding practices if these practices were causal
was reported to be 14% and ranged from 2 to 26% according to breast-feeding prevalence
reported in each study (Mayer et al ., 1988). Similarly, Scott (1994) reported that as much
as 14% of IDDM may be attributed to a lack of breast-feeding. Children with IDDM were
less likely to have been breast-fed or were breast-fed for a shorter period of time.
Lack of Association Between Breast-Feeding and Risk of
Developing Insulin Dependent Diabetes Mellitus
In contrast to studies supporting a protective effect of breast-feeding, others have
reported little if any association between breast-feeding incidence and duration and later
development of IDDM in childhood. A case-control study of 268 children developing
IDDM prior to age 15 in the United Kingdom found that short duration of breast-feeding,
defined as partial or exclusive breast-feeding of less than 3 months , had no inlluence on the
incidence of IDDM (Bodington, McNally, & Burden, 1994).

Similarly, in another

comparison of breast-feeding rates in diabetic probands with non-diabetic siblings and pairmatched controls, no difference in breast-feeding rates was observed between the three
groups (Fort et al., 1986). Breast-feeding incidence was only 18% in all three groups
(Fort et al., 1986), which was notably low compared with national and regional data
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(Mayer et al., 1988). As previously noted , where the prevalence and duration of breastfeeding is low, it 1s difficult to determine the impact, if any, of breast-feeding on the
incidence of !DOM.
Studies relating breast-feeding practices to incidence of !DOM have been cnt1cized
because much of the data has been based on parental recall many years after the fact (Ellis
& Atkinson, 1996). Only two studies on breast-feeding reported in the literature have used
data on the duration of breast-feeding that was collected during infancy, rather than after the
diagnosis of diabetes (Kyvik et al., 1992; Nigro, Campea, De Novellis, & Orsini, 1985) .
Kyv1k and colleagues ( 1992) failed to find evidence to support the hypothesis that
increased duration of breast-feeding reduces subsequent risk of developing IDDM. Nigro
and colleagues ( 1985), found that diabetic children had in fact been breast-fed slightly
longer than the background population. These studies do not support the results reported
in retrospective studies that relied on long-term recall to establish the history of infant
feeding practices (Kostraba, 1994). Accuracy of recall in reporting infant feeding practices
retrospectively and the potential of bias due to a known diagnosis of !DOM may impact
results.
Abrams. Schrans, Vertommen, and De Leeuw ( 1994) looked specifically at those
diagnosed with !DOM between 15 to 40 years of age for a relationship between infant
feeding practices and autoimmune aggression (i .e., islet cell antibodies, insulin
autoantibodies, and C-peptide concentrations) . While a small, but significant protective
effect of breast-feeding has been observed in children who develop diabetes between the
ages of 0 and 15 (Gerstein, 1994), there were no significant differences related to the mode
of infant feeding in autoimmune aggression, C-peptide levels, and age of diagnosis of
!DOM (Abrams et al., 1994). However, in those with clinical diabetes it would seem
unlikely that these general pathological findings would differ regardless of infant feeding
practices. These results are not surprising given that the studies previously reporting a
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which could have direct effects or alter normal gastrointestinal function (Scott, 1994).
Human colostrum protects the infant against early gastrointestinal infections (Samuelsson et
al., 1993) . Breast milk compensates for the deficiency of local gut immunoglobin
production during early infancy, further protecting the infant from gastrointestinal
infections (Akerblom, Dosch, et al., 1993). Improved anti-inflammatory response,
decreased free radical production, and increased free radical scavengers delivered to breastfed infants may decrease the intracellular immune response and beta-cell destruction (Mayer
et al., 1988). In addition, mothers who breast-feed longer are less likely to smoke or to
have children in daycare (ESPGAN Committee on Nutrition et al., 1993). Both of these
factors may decrease risk of IDDM by protecting against exposure to viral infections
independent of breast-milk composition.
Decreased Exposure to Exogenous Food Antigens
An alternative explanation is that chemicals or proteins present in infant formula
may be directly or indirectly damaging to the beta-cells (Borsch-Johnson et al., 1984).
Mothers who breast-feed longer are more likely to delay introduction of solid foods
(ESPGAN Committee on Nutrition et al., 1993), a number of which have been cited as
potential antigenic triggers of IDDM. Breast-fed infants are less likely to receive solids
prior to 3 months of age and are exposed to a less diverse diet in terms offood antigens
(Kostraba, 1994). Introduction of solid foods prior to 3 months of age is associated with a
highly significant 2.5 fold increased nsk of IDDM (Kostraba et al., 1992).
Growth Patterns in Breast-Fed and Formula-Fed Infants
Breast-feeding may exert its protective effect by limiting weight gain in infancy as
compared to formula feeding (Samuelsson et al., 1993). Children who are exclusively
breast-fed have a lower energy intake. This results in a lower rate of growth after 3 months
of age (Fomon, Thomas, Filer, Ziegler, & Leonard, 1971; Hithcock, Gracey, & Gilmour,
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1985). Increased weight gain in infancy due to supplemental formula feeding could
increase insulin demand and serve as a contributing environmental factor in the
pathogenesis of IDDM (Yirtanen & Aro, 1994).
The DARLING Study (Davis Area Research on Lactation, Infant Nutrition , and
Growth) found that growth differences were related to intake and were higher in the
formula-fed infants than in the breast-fed infants between 3 and 9 months of age . Intake
was consistently and significantly higher in formula-fed than in breast-fed infants. Once
solids were introduced, total calorie and protein intake remained significantly higher in the
formula-fed infants; however, the percent of total calories contributed by either breast milk
or formula did not differ significantly. Breast-fed infants, however, exhibited a greater
percentage gain in lean body mass (Heinig, Nommsen, Peerson, Lonnerdal , & Dewey ,
1993).
In a similar study conducted by Johansson , Samuelsson, and Ludvigsson ( 1994) ,
growth patterns were evaluated in 297 children who had been diagnosed with !DOM and
compared to reference children. Birth weight in children who developed diabetes was less
than reference children; however, rate of growth and weight gain at 6 , 9, 18, and 30
months was significantly greater in the diabetic children (Q < 0 .02) . There was also a
correlation between formula feeding and weight gain , which has also been observed in the
general population. Weight gain of children who had not been breast-fed was significantly
greater for both diabetic and control children . Children developing diabetes in the 0 to 4
age category had the lowest birth weights but showed rapid weight gain in infancy
(Johansson et al., 1994). In contrast, Metcalfe and Baum (1992) reported that children
who developed diabetes were more likely to be heavier at birth compared to the national
reference data from the British Isles. Among those exclusively breast-fed for greater than 2
months, diabetic children gained significantly more weight (Johansson et al., 1994) . These
findings support earlier work conducted by Baum, Ounsted, and Smith ( 1975) reporting

Breast-Feeding Patterns of Wo men \vith Insulin
Dependent Diabetes Mellitus

Women \vi th !DOM discontinue breast-feeding and intrcxiuce fonnula significantly
earlier than non-diabetic mothers. The mean duration of breast-feeding was reported to be

22 days in diabetic mothers compared to 52 days in non-diabetic women (Ferris et al .,
1993). These observations are further supported by a Finnish pilot study of the feasibility

of avoidance of intact cow's milk protein during infancy. Only 1 of 20 infants o f mothers
with !DOM exclusively breast-fed for 6 months (Akerblom, Savilahti , et al. , 1993) .
Unfortunately,mothers with !DOM are more likely to supplement formula earlier than
non-diabetic mothers despite intentions to breast-feed at a similar rate (Gerstein , Simpson ,
Atkinson, Taylor, & VanderMeulen, 1995). This is notable in that the risk of IDDM is
significantly higher in first degree relatives. The interaction of genetic predisposition with
lack of breast-feeding, supplementation with cow's-milk based-infant formulas, and early
intrcxiuction of solids may pose increased risk for the infant of contracting !DOM in
childhocxi.
Comment on Breast-Feeding Studies
Exclusive breast-feeding appears to be limited. Only two of the studies reviewed
above reported on exclusive breast-feeding (Virtanen, Rasanen, Aro, Lindstrom , Sippola,
et al., 1991; Virtanen, Rasanen , Aro, Lindstrom , Tuomilehto, et al. , 1991 ; Virtanen et al. ,
1992) . In a recent f easib11ity study of mothers already having one diabetic child , ITT%

indicated that their next child would be breast-fed . Of those planning to breast-feed, only
5 .6 % reported plans to exclusively breast-feed for more than 2 months (Gerstein et al. ,
1995). One apparent confounding factor in most studies is that they fail to consider

duration of exclusive breast-feeding rather than duration of breast-feeding despite
intrcxiuction of supplemental feedings. It is only exclusive breast-feeding that protects

67
from cow's milk and other foreign dietary proteins (Akerblom, Savilaht1, et al., 1993).
Intrcxiuction of cow's-milk-based formula, as full or supplemental feedings, provides
dietary antigens that have been associated with an increased risk of developing !DOM later
in childhood. An increased caloric load and insulin response may prime the pancreas
making the beta-cells targets for autoimmune attack and destruction . Most studies failed to
take into account age of intrcxiuction of supplemental formula feedings , the type of formula
introduced, and other foods consumed by the infant within the first year of life independent
of breast-feeding practices. Therefore, the likelihood of contammation and confoundmg of
study results with cow's-milk-based formula exists. Enough cow's milk could have been
provided as supplemental feedings to breast-fed infants to elicit the autoimmune response
leading to IDDM. History of cow's milk exposure prior to 3 to 4 months of age with
supplemental feedings may have a greater influence on the pathogenesis of IDDM than the
total duration of breast-feeding. The duration of breast-feeding may not be as important 10
the etiology of IDDM as the age of introduction of breast-milk substitutes, in particular
cow's-milk-based infant formula.
Cow's Milk and Cow's-Milk-Based Infant Formula
Considerable attention, in both the scientific and lay literature, has been focused on
the potential contribution of cow's milk to the autoimmune pathogenesis of IDDM. The
process of autoimmunity induced by milk proteins is thought to result from formation of
immunological memory cells and increased antibody production in response to cow 's milk
proteins followed by a cross-reactive immune response with a protein on the pancreatic
beta-cells (Virtanen et al ., 1994). Through this mechanism, known as molecular
mimicry, the ability to produce insulin fails resulting in clinical IDDM. Exposure to cow's
milk proteins in early infancy, prior to gut closure, to an immature immune system may
promote IDDM in genetically predisposed individuals.
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The protein content of cow's milk differs from human milk. Cow's milk is higher
in protein, and this difference is largely reOected in the casein content. Beta-lactoglobulin
present in cow's milk is essentially absent from human milk and has been extensively
associated with milk allergy in infants . In addition, bovine serum albumin (BSA), a minor
whey protein, shows slight variations in amino acid sequence and maJor variations in
antigenicity from human serum albumin (Martin, Trink, Daneman, Dosch, & Robinson,
1991).
Cow's milk is considered to be a strong antigen, and it would be expected that
infant formulas containing intact cow's milk proteins exhibit antigenic characteristics.
Infant formulas containing intact cow's milk protein (e.g., Enfamil, Similac, Gerber, and
SMA) and partially hydrolyzed whey protein fractions (e.g., Good Start) have infact been
demonstrated to be strong immunogens (Cordle et al., 1994). This has been shown to be
true of the partially hydrolyzed product despite a significant reduction in antigen load (8085%). Antigenicity of infant formulas has been demonstrated in neonates where absorption of intact antigens is largely attributed to increased permeability of the immature
intestine and a relative deficiency in secretory IgA (Eastham et al., 1978). While increased
absorption of intact protein in infancy was once thought to be of little pathological
significance (Eastham et al., 1978), recent evidence points to the potential involvement
of milk protein antigens in the autoimmune pathogenesis of IDDM.
Animal Studies: Cow's Milk Protein and Insulin
Dependent Diabetes Mellitus
Animal studies in the spontaneously diabetic biobreed (BB) rat and non-obese
diabetic (NOD) mouse have revealed a significant impact of dietary cow's milk proteins on
the incidence of diabetes. BB rats fed skim milk powder had a 52% incidence of IDDM
compared to animals fed either casein or hydrolyzed lactalbumin having an incidence of
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diabetes of only 7C/c and 2%, respecuvely (Scott, Elliot, & Kolb, 1989). BB rats fed a diet
devoid of intact protein, containing synthetic amino acids, had a 15% incidence of IDDM as
compared to an incidence of over 50% of animals receiving intact cow's milk protein
(Elliott & Martin, 1984). Elimination of intact cow's milk protein from the diet of the BB
rat significantly reduced the incidence of IDDM (Martin et al., 1991).
Greater than 70% of non-obese diabetic mice (NOD) exhibit diabetes by 30 weeks .
Coleman and colleagues ( 1990) were able to eliminate IDDM in NOD mice by feeding a
hypoallergenic infant formula containing casein hydrolysates as the protein source
(Pregestimil). Animals remained free of diabetes throughout the 1-year study period.
Similarly, Pregestimil was effective in preventing spontaneous IDDM in female NOD
mice , and cyclosphophamide induced diabetes in male NOD mice (Hermine et al., 1995).
Pregestimil was effective in preventing early appearance of widespread insuliriitis, a major
feature of diabetes in NOD mice (Hermitte et al., 1995; Coleman et al., 1990). A significant reduction in the number of beta-cells invaded by macrophages was observed.
However, the protective effect of the protein hydrolysate could not be explained by alterations in immune response directly attributed to Pregestimil (Hermine et al., 1995).
These early animal studies suggest that intact cow's milk protein may in some way
contribute to the expression of IDDM. Elimination of intact cow's milk protein and/or
other potential diabetogenic agents present in the natural diet may confer protection (Elliott
et al., 1988). Avoidance of the intact milk proteins was most effective in reducing
incidence of IDDM when done during the pre-weaning period. The protective effect of the
hydrolyzed protein diet fed during the pre-weaning period appeared to carry over even
when dairy products were reintroduced into the diet at an later age.
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Epidemiological Population-Based Studies of Milk Consumption
Patterns and Disease PreYalence

IDDM is geographically related to cow's milk consumption and infant feeding
practices (Gerstein, 1994). A significant positive correlation exists bet\veen the
consumption of unfermented cow's-milk-protein and the incidence of !DOM (Scott, 1990).
Data gathered on the incidence of IDDM from countries with established diabetes registries
were correlated with data on cow's milk consumption obtained from the International Da1ry
Federation (Dahl-Jorgensen et al., 1991). A direct linear relationship was observed in the
incidence of IDDM and cow's milk consumption (I= 0.96), Figure 2. In Japan , where
milk protein consumption is estimated to be below 5 grams per day, approximately 1
person per 100,()(X) will develop IDDM. Of countries extensively studied, this reflects the
lowest incidence of !DOM and milk consumption worldwide. Americans consume 19
grams of milk protein per day, and the incidence of IDDM rises to 15 cases per 100,000.
The highest prevalence of IDDM is reported in Finland of 28 cases per 100,()(X) where milk
consumption is estimated to provide 30 grams of protein per day (Cerrato, 1993).
A correlation between milk protein consumption and incidence of IDDM from
region to region within the same country having a genetically homogenous population has
been demonstrated by Fava, Leslie, and Pozzilli ( 1994). The incidence of IDDM in
children 0 to 14 was reported to vary significantly across regions within Italy and was
highly correlated with fluid milk consumption (I = 0.84, p < 0.004). The highest incidence
o f both IDDM and cow's mtlk consumption was seen in Sardinia, an area with a diabetes
incidence similar to the Northern Scandinavian countries of Europe and higher than any
o ther region of Italy.
Polynesians have a slightly higher incidence of IDDM than the Japanese , but are a
low-risk population. The traditional Polynesian diet is high inf ruits and fish. Following
migration to New Zealand, Polynesians exhibit an incidence of IDDM consistent with the
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Figure 2. International patterns of cow's milk consumption and prevalence of
insulin dependent diabetes mellitus. Adapted from Rennie ( 1992).

population of New Zealand. Once weaned , the child is given the traditional local diet high
in cow's milk and meat (Cerrato, 1993). This suggests that milk consumption impacts the
expression of diabetes independent of ethnic background. It has been estimated that 7494% of the geographic variation in disease incidence might be explained by differences in
milk consumption (Dahl-Jorgensen, Joner, & Hansses, 1991 ; Gerstein, 1994).
Case Control Studies of the Impact of Early Introduction of Cow's Milk
Proteins and Risk of Insulin Dependent Diabetes Mellitus
Early introduction of cow's milk and cow's-milk-based infant formula has been
associated with an increased risk of IDDM. This is particularly true when cow's milk
proteins are introduced prior to 3 months of age (Kostraba et al., 1992; Verge et al ., 1992) .
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It can be assumed that infants who are not breast-fed or who are breast-fed for only a short
period are very likely to receive cow's-milk-based infant formula as an alternative to breast
milk. The first study to independently take into account both the duration of breastfeeding and the age of introduction of supplementary milk feedrng and its impact on
prevalence of !DOM suggested a stronger link with introduction of artificial breast milk
substitutes as compared to an independent protective effect of breast-feeding. Children who
were introduced to supplementary milk feedings prior to 2 months and 3 months of age had
. an increased risk of !DOM (odds ratio 1.54 and 1.52, respectively) . Finnish children
diagnosed with diabetes prior to age 7 were reported to be significantly more likely to have
received supplemental milk feeding in infancy compared to control children at each interval
evaluated: 2 months (15% vs. 5%, Q < 0.005), 3 months (25% vs. 12%, Q < 0.05), and 4
months (38% vs. 21 %, Q < 0 .03). In a follow-up study, early introduction of dairy
products was associated with an increased risk of IDDM in Finnish children with age of
introduction of dairy products identified as the most important risk determrnant of IDDM
(Virtanen et al ., 1993). The protective effect of breast-feeding has previously been
reported to be related to the age of exposure to breast milk substitutes (Kostraba et al.,
1992) . Early introduction of dairy products is an independent nsk factor for IDDM
regardless of breast-feeding practices. This appears to be particularly true when cow's
milk proteins are introduced prior to 3 months of age. Here intact milk proteins are likely
to cross the mucosa! barrier prior to gut closure and development of gut immunity. This ,
in tum, may precipitate the complex process of autoimmunity leading to IDDM.
Meta-Analysis of the Effect of Earlv Introduction of Cow 's Milk
Proteins and the Incidence of IDDM
In a recent meta-analysis of breast-feeding and use of artificial breast milk
substitutes most studies have shown a weak, but significant association between infant
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feeding practices and the risk of !DOM (odds ratio l.5; Gerstein, 1994). Children with
!DOM had been consistently exposed to cow's milk earlier than were healthy non-diabetic
indi,·iduals . Introduction of cow's milk prior to 3 months of age \\'as associated \\'ith an
odds ratio of 1.63 for risk of !DOM. It was estimated that the risk of !DOM could be
reduced by as much as 30-40% if cow's milk were eliminated from the diet for the first
three months of life. Gerstein ( 1994) suggested that the impact of cow's milk protein in the
pathogenesis of IDDM may have a much stronger link to IDDM than reported if genetically
predisposed individuals were matched as controls. Only two of the studies included in the
meta-analysis used family members as the control group, but no further genetic screening
was performed.

Genetic Predisposition, Cow's Milk Exposure, and Disease Risk

The impact of genetic contribution was convincingly demonstrated by Kostraba and
colleagues (1993) . The effect of early introduction of cow's milk was evaluated in a
population predisposed to !DOM based on HLA region genetic markers. Genetic risk was
determined as high and low by the HLA-81 marker where susceptibility is conferred by the
absence of aspartate at position 57 of the HLA-DQB chain. Children exposed to cow's milk
prior to 3 months of age had an increased risk of developing IDDM (odds ratio= 2.9)
compared to genetically matched controls. Similarly, genetic predisposition alone
accounted for a substantial increased risk (odds ratio= 3.2). The interaction between
genetic predisposition and the environmental intluence of early cow's milk exposure where
both risk factors were present, resulted in an impressive 11-fold increased risk of IDDM
compared to those having neither risk factor (odds ratio= 1 l.3; Kostraba et al., 1993) .
Clearly the impact of genetic predisposition to IDDM cannot be overlooked when
attempting to evaluate the role of environmental factors in the immunopathogenesis of
lDDM.
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Immunological Response to Cow's Milk Proteins
Intrcxiuction of cow's milk to the infants diet soon after birth results in systemic
cow's milk protein antibody prcxiuction (Saukkonen et al., 1994). The pattern of antibody
response to cmv's milk proteins was reported as early as 1971 by Kletter, Gery, Freier,
and Davies. Neonates prcxiuce antibodies to cow's milk proteins. The peak rise in lgG
antibodies occurred at three 3 months of age, followed by an IgA peak at 7 months of age,
and then gradually tapered off (Kletter et al ., 1971) . IgG antibodies were markedly higher
than antibodies in other classes. The IgM response was small. These observations were
again independently reported by Eastham and colleagues ( 1978). Infants initiated on
cow's-milk-based formula at birth had a steady increase in cow's milk protein antibodies
during the first 3 months of life. Antibody titres tended to plateau at 3 months and show a
downward trend by 1 year of age. The decreased immunological response after the pericxi
of infancy may be anributed to a change in the permeability of the gut to protein,
decreased milk consumption following 1 year of age, or the development of a state
of tolerance toward milk protein ( Kletter et al ., 1971) .
The presence of cow's milk protein antibodies was followed for a pericxi of 28
months in healthy infants in order to compare the impact of breast-feeding and bottlefceding practJces (Tainio et al. , 1988). Low levels of IgG cow's milk antibodies were
detected at birth in all infants. Small amounts of BSA and other cow's milk proteins
have been detected in human breast mtlk. IgG levels, in exclusively breast-fed infants,
remained low over the 9-month pericxi. The greatest rise in IgG antibody titres was
seen in infants exposed to formula prior to 30 days of age. This observation may be due
to decreased mucosa! barrier protection allowing absorption of greater quantities of intact
antigens. Mucosa! secretory IgA in the developed gut combines with lumenal proteins
inhibiting their absorption. The secretory immune system is not developed fully in
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neonates (Walker, 1985). Mean IgG levels peaked in all infants at 4 to 5 months following initial exposure to formula A second peak was observed that corresponded to initiation
of \\·hole cow's mtlk, which may have stronger antigenicity than processed formulas
(Tainio et al., 1988). IgA and IgM antibodies 1,vere absent at birth and were not a
differential marker of cow's milk exposure (Tainio et al., 1988). Proliferation of blood
mononuclear cells, in response to lactoglobulin, has been reported to be prominent in the
infants at 9 months exposed to intact cow's-mlik-based infant formula (Virtanen & Aro,
1994).
The Nationwide Childhcxxi Diabetes in Finland study revealed that early
introduction of dairy products and high milk consumption was positively associated with
higher antibody titres. B-lactoglobulin antibody titres were shown to be inversely related to
the duration of breast-feeding and positively correlated with the incidence of IDDM
(Virtanen et al., 1994) . These findings are consistent \.Vith work previously reported by
Dahlquist, Savilahti, and Landin-Olsson ( 1992), who found a significant risk associated
with age of introduction of formula and levels of B-lactoglobulin IgG and cow's milk
protein IgA. Insulin autoantibodies, BSA IgA antibodies (odds ratio 1.59), /3lactoglobulin (odds ratio 1.44), lgM antibodies to cow's milk formula (odds ratio 0.62) ,
but not islet cell antibodies, were affected by the age of introduction of dairy products.
High lgA antibodies, in particular to BSA and 13-lactoglobulin, have been associated with
increased risk of !DOM (Dahlquist et al., 1992 ; Virtanen et al., 1994). Cow's milk protein
antibodies of several types including anti-BSA and anti-B-lactoglobulin have been shown to
be correlated with each other and to islet cell antibodies (Dahlquist et al ., 1992). This lends
further support to earlier findings of elevated antibody titres to both 13-lactoglobulin and to
BSA found

in

new onset diabetic humans and animal models (Martin et al., 1991).

Children with early onset !DOM, 0 to 5 years, have increased levels and frequency
of antibodies to a variety of milk proteins (Savilahti et al., 1988). Supranorrnal and
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significantly higher levels of lgA antibodies to cow's milk were detected in diabetics
(Q

= 0.0002) while IgG levels were similar in both diabetics and controls. Both IgG and

lgA anubodies to B-lactoglobulin were higher than age matched controls . The authors
implied that these results might be anributed to increased cow's milk consumption ,
increased immunological reactivity to cow's milk proteins, or greater than normal
gastrointestinal permeability to cow's milk proteins. Interestingly, immune response to
cow's milk did not correlate with the presence or absence of HLA-DR antigens (Sanlahti
et al., 1988). In a subsequent study by the same research group, diabetic children less than
3 years of age had significantly elevated median levels of IgG (Q = 0 .030) and IgA
antibodies (Q

=0.002) to cow's milk and IgG antibodies to B-lactoglobulin (Q =0.03;

Savilahti et al. , 1993). In the youngest age group, the antibody levels were six to seven
times higher than the reference population. Diabetic children 3.0 to 6.9 and 7 .0 to 14.9
years of age also exhibited significantly elevated levels of IgA antibodies to cow's milk and
13-lactoglobulin, although the observed values were somewhat closer to the control
population than in the youngest age group. lgG and lgA 13-lactoglobulin antibodies were
significantly associated with risk of IDDM at a young age independent of islet cell antibody
status and early weaning to cow's milk formula. An abnormally strong humoral immune
response to cow's-milk-proteins 1s particularly apparent in the youngest patients diagnosed
with IDDM. However, the authors concluded that these findings do not suggest a direct
autoimmune process of pancreatic beta-cell destruction due to marked overlap in antibody
titres between diabetics , siblings, and controls. Further, antibody titres did not fall as
!DOM progressed in this population despite progressive destruction of the pancreatic betacells (Savilahti et al., 1993).
In summary, the immunological studies re viewed suggest a contribution of milk
proteins to the pathogenesis of IDDM. Immunological responses to milk proteins appear to
occur with early exposure to intact protein prior to gut closure and full de velopment of gut
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immunity. Exacerbated immunological responses to cow's milk protein in patients newly
diagnosed with !DOM, increased nsk of !DOM with early introduction of cow's-m1lkbased infant formula, and correlation of geographical panems of mtlk consumption with
prevalence of !DOM lend support to the involvement of bovine proteins in the autoimmune
pathogenesis of !DOM. The effects of infant feeding practices on the autoimmune
pathogenesis of !DOM appear to be most pronounced in cases diagnosed prior to age 5.

Conflicting Reports on the Role of Cow's Milk Protein in the Pathogenesis
of Insulin Dependent Diabetes Mellitus
A review of several animal and human studies provides some evidence that does not
support the hypothesis that milk proteins are involved in the pathogenesis of IDDM. One
animal study has been cited repeatedly that reported that an addition of 10% skim milk
powder to rat chow containing 10% casein did not increase the incidence of !DOM in NOD
mice. However, the authors noted that it may have been difficult to discriminate the
additional contribution of skim milk powder to an already diabetogemc mixed diet
(Coleman et al., 1990). All other animal studies have shown cow's milk protein to be a
potent contributor to risk of IDDM .
Ep1demiological studies showing a positive correlation between cow's milk intake
and incidence of IDDM have been criticized for fatlrng to account for genetic bias or the
age of exposure to cow's mtlk proteins (Ellis & Atkinson, 1996). Sardinia, a large
Mediterranean island, has a high diabetes incidence second onl y to Finland. The Sardinian
pathological profile is similar to that of Finland since both are characterized by high levels
of islet cell antibodies. While the incidence of IDDM correlates with the consumption of
dairy products, the actual prevalence of IDDM was cited as being three times higher than
could be predicted by milk consumption alone (Muntoni, Loddo, Stabilini, Stabilini , &
Muntani, 1994) .
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relatively small study group, particularly of young diabetic patients less than 3 years of age
(Savilahti, Saukkonen, Akerblom, Virtanen, & Dahlquist, 1994). This may, in part,
explain the lack of significant increases in the level of IgG antibodies to 13-lactoglobulrn and
a relation to infant feeding practices.
Savilahti and colleagues ( 1994) argued that antibodies to milk proteins may not be
directly associated with the disease process, but rather provide an early and potent
immunization of individuals prone to develop !DOM. Increased antibodies to cow's milk
proteins, including BSA , could result from a nonspecific immune response at the onset of
IDDM. Alternatively, reports of a recent episode of gastroenteritis prior to the onset of
clinical symptoms of IDDM may result in an elevation of cow's milk and other food
antibodies reported in newly diagnosed diabetics (Kostraba, 1994), but not necessarily
contribute to the pathogenesis of the disease. Detennining whether these antibodies to
cow's milk antigens, in particular BSA and the AB BOS peptide, are present prior to betacell damage and clinical onset of disease may help to clarify this issue. It is also unclear
if certain HLA genes are required for the fonnation of antibodies to cow's milk proteins
(Kostraba, 1994).
The most recent study to address the issue of association between early exposure to
cow's milk, and in this case beta-cell autoimmuruty rather than clinical IDDM, used a
cross-sectional design with retrospective analysis in genetically predisposed individuals
(Norris et al ., 1996). Of 253 children from families with IDDM, only 18 exhibited betacell autoimmunity. Only 3 of these had been exposed to cow's milk prior to 3 months of
age. There were no significant differences between children up to 7 years of age exhibiting
beta-cell autoimmunity and control children in response to cow's milk exposure prior to
either 3 or 6 months of age. In fact, there were no differences seen with any other dietary
antigens including cereals, fruits, vegetables , or meat proteins. This is in conflict to all
animal studies that have shown that intact proteins from a number of sources appear to be
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required for full expression of IDDM. Of note , children who were previously identified as
having diabetes related antibodies were excluded from the study. Smee the autoimmune
diabetic prodrome is known to be long and is proposed to be initiated in infancy , it would
seem most of the high-risk children who were likely to develop !DOM prior to age 5 were
excluded from the study. In addition, the lack of a positive contribu-tion of early infant
feeding practices and IDDM may be due to the intermediate marker of beta-cell
autoimmunity, in which less than half of positive subjects will progress to !DOM within 5
years. Progression to !DOM, even in beta-cell autoimmune positive subjects , may requ1re
a second environmental factor (Noms et al., 1996). In addition, as previously noted ,

•

genetic predisposition may be required for earl y exposure to cow's milk to contribute to
the etiology of diabetes (Kostraba, 1993).
Summary of Earlv Exposure to Cow's Milk Proteins
Supplementary feeding prior to 3 to 4 months of age is more likely to show a
significant effect on the incidence of IDDM if formula feeding is limited to intact cow 'smilk-based products (Dahlquist et al. , 1992 ; Kostraba et al. , 1992). Infant formulas are
likely to be heterogeneous in terms of ingredients , processing, and treatment. Studies
using age as a marker of gut maturity may also be subject to error (Kostraba, 1993) since
gut closure is variable over the first year of !ife . Components of the infant diet are not
independent in terms of their contributio n to ri sk of !DOM. This has been demo nstrated by
a significant correlation between the durati on of breast-feeding and age of exposure to
cow's milk protein(£< 0.01; Norris et al ., 1996) . Gerstein (1994) concluded from a
comprehensive meta-analysis of breast-feeding incidence and duration and the age of
introducti on of cow's milk protein that there was a 1.5-fold increase in the incidence of
IDDM with a history of earl y exposure to cow's milk and short duration of breast-feeding.
Similar findings were reported by (Norris & Scott, 1996). In addition, elevated risk of
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IDDM was consistently associated with age of first exposure to breast-milk substitutes
\\'hen this occurs prior to 6 months of age (Noms & Scott, 1996). The impact of early
introduction of cow's milk proteins in the autoimmune pathogenesis of IDDM is likelv to
be most notable in those developing IDDM in early childhood.
There is mixed but substantial evidence to suggest that early introduction of cow's
milk protein may be linked to the complex autoimmune pathology of IDDM. A large,
prospective, randomized trial has been initiated in the Scandinavian countries to determine
whether providing a diet of breast milk and/or a diet devoid of intact cow's milk protein
will decrease the incidence of IDDM in those who are genetically at risk (Akerblom, Dosch,
et al., 1993). Evaluation of the interaction of interrelated environmental factors (e.g. ,
breast-feeding and introduction of infant formula) and genetic predisposition should
provide insight into this complex issue.
Bovine Serum Albumin
The whey protein, bovine serum albumin (BSA), has been implicated as the most
likely dietary factor involved in the pathogenesis of IDDM . Serum albumin is present in a
higher concentration in cow's milk compared to rat and human milk. BSA consists of 608
amino acids and is immunologically distinct from human serum albumin showing linle or
no cross-reactivity (American Academy of Pediatrics, 1994). There are several sequences
of BSA that differ from human serum albumin. The peptide sequence, AB BOS , containing
17 amino acids in the region of the BSA molecule from residues 152 to 168
(FKADEKKFWGKYLYEIARR) accounts for the major sequence differences between
human , cow, rat, and mouse albumin (Bach, 1994; Dosch et al., 1992; Glerum , Robinson,
& Martin, 1989). Where the deviation between the amino acid sequences of human and

bovine serum albumin is the greatest, lies the area most likely to act as an antigenic epitope
(Glerum et al. , 1989) .
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It is proposed that an antigen-driven, selective immune response may initiate the
autoimmune process implicated in the pathogenesis of IDDM (Dosch et al., 1992). The
AB BOS peptide has been identified as a possible trigger for IDDM based on a crossreactive immune response between the peptide and a beta-cell membrane antigen
(KarJalainen, Martin et al ., 1992 ; Karjalainen, Saukkonen, Savilahti , & Dosch , 1992) .
Antibodies to BSA have been shown to recognize islet cell surface proteins , in particular
ICA p69. Immaturity of the gastrointestinal immune system and selective resistance of
BSA to enzymatic hydrolysis by trypsin may allow passage of intact BSA and/or the
ABBOS epitope into the blood stream conferring an abnormal immunological response that
results in pancreatic beta-cell destruction and insulin deficiency.
Proposed Mechanism of BSA-Induced Autoimmunitv in
Insulin Dependent Diabetes Mellitus
The molecular basis for the immunological response to BSA has been attributed to
the observation that the beta-cell autoantigen ICA 69 and BSA share three regions of short
sequence homology. One region lies between amino acids 38 and 47 (iKAtgKKede) and
amino acids 152 and 161 of the BSA ABBOS peptide (fKAdeKKfwg; Figure 3 ;
Eisenbarth, Gianani , Pugliese, Verge, & Pietropaolo, 1994; Pietropaolo et al., 1993) .
Anti-BSA antibodies have been shown to cross-react with a rat islet beta-cell protein of
67-69,000 molecular weight. Immuruzation of animals with the ABBOS peptide results in
production of antibodies that are able to react with the p69 beta-cell surface protein (Fourth
International Onnela Workshop, 1990; Karjalainen , Saukkonen, et al. , 1992).
Specifically, the N-tenninus of the beta-cell protein p69 has an amino acid sequence
homologous to the AB BOS peptide. T-cells that are reactive to a synthetic analog of this
region have been detected in preliminary evaluation of eight of eight children recently
diagnosed with !DOM (Cheung et al., 1994). A cow's-milk-induced anti-islet T-cell
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response could precipitate beta-cell destruction through molecular mimicry due to the
ABBOS sequence common to both BSA and a 69-kD beta cell protein (Figure 3; Bach,
1994; Karjalainen , Martin, et al., 1992). The 69 kD beta-cell autoantigen (p69) has been
reported to be identical to islet cell antibody ICA 69 (Miyazaki et al ., 1995) . If the
ABBOS peptide were to be introduced through a leaky immature gut in early infancy , it
could induce an immune reaction that could be boostered by ICA 69, induce beta-cell
damage, and ultimately set in motion the complex sequence of events leading to !DOM
(Dahlquist, 1994; Karjalainen, Martin , et al ., 1992).
Beta-cell p69 does not appear to be a native protein but rather is induced in islet
cells by gamma-interferon stimulation, which functions to mediate inflammatory responses
(Glerum et al ., 1989; Karjalainen, Martin, et al., 1992). It is suggested that during the
prediabetic phase , the body releases gamma-interferon upon exposure to viruses. The
gamma-interferon results in the presentation, or studding, of the beta-cell surface with p69.
Primed by exposure to the AB BOS epitope of BSA , the immune system now sees the p69
protein as foreign and ultimately mounts a response that destroys the islet cells (Renme,
1992) . This immunological response, known as molecular mimicry, underlies the
hypothesis by which BSA triggers the immunopathogenesis of IDDM.
Interaction of Genetic Predeterminants of Insulin Dependent Diabetes
Mellitus, Exposure to BSA, and Islet Cell Autoimmunity
Immunological consequences of oral exposure to BSA are impacted by genetic
factors that predispose individuals to IDDM (Saukkonen et al ., 1994). A region of BSA is
homologous to the 8-subunits of MHC class II proteins Ia, DQ, and DR. The overlapping
region lies between amino acids 157 to 175 (Glerum et al ., 1989; Martin et al., 1991) . A
molecular basis for BSA binding to MHC class II proteins and affecting antigen
presentation has been proposed by Dosch and colleagues (1992) . Cells contairung MHC
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Figure 3 . Homologous regions of bovine serum albumin (BSA), human serum
albumin (HSA), ABBOS peptide, and islet cell antibody (ICA) 69. The regions of
similarity are noted in bold type . Adapted from Pietropaolo et al. ( 1993).

class II antigens appear to prcx:luce antibodies and cytotoxic T-lymphocytes against the
region of BSA which shares a common epitope with the MHC class II protein. Isolation
of islet cells from the BB rat using rat anti-BSA antiserum revealed a cross-reacting protein
(Mr= 69,()(X)) . The structure of the beta unit of the islet cell protein was found to have a
region of homology in the DQ and DR region with BSA . Further analysis of the amino
acid homology in relation to the combined DRJDQ human allotype was strongly correlated
with BSA and the incidence of IDDM. Individuals with poor DR and DQ homology appear
to be protected against the anti-BSA autoimmune response (Glerum et al., 1989).
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Antigen presentation of AB BOS by diabetes associated MHC-class II molecules
and a delay in oral (or mucosa!) tolerance underlies the BSA hypothesis. Environmental
antigens are presented to T-cells in conjunction with HLA class II antigens. DR antigens
play a maJOr role in antigen presentation within the intestinal epithelial cells. It 1s here that
the primary immune reaction tooral BSA takes place (Saukkonen et al., 1994) . The single
highest marker of diabetes risk is DQB non-aspartate 57, which also marks susceptibility to
IgA deficiency, a regulatory abnormality in mucosa! immunity (KaIJalainen, Saukkonen, et
al., 1992).
Human albumin has been noted to have an aspartic acid residue at position 57 of
the DQB chain while BSA has an alanine at the 57 position. The ABBOS epitope appears
to show sufficient homology to the available human DQB structure to fit into the peptidebinding groove of the MHC class II molecule. The antigenic epitope appears only to fit
when the key aspartate 57 residue is replaced with either alanine or serine. Non-aspartate57 of the DQB chain is a highly predictive marker of genetic predisposition to IDDM and
has been reported to be present in 96% of patients with IDDM (Dosch et al., 1992). In
humans, DR and DQ allotypes have been shown to be strongly correlated with the
incidence of IDDM (Robinson et al., 1993). Diabetes associated DR alleles show strong
affinity for BSA and its peptides (Sauk.konen et al. , 1994).
Presentation of the AB BOS peptide 1s particularly likely to occur in the intestine
where surface epithelial cells express DR antigens. The predispos1t1on to IDDM is based
on the identity of MHC class II proteins, interaction between and self-recognition of the
islet beta-cell membrane antigen peptide, and the strength of the immune response to the
ABBOS peptide presented by DR rather than DQ. Non-aspartate-57 DQ individuals
(homozygous), at high risk of developing IDDM, would have poor tolerance to ABBOS
due to poor presentation and failure to arrest induction of self recognition and tolerance.
Strong tolerance is conferred by the presence of Asp 57 on DQ. This model not only

86
provides a role of ABBOS in the pathogenesis of IDDM, but also provides evidence for
and interaction between cow's milk exposure and the genetic factors contributing high
susceptibility to IDDM. The presence of both DR and DQ allotypes and the lack of
aspartate at position 57 on the DQl3 chain confer high risk of IDDM (Robinson et al .,
1993).

The theory is that if islet cell autoantigen p69 is displayed on the beta-cell prior to
exposure to milk proteins, specifically ABBOS , the infant's immune system will see the
islet cell protein p69 as self. However, if the exogenous ABBOS epitope is presented to
the immune systems first, the infant is likely to establish an immune response to this
foreign peptide (Mccarren, 1992). Through the process of molecular mimicry, the
sensitization to AB BOS now makes the beta-cell vulnerable to attack by the host immune
defense mechanisms. In this model , exposure to dietary BSA in infancy would mediate a
T-cell response prior to establishment of p69 self-tolerance (Cheung et al ., 1994). BSAinduced autoimmunity is boostered by garnma-interferon-induced expression of MHC class
II antigens on the surface of the beta-cell supporting a complex series of events that
ultimately leads to beta-cell destruction.
Bovine Serum Albumin Triggered Islet Cell Autoimmunitv: A Hvpothesis
A hypothesis has been proposed by Karjalainen, Martin, and colleagues ( 1992) that
rehes on an elaborate sequence of events that ultimately results in the destruction of the
beta-cells and concominant clinical diabetes. The AB BOS peptide crosses the immature
gastrointestinal tract intact. This peptide is immunogenic in individuals genetically prone to
develop IDDM. Those individuals with the diabetes-associated Hl....A Class II (DRJDQ)
haplotypes are able to bind and present this antigen. Exposure leads to immunological
sensitization and development of memory cells for ABBOS. Since ABBOS and p69 share
a common epitope, p69 should be able to boost and sustain AB BOS-specific immune
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memory following gut closure. The cross-reactive beta-cell p69 maintains the antibody
response until the destruction of the islet cell is complete and p69 is no longer available.
Elevated gamma-interferon, associated with infections, would induce expression of p69
on the surface of the beta-cell (Dosch , 1993; Karjalainen, Martin, et al ., 1992: Karjalainen,
Saukkonen, et al., 1992). Presence of p69 activates beta-cells, making them transiently
subject to immune attack. The AB80S-mediated immune response could cause destruction of the beta-cells by cross-reactivity with p69 and function as the possible molecular
mimicry epitope (Karjalainen, Saukkonen, et al., 1992). The long preclinical course could
be explained by the short-lived, but recurrent, nature of episodic expression of p69 on the
pancreatic beta-cells (Karjalainen, Martin, et al., 1992). Induction of p69 expression by
gamma interferon by variable and etiologically unrelated infections would impact
progression to overt clinical disease. Recruitment of additional pathogenic (p69-specific)
and disease-associated islet cell antibody-specific lymphocytes accelerates beta-cell
destruction (Akerblom, Dosch, et al. , 1993). The long, latent period of IDDM of 8 to 10
years suggests the need for multiple viral events to ultimately produce destruction of 90%
of islet cells associated with clinical disease . This hypothesis is enticing as it takes
into account genetic predisposition, autoimmune mechanisms, and the environmental
influence of both cow's milk protein and exposure to viral infections.
A Review of the Critical Evidence Implicating Bovine Serum
Albumin as a Causati ve Agent in the Pathogenesis of
Insulin Dependent Diabetes Mellitus
Animal Studies
Early experimental studies anempting to establish a link between BSA and IDDM
were conducted by Elliott and Martin using the spontaneously diabetic BB rat model
( 1984) . A significant increase in antibodies to BSA was found at the time of diagnosis m
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all rats progressing to IDDM . Rats that became diabetic were shown to have the highest
titres of anti-BSA-antibodies at 90 days compared to those with only a subclinical picture.
Peak anti-BSA-antibody titres were observed at 120 days (Elliott & Martin, 1984). Sera
from nonnal and diabetic Sprague Dawley rats has been shown to contain anti-albumin
antibodies which bind to albumin contaminated rat islet preparations (Marshall &
Gotfredsen, 1986). BSA-IgM antibodies have also been detected at significantly higher
levels in diabetic versus nondiabetic rats (Scott et al., 1989).
NOD mice have also been used to study the potential contnbution of BSA in the
autoimmune pathogenesis of IDDM due to their known exaggerated autoimmune responses
to exogenous antigens (Beppu, Winter, Atkinson, Fujita, & Takahashi, 1986). Beppu and
colleagues ( 1987) found abnonnal immunological responses to BSA in NOD mice, which
included high levels of BSA binding and the presence of anti-BSA antibodies. Mice
developing diabetes exhibited the highest BSA binding.
While critics of the BSA hypothesis have argued that the presence of BSA antibodies
prior to the clinical onset of IDDM has not been established in humans, anti-BSA
antibodies have been detected prior to diagnosis of diabetes in rodent models. These
findings suggest a possible role of BSA in the pathogenesis of IDDM (Beppu et al., 1986).
Anti-BSA antibody titres have shown to be inversely proportional to the age of disease
presentation in biobreed rats (Martin et al., 1991 ). Withholding dietary BSA has been
shown to prevent IDDM in experimental animals (Karjalainen, Saukkonen, et al., 1992).
Immunization to BSA may be the result of defective immuno-regulation or tolerance to
ingested antigens (Maclaren & Atkinson, 1992) . This is supported by the observation that
induction of tolerance in early life with BSA has been shown to prevent the development of
IDDM in diabetic prone rcx.ients (Akerblom, Dosch, et al ., 1993; Karjalainen, Saukkonen,
et al., 1992). Tolerance induced by BSA in laboratory animals provides evidence that BSA
is involved in the pathogenesis of IDDM (Dosch et al., 1992).
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Demonstrated Autoimmunitv to Bovine Serum
Albumin in Newlv Diagnosed Diabetics
Anti-BSA antibodies. The pioneering work establishing the presence of BSA
autoimmunity in patients with IDDM was conducted by Karjalainen, Martin, and colleagues
( 1992) . Serum concentrations of antibodies against BSA were found to be significantly higher in
newly diagnosed diabetics than in control children. Elevated serum concentrations of IgG and lgA
anti-BSA antibodies were detected in 44 ( 100%) of newly diagnosed diabetics by particle
concentration fluoroimmunoassay (PCFIA) compared to only 4% of control subjects. A
significant note regarding methcxiology was reported. PCFIA had both a high specificity and
sensitivity compared to enzyme-linked immunosorbant assays (ELISA). Only 25% of diabetic
children in the same population tested positive for anti-BSA antibodies using ELISA with as many
of 10% of the control children sera positive (Karjalainen, Martin, et al., 1992).
Saukkonen and colleagues ( 1994) detected significantly elevated levels of IgG and
IgA immunoglobin antibodies to BSA using ELISA in newly diagnosed diabetic children
less than 7 years of age than in unrelated control children (Q = 0.0001; Q = 0.0009,
respectively) . In contrast to earlier reports by Karjalainen, Martin and colleagues ( 1992),
similar elevations in levels of IgG and IgA antibodies to BSA were obtained using PCFIA.
Elevated IgG antibodies to BSA have consistently been found to be significantly
higher in newly diagnosed diabetic children compared to the nondiabetic, normoglycemic
control population in several independent studies (Dosch et al., 1992; Luhder et al., 1994;
Pardini et al., 1996; Pigny, Morteux, Racadot, Stuckens, & Boersma 1995). Sheard
( 1993) has reported the mean anti-BSA antibody titres to as much as seven-fold higher in
children with diabetes compared to healthy controls. Significantly higher titres of IgG and
IgA class antibodies to BSA have been found in newly diagnosed diabetics across all age
groups as compared to the reference population (Saukkonen et al., 1994). These findings
are supported by the work of Krokowski and colleagues ( 1995) who reported that levels of
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anti-BSA antibody were significantly higher in those with adult onset IDDM than in healthy
control subjects (Q < 0.01) .
Evidence of the presence of anti-BSA antibodies prior to disease onset. Early
studies cnticizing the BSA hypothesis in the pathogenesis of IDDM point to the lack of
evidence in human studies confirming the presence of BSA autoimmunity prior to the onset
of clinical symptoms. Saukkonen and colleagues ( l 994) followed siblings of diabetic
probands for lO years following diagnosis. Siblings who developed IDDM during the
follow-up period were significantly more likely to have had positive anti-BSA antibody
titres during the study period than those siblings who remained disease free (60% and 34%
respectively; 2 = 0.04) . Krakowski and colleagues ( 1995) found two out of five diabetic
patients had significant anti-BSA antibody titres prior to clinical onset of the disease.
Presence of antibodies directed specifically against the AB BOS peptide. Elevated
serum concentrations of IgG anti-BSA antibodies were detected in 100% of patients with
IDDM. The bulk of these antibodies were reported to be directed against the AB BOS
epitope. Low levels of anti-BSA antibody, significantly lower than in newly diagnosed
diabetics, were found in all control subjects, and only 1.5% of this population expressed
ABBOS-specific IgG antibodies (Karjalainen, Martin, et al., l 992). At the time of
diagnosis, diabetic children have been shown to have higher mean anti-ABBOS-antibody
levels of IgG, IgM, and IgA isotypes (Q < 0.001). By 3 months after initial diagnosis of
IDDM, these begin to fall. ABBOS antibodies were shown to correlate with anti-BSA
antibody levels for all isotopes at the time of diagnosis and at the 3-month follow-up
(.Q < 0.0001). These data suggest a heavy bias towards in vivo selection of ABBOS-

specific clones (Karjalainen, Saukkonen, et al., 1992).
A direct link between the AB BOS epitope and pancreatic beta-cells was elucidated
with first polyclonal and then monoclonal anti-ABBOS antibodies. The anti-ABB OS
antibodies were shown to recognize an epitope on p69 an interferon-inducible beta-cell
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surface protein (Akerblom, Savilahti , et al., 1993) . These authors proposed that a selective
immune response against the BSA derived peptide drives the immune response leading to
IDDM(Akerblom, Savilahti, et al., 1993; Karjalainen, Martin, et al ., 1992; Karjalainen,
Saukkonen, et al., 1992) .
T-cell response to BSA . IDDM is a T-cell mediated disease and earlv invasion of
insulin producing beta-cells by macrophages and T-cells is critical to the pathogenesis and
progression of the disease. Specific T-cell response to BSA are consistent with an
· autoimmune process where exposure to BSA has failed to induce normal tolerance. BSA
reactive T-cells have been reported to be present in 68 of 78 children at the time of
diagnosis of IDDM (Miyazaki et al., 1995). T-cell recognition was demonstrated to islet
cell antigen p69, specifically T -cell epitope p69 (Tep69) located near the N-terminus of the
antigen. Tep69 has a homologous region to BSA, which was recognized by isolated
lymphocytes from patients with diabetes but not by lymphocyte extractions from nondiabetic patients. BSA causes T-cell proliferation. The p69 protein induces early activation
of T -cells but insufficient interleukin-2 production to warrant anergy. Normally, the high
affinity self-peptide results in anergy, but the low-affinity mimicry antigen (i .e., BSA)
causes T-cell proliferation (Miyazaki et al. , 1995) . These findings are consistent with the
hypothesis proposed by Karjalainen, Saukkonen, and colleagues ( 1992) suggesting that the
auto1mmuruty induced by BSA results from molecular mimicry.
Cheung and colleagues ( 1994) were able to detect BSA-specific T-cell activity and
were further able to map the response to the ABB OS ep1tope (pre-BSA position 152-169).
ABBOS-sensitive T-cells were found in 28 of 31 children with new onset IDDM, but were
absent in controls. The magnitude of proliferative responses to BSA and ABBOS were
similar. There were no cumulative antigenic responses of BSA and ABBOS further
suggesting that the AB BOS epitope is the immunologically active peptide on BSA . The
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decline in responsiveness to BSA and AB BOS with no patient remaining positive for one
and negative for the other. The presence of BSA ABBOS peptide specific T-cells
strengthens the 1mmunological link between BSA and IDDM (Cheung et al., 1994).
Earlv onset IDDM. The frequency and titres of IgG and IgA antibodies to BSA in
newly diagnosed diabetics compared to nondiabetic controls has been demonstrated to be
significant across all age groups (Krowkowski et al ., 1995; Pardini et al., 1996;
Saukkonen et al., 1994). However, Saukkonen and colleagues ( 1994) found the
difference in antibody titres to be greatest in the youngest age group where children ranged
from 0 .8 to 2.9 years of age.

Further, with adult onset IDDM incidence and titres of anti-

BSA antibodies were found to be lower than previously reported in children (Krokowski et
al., 1995). These findings may not be surprising given that the likelihood of BSA
contributing to the pathogenesis of IDDM is more relevant to those who develop IDDM at a
younger age. Anti-BSA antibody titres have been shown to be inversely correlated with
age of diagnosis (Pardini et al ., 1996). Higher insulin antibody titres have also been
observed in juvenile onset versus adult onset IDDM (Krokowski et al. , 1995).

In

addition , levels of anti-BSA antibodies prior to diagnosis of diabetes in the BB rat model
have been shown to be inversely proportional to the age of disease presentation (Martin et
al. , 1991). These findings are consistent with a review of earlier epidemiological studies
reporting that the association of IDDM and early cow's milk exposure decreases with
increasing age of diagnosis of the disease (Gerstein , 1994). IDDM-associated BSA
autoimmunity appears to be most remarkable in the youngest patients.
Mechanism of BSA induced autoimmunity. Elevated concentrations of IgG and
IgA isotypes to BSA are implicated to be consistent with an antigen driven response
(Karjalainen, Martin , et al. , 1992). Anti-BSA antibodies were shown to cross-react with
islet antigens demonstrated by the observed binding of anti-BSA antibodies from newl y
diagnosed patients with IDDM to ICA p69 (Karjalainen, Saukkonen, et al., 1992).
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Savilahti and colleagues ( 1993) suggested that the levels of BSA and AB BOS antibodies
are reinforced by an ongoing autoimmune process in the pancreatic islet cells. They
suggested that there is a specific response to BSA and not a general immune response to all
cow's milk proteins in patients with IDDM given that antibodies to other cow's milk
proteins were not detected or not detected at significant levels (Karjalainen, Saukkonen, et
al., 1992; Sheard, 1993). Mononuclear cells from 90% of children with newly diagnosed
IDDM have been reported to show a significant proliferative response to BSA but not to
several other albumins (Q < 0.0001; Cheung et al., 1994).
Association between anti-BSA antibodies and other immunological markers of
disease risk. Luhder and colleagues ( 1994) have reported increased levels of anti-BSA
antibodies in newly diagnosed diabetics over controls (Q < 0.01). However, there was no
association between ant-BSA antibcx:lies and islet cell reactive antibodies, cytoplasmic islet
cell antibodies, and glutamate decarboxylase autoantibodies, all of which were detected at
significantly higher levels in diabetics. These findings are consistent with earlier reports
that failed to show an association between anti-BSA and ABBOS antibody titres with either
islet cell antibcx:lies or insulin autoantibodies (Karjalainen, Martin, et al., 1992). Given the
lack of correlation with BSA antibodies and other known markers of IDDM, Luhder and
colleagues ( 1994) proposed a slightly different alternative mechanism of action for
elevations in anti-BSA antibodies. They suggested that the humoral immune response to
BSA in IDDM may reflect a nonspecific defect of the immune system.
Anti-bovine serum albumin antibodies were measured in sera by particle
concentration fluoroimmunoassays and compared with the presence of islet cell antibodies
and human leucocyte antigen (HLA)-DGB genotypes (Levy-Marchal, Karjalainen, Dubois,
Czemichow, & Dosch, 1995). Sera from French children who were newly diagnosed with
IDDM were compared to nondiabetic children with positive islet cell antibodies, and to islet
cell negative healthy control children. Elevated anti-BSA antibodies were found in 74% of
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diabetic children compared to 5.5% of controls. Approximately two thirds of anti-BSA
positive diabetic children were also positive for islet cell antibodies. These findings are m
contrast to those reported by Luhder and colleagues ( 1994), who failed to show correlation
between anti-BSA antibodies and islet cell antibodies . Elevated IgG anti-BSA antibodies
were associated with IDDM in the French population, which lends support to the
hypothesis that BSA plays a role in diabetic autoimmunity (Levy-Marchal et al., 1995).
Genetic markers and BSA induced autoimmunity. The pioneering research of
Karjalainen, Saukkonen, and colleagues ( 1992) revealed no correlation between anti-BSAantibodies and any diabetes associated combination of HLA haplotypes. A similar
disassociation has been reported between islet cell antibodies and HLA haplotypes. This
lack of association of immunological responses to milk proteins with HLA genetic markers
has previously been observed (Karjalainen, Martin, et al ., 1992). The authors suggested
that HLA haplotypes are likely required during the initiation of the immune response
specific to BSA and ABBOS, but they do not appear to determine its intensity.
Krokowski and colleagues ( 1995) were the first to report genetic interactions
between the BSA antigen and known HLA markers of IDDM. Anti-BSA antibody titres
were shown to be higher in HLA-DR3 and/or DR4 positive patients compared with DR3
and/or DR4 positive control subjects (Q < 0.001). Further, the interaction of autoimmunity
to BSA and genetic predisposition is highlighted by the observation that antibody titres to
BSA were four-fold higher in DR3 and/or DR4 positive patients than DR3 and/or DR4
negative patients. A stronger link appears to exist with DR3 positivity found in 9 of 10
anti-BSA positive diabetics (Krokowski et al., 1995). This high level of significance may
again point to the need to use genetically predisposed individuals as the control group when
trying to isolate the specific impact of BSA on the autoimmune pathogenesis of IDDM.

%
Predictive and Diagnostic Value of Anti-Bovine
Serum Albumin Antibodies

While anti-BSA antibodies are detected more frequently in patients with IDDM,
particularly newly diagnosed cases, anti-BSA antibodies do not appear to be sensitive or
specific biological markers of IDDM (Pardini et al. , 1996), and do not reflect an
independent risk factor for diabetes (Saukkonen et al ., 1995) . No patient with IDDM was
found to be positive for anti-BSA antibodies in the absence of other antibody markers or
IDDM. Presence of anti-BSA antibodies has no additional diagnostic value in IDDM
(Luhder et al., 1994). There was no correlation with the presence of islet cell antibodies
and there was overlap with control subjects (Krokowski et al., 1995). There is no evidence
that members of the general population positive for anti-BSA antibodies would have the
potential to develop IDDM in the absence of genetic predisposition. Anti-BSA antibodies
do not appear to be a relevant predictive marker of IDDM.
Conflicts and Controversies Surrounding the
BSA Hypothesis
Controversy still surrounds the role of BSA , if any, as a causative agent in the
pathogenesis of IDDM. In contrast to previous reports that have shown that BSA can
induce tolerance in laboratory animals (Akerblom, Savilahti, et al., 1993; Dosch et al.,
1992; Karjalainen, Saukkonen, et al., 1992), Petersen and colleagues (1994) failed to
demonstrate that neonatal tolerance could be induced by BSA in NOD mice. No correlation
was found between the BSA antibodies and the development of IDDM (Petersen et al.,
1994) . In both autoimmune spontaneously diabetic female NOD mice and
cyclosphophamide-induced male NOD mice, casein hydrolysate has been previously
reported to be almost 100% effective in preventing IDDM. When BSA was added to the
casein hydrolysate, animals did not develop IDDM (Hermitte et al., 1995), suggesting that
BSA is not a causitive factor in the pathogenesis of IDDM. However, these reports are in
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contrast to other animal studies that have shown that most cases of spontaneous diabetes in
rcxients are food induced (Scott, 1996), and can be induced with cow's milk protein (Elliott
& Martin, 1984).

Other arguments point to the lack of evidence confirming specificity of immunity to
BSA in patients with IDDM. Pocecco, Nicoloso, Tonini, Presani, and Marinoni ( i991)
observed elevated levels of IgA antibcxiies to cow's milk in 10 of 20 newly diagnosed
diabetes. However, there were no significant differences between diabetic and control
subjects with regard to duration of breast-feeding, history of cow's milk intolerance,
presence of islet cell antibodies, and other autoantibcxiies (Pocecco et al., 1991).
In contrast to several epidemiological, ecological, time-series, and experimental
studies, Atkinson, Koa, and Maclaren ( 1994) report a lack of B-cell and T-cell immunity
to BSA. Ellis and Atkinson ( 1996) have argued against the BSA hypothesis as their
research has shown similar incidence and titres of antibcxiies to BSA in children with
!DOM and healthy control subjects (Atkinson et al., 1993). A similar lack of a significant
lg and IgG immune response to BSA was reported by Pigny and colleagues (1995). Of
interest, slightly higher levels of BSA and anti-BSA antibcxiies have been detected in
individuals with other autoimmune diseases (e.g., rheumatoid arthrtis, multiple sclerosis,
and systemic lupus erythematosis; Atkinson et al., 1993; Strand, 1994). In general ,
individuals with autoimmune diseases had antibcxiies with higher affinities for all antigens ,
therefore, antibodies to BSA in patients with IDDM have been suggested to reflect a nonspecific defect in immunological tolerance associated with a predisposition to autoimmunity
rather than specifically to beta-cells (Atkinson et al. , 1993, 1994; Norris & Peitropaolo,
1994). Specific ABBOS sensitized T-cells have been detected, only, in children with
IDDM but not with systemic lupus erythematosis (SLE) or juvenile rheumatoid arthritis
(JRA) (Cheung et al. , 1994).
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Specificity of peripheral -blood mononuclear cell responses, supposedly stimulated
in response to BSA and ABBOS, has not been established (Ellis & Atkinson, 1996).
While chronic mononuclear-cell infiltration of the pancreatic islet cells has been cited as the
pathological hallmark of !DOM, it is not certain whether this is the mechanism by which
BSA or ABBOS exert their effects. Atkinson and colleagues ( 1993) found no activity to
peripheral blood mononuclear cells in response to either BSA or ABBOS in patients with
new onset !DOM or those at increased risk. Since other recognized islet cell antigens have
been shown to stimulate peripheral blood mononuclear cells, the research by Atkinson and
colleagues ( 1993) raised questions regarding the role of BSA and ABBOS autoimmunity in
the pathogenesis of !DOM. Gut immaturity and exposure to rota viral or other infections
may allow excessive permeability of intact proteins resulting in the production of antibodies
to BSA and other cow's milk proteins. Despite these findings, a high incidence of !DOM
has not been reported in this population (Atkinson et al., 1993).
Critics of the work of Karjalainen, Saukkonen, and colleagues ( 1992) , while
acknowledging some merit to the scheme of BSA ABBOS peptide induced molecular
mimicry with the ICA 69 islet cell protein , cast doubt on the hypothesis due to a lack of
proof that the process occurs only in hosts with diabetes associated HLA class II (DR/DQ)
haplotypes capable of binding and presenting the antigen and that early exposure to cow's
milk initiates the process. Despite reports of uniform recognition frequencies for antiABBOS antibodies in patients with !DOM, o nly a small fraction of patients with IDDM
have antibodies that react with islet-cell p69. The 100% sensitivity for anti-BSA antibodies
in newly diagnosed diabetics reported by Karjalainen's and Martin's group ( 1992) is
criticized as being remarkably high given that the" gold standard" for islet cell antibody
detection is only 75%. In addition, there is no evidence that anti-BSA antibodies are
present prior to beta-cell damage or clinical onset of diabetes (Norris & Peitropaolo, 1994).
If BSA is indeed a principal culprit in the pathogenesis of IDDM, antibodies would likely
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evaluation of the presence of islet cell antibodies , glutamic acid decarboxylase antibodies,
and BSA/ABBOS antibodies (Akerblom, Dosch, et al., 1993) .

Summary of Infant Feeding Practices in the Pathogenesis of !DOM
Infant feeding practices have received attention in the search to identify an
environmental dietary antigenic trigger of the autoimmune process that leads to beta-cell
destruction and IDDM. The infant's immature gastrointestinal mucosal banier and
immature immune system make the infant vulnerable to potential dietary antigens. Failure
to establish normal tolerance is a hallmark of any aui'Jimmune disease, including IDDM.
Through a process of molecular mimicry it is postulated that a dietary antigen could crossreact with a protein on the surface of the beta-cell, in this case ICA 69, which is induced
by gamma interferon associated with viral infections. The long diabetic prodrome is
associated with a battery of abnormal immunological responses that ultimately result in
beta-cell failure and frank insulin deficiency.
Breast-feeding likely exerts its protective effect by enhancing immunological
function in the newborn, helping to prevent contraction of viral infections, and providing
optimal nutrition to the infant without exposure to foreign antigens present in cow's-milkbased infant formulas and other foods. There 1s substantial, but not totally convincing,
evidence from epidemiological, population , and case-control studies that early introduction of cow's milk protein, in particular BSA, is associated with IDDM. Observations of
specific immunological responses to BSA and cow's milk protein, autoimmune abnormalities, and in some cases , associated genetic markers of predispo-sition to IDDM further
support a role of cow's milk proteins in the autoimmune pathogenesis of IDDM. The
association of IDDM and cow's milk exposure decreases with increasing age of disease
diagnosis (Gerstein, 1994) . IDDM developing in the first one to four years of hfe may be
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more likely to be related to breast-feeding frequency and duration and timing of intrcxiuction of cow's milk proteins than IDDM developing in later childhood and adolescence.
[t still remains unclear why BSA, one exogenous substance absorbed intact that
comes in contact with the immune system, is non-antigenic in normal controls but has been
shown repeatedly to be antigenic in diabetic patients (Yokota et al., 1990). While
antibodies to BSA are detected at some frequency in even normal children, they appear to
disappear in adulthood. Unfortunately, conflicting reports exist that both support and
· undermine the BSA autoantigen hypothesis. The discrepancy in results linking BSA
immunity to IDDM may be due to differences in study populations, specificity and
sensitivity of antibody assay techniques, and the cutoff points for positive determinants .
There appears to be a large overlap of antibody titres in IDDM and controls (Pardini et al.,
1996). This may be partially explained by the heterogeneous pathophysiology of IDDM.
Genetic protection may override environmental factors such as early exposure to cow's
milk protein, in particular BSA , despite elevated anti-BSA antibody titres. Food-induced
diabetes would require both initiation and maintenance of diabetogenesis that depends on
frequent exposure to common dietary antigens and occurs only in geneticall y predisposed
individuals. The BSA hypothesis remains controversial.
IMPLICATIONS FOR FEEDING INFANTS
If the BSA hypothesis holds true , infant feeding practices , in particular intrcxiuctio n of cow's milk and cow's-milk-based infant formulas as breast-milk substitutes , need
to be reevaluated for their potential contribution to the pathogenesis of IDDM in geneticall y
predisposed indi viduals. The following sections provide a brief history of infant formula,
trends in breast-feeding and bottle-feeding, and implications of breast-feeding and bottle-

reeding m developing nations.

The nutritional composition of breast milk compared to

cow 's milk is provided along with recommendations for intrcxiuction of whole cow's milk
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into the diet. An in-depth summary of the characteristics of cow's-milk-based infant
formulas, with special attention to protein composition and BSA content, is also provided.

Infant Formula: A Historical Perspective

In the early part of the nineteenth century, few infants survived who were not
breast-fed (Fomon, 1974). When a mother died in childbirth or was unable to nurse the
infant, a wet nurse was usually employed. In the southern regions of the Unites States,
use of "negro" wet nurses to nurse White infants was common. Breast-feeding remained
the most common means of feeding infants well into the twentieth century (Fomon, 1974).
Increased feasibility and success ofbottle-feeding emerged in the late 1800s and
early 19(X)s. One of the most important factors contributing to success of bottle-feeding
during this period was chlorination of water and the development of safer water supplies.
However, bacterial contamination of milk remained a problem until the early part of the
twentieth century when the kitchen icebox became popular (Fomon, 1974). Advances in
controlled heating and acidification of milk resulted in decreased bacterial growth and
contamination (Fomon, 1974). Reduction in curd tension, which results in increased
digestibility and nutritional quality of cow's milk, was accomplished by acidification,
boiling , dilution, modificauon of mineral content, treatment with enzymes , and
homogenation (Fomon, 1974). By the tum of the century, a product similar to today's
sweetened condensed milk was widely used for infant feeding (Fomon, 1974). However,
problems arose due to the high carbohydrate content, high caloric density, high osmolality,
and low water content of these preparations. By the 1920s, commercial canned evaporated
milk became widely used as an infant feeding alternative and was recognized as being
readily digestible and well tolerated by the young infant. Evaporated milk or fluid whole
cow's milk with added carbohydrate became the mainstay of formula-feeding until the
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1950s (Fomon , 1974). Ascorbic acid and Vitamin D deficiencies \Vere seen, but poorly
understood until the latter half of this century.
By the 1950s commercial infant formula, derived from cmv's milk with added
carbohydrate and often vitamins, was provided in both powdered and concentrated liquid
form. Concentrated liquid formulas held the majority of the infant formula market for the
next 25 years. However, the lowest income groups continued to use evaporated milk
(Fomon, 1974) with or without modifications in carbohydrate content and vitamin
supplementation.
Increased safety and convenience of infant formula from the late 1940s well into
the 1970s, accompanied by failure of investigators to provide evidence of definite
superiority of breast-feeding over formula-feeding during this period, resulted in
physicians becoming unenthusiastic about promoting breast-feeding (Fomon, 1974).
Hill ( 1968, p. 161) observed that "formula-feeding has become so simple, safe, and
uniformly successful that breast-feeding no longer seems worth the bother." It was
recognized that where good hygiene was possible, there was little difference between
formula and human milk (Minchin , 1987). During this period, hospital nurseries adopted
use of commercial formula services. By the late 1960s, sterile ready-to-serve formulas
with disposable nipples were provided to hospitals and to new mothers free of charge by
maJOr manufacturers. Today, it can be assumed that the bulk of infants not breast-fed
receive commercial infant formula.
Trends in Breast-Feeding and Bottle-Feeding
The advent of readily available infant formulas that were seen even by medical
professionals as nutritionally sound, and

in

some cases superior, breast milk alternatives

had a dramatic impact on breast-feeding incidence following World War II in North
America and most of Europe. In the United States 65% of newborns were breast-fed in
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1940. By 1958, only 25% of infants born in the United States were breast-fed at 7 days
(Martinez & Nalezienski, 1979). Reported in Fomon ( 1974), similar trends have been
obser. ed in many northern European countries including the United Kingdom, Nor.vay,
and Sweden. A small decline in the prevalence of breast-feeding occurred between 1955
and the early 1970s according to both the Ross Laboratories Mothers Survey and National
Surveys of Family Growth (Ryan et al., 1991). Breast-feeding prevalence at l \veek
reached a peak in 1982, which was two-fold higher than in 1955. Sixty-two percent of
mothers were breast-feeding at hospital discharge and 30% continued to breast-feed at 6
months postpartum (Department of Health and Human Services, 1990a). A gradual
decrease in breast-feeding rates was apparent throughout the remainder of the 1980s
(Ryan et al., 1991). Breast-feeding trends in the United States are reported in Figure 4.
Breast-feeding rates are highest among women who are White, married, have had
at least some college education, and who live in the western United States (Department of
Health and Human Services, 1990a). A lower incidence of breast-feeding is reported in
women less than 25 years of age, those in lower socioeconomic groups, Black women,
and those living in the southeastern United States (Department of Health and Human
Services, 1990a; Ryan et al., 1991). Breast-feeding incidence is unfortunately lowest in
those infants who could benefit most from the immunological advantages of human milk
(Spisak & Gross, 1991).
Health experts worldwide now agree that breast-feeding is the best way to nurture
infants and should be practiced whenever possible (Spisak & Gross, 1991). Breastfeeding provides optimal nutrition for nonnal growth and development, protection against
disease, decreased risk of allergies, and ultimately, decreased health care cost for infants.
Breast milk provides a number of immunologically protective factors and likely unknown
agents that cannot be mimicked in infant formulas (Cunningham, Jeiliffe, & Jeiliffe , 1991;
Minchin, 1987), despite attempts to "humanize" these preparations. Even in industrialized
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Figure 4. Trends in duration of total breast-feeding in the United States. Data taken from
Ross Mothers Survey, Updated Breast-feeding Trend, 1986-1994 (Ross Laboratories,
1996).

nations, breast-feeding's protection against outis media and respiratory infections (e.g ,
respiratory syncytial virus) cannot be ignored. In addition, breast-feeding has been
reported to prevent bacteremia and meningitis associated with Haemophilus influenzae

1nfections and reduce septicemia and death due to neonatal necretizing enterocolitis
(Cunningham et al., 1991). Significantly lower rates of diarrhea, otitis media, juvenile
diabetes, ulcerative colitis, lymphomas, and Sudden Infant Death Syndrome occur among
breast-fed infants and children in the United States (U.S . Committee for UNICEF and
Wellstart International , 1996). It is still not entirely clear how breast-feeding exerts its
protection against various diseases, or for that matter, how introduction of infant fonnula
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may precipitate disease. In addition, Lucas , Morley, Cole, Lister, and Leeson-Payne
( 1992) found that premature infants fed breast milk had an 8.3 point IQ advantage over
formula-fed infants at 7.5-8 years of age after adjusting for maternal educational level and
social class (Q < 0.0001). It appears possible that early feeding practices may affect mental
development as well as physical health and growth.
The renewed emphasis on breast-feeding and health has prompted a number of
policy statements regarding breast-feeding practices in the United States. [n the l' S .
. Department of Health and Human Services publication, Promoting Health/Preventing

Disease: Objectives for the Nation, the goal for breast-feeding for the year 1990 was to
increase the proportion of women who breast-feed their babies at hospital discharge to
75% and 35% at 6 months of age (1980). Breast-feeding promotion in the United States
became a nutrition priority area by 1990. The breast-feeding objective was updated in

Healthy People 2000: National Health Promotion and Disease Prevention Objectives to
"increase to at least 75% the proportion of women who breast-feed their babies in the early
postpartum period and to at least 50% the proportion who continue breast-feeding until
their babies are 5 to 6 months old" (Department of Health and Human Services, 1990b,
p. 379) . If these initiatives are successful, increased rates of breast-feeding are likely to
have a profound impact on the infant formula industry. The most recent data from the Ross
Laboratories Mothers Survey ( 1996), "Updated Breast-feeding Trends 1986-1994," reveal
that rate and durauon of breast-feeding continue to lag behind the national objective.
Infant Feeding Practices in Developing Countries:
An International Perspective
Many of the problems that contributed to unsuccessful bottle feeding at the turn of
the century in the United States and Northern Europe remain critical factors , contributing to
the high infant mortality and morbidity of bottle fed infants , in developing nations today.
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The availability of clean water, free of pathogenic microorganisms, remains a paramount
issue in the success of bottle feeding . It is well recognized that worldwide nutrition relief
efforts failing to recognize and implement concurrent programs in waste-water treatment,
safe drinking water, and fcxxf safety and sanitation have met with only marginal success.
Breast-feeding can circumvent many of these issues.
Breast-feeding has been shown to prevent infanti le diarrhea in all settings and
improve infant survival rates in poor countries (Cunningham et al., 1991). Most deaths
related to bottle feeding worldwide can be attributed to diarrheal disease with mortality rates
reported to be as high as 14-fold that of breast-fed infants. The risk of dying from a lower
respiratory tract infection in the urban environment of developing nations is four-fold
higher in bottle-fed infants (Cunningham et al ., 1991). The high prevalence of diarrheal
and respiratory disease and associated mortality seen with bottle-feeding in developing
countries often overshadows less common diseases that are now recognized in developed
countries to be associated with either a lack of breast-feeding or the introduction of infant
formula. The negative impact offormula-feeding on initiation, success, and duration of
breast-feeding cannot be overlooked. In addition, breast-feeding serves an important role
in child spacing (Minchin , 1985), which has been associated with decreased mortality in
children less than age 5.
Due to the striking negative impact of infant formula and bottle-feeding on
morbidity and mortality in developing countries, the formula industry has come under close
scrutiny by a number of breast-feeding advocacy groups, including LaLeche League
International, United Nation's Children's Fund (UNICEF), Well.start International, and the
World Health Organization (WHO). To address these concerns, the World Health
Organization has developed a code for marketing breast-milk substitutes. WHO
acknowledges that breast-milk substitutes should be available through commercial and noncommercial distribution systems, but marketing or distribution of these products in \vays
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that interfere with the protection and promotion of breast-feeding is in violation of the
WHO code (Minchin, 1985). Current marketing of infant formula and free distribution of
infant formulas to new mothers in the United States are clearly in violation of the code.
Health care practices have been shown to play a major role in breast-feeding
i ni ti a ti on and success. In 1991 UNICEF and WHO established the Baby-Friend! y Hosp1 ta!
Iniuative (BFHI) . A major emphasis of the Baby-Friendly Hospital Initiative is to target
the national ministry of health, hospitals, physicians, nurses, midwives. and other
influential health professionals and to emphasize the critical need for all to promote the
superiority of breast-feeding over bottle feeding. The BFHI is a global program to
encourage and recognize hospital and birthing centers that offer an optimal level of care for
breast-feeding. Ten steps to successful breast-feeding are outlined to facilitate the role of
the hospital or birthing center in providing women the choice and opportunity to breastfeed . The BFHI has been undertaken in over 170 countries and 4,000 hospitals in both
developing and industrialized nations (U.S . Committee for UNICEF and Wellstart
International , 1996).
Nutritional Composition of Human Milk
The macronutrient composition of human milk is provided in Table 1. The caseinto-whey ratio of human milk is reported to range from 60% whey and 40% casein up to
80% whey and 20% casein (Jost et al. , 1987). Lactalbumin is the prominent protein in

human milk and is of high biological value. Human milk contains a relatively small amount
of casein and forms a soft, flocculent curd with increased digestibility compared to cow's
milk protein (Fomon, 1974). Lactose is the major carbohydrate in human milk. Fifty
percent of the calories in human milk are provided by fat in the form of triglycerides. The
fatty acid composition of human milk reflects maternal intake. Linoleic acid contributes 4%
of the total calories in human milk. The concentration of water-soluble vitamins in human

Table l
Nutrient Composition of Human Milk, Cow's Milk, and Cow's-Milk-Based Infant Formula per Liter

Milk/formula

Calories

Human milk
Cow's milk

750

11

45

70

Lactalbumin, casein

40:60

Skim

357

35

2

50

Casein, whey

80:20

2%

503

34

20

49

Casein, whey

80:20

Whole

624

33

34

47

Casein, whey

80:20

Protein (gms) Fat (gms)

CHO (gms)

Protein source

Casein: whey

Standard infant formulas
Similac

676

15

36.3

72.3

Nonfat milk (casein)

80:20

Enfamil

676

15

33

69

Nonfat milk, reduced
mineral whey

40:60

SMA

676

15

36

72

Nonfat milk,
demineralized whey

40:60

Bonam ii

676

15

38

71

Nonfat milk (casein)

80:20

Gerber

670

15

36

71

Nonfat milk (casein)

80:20
(table continues)

-

8

Milk/formula

Calories

Protein (gms) Fat (gms)

CHO (gms)

Protein source

Casein:whcy

Hydrolyzed infant formulas
Good Start

670

16

34

74

Hydrolyzed,
demineralized whey

100% whey

Nutramagen

670

19

26

90

Casein hydrolsate

100% casein

Pregestimil

670

19

27

90

Casein hydrolsate

100% casein

Ali men tum

676

19

38

69

Casein hydrolsate

100% casein

0
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milk generally reflects maternal intake, and for this reason it is recommended that lactating
mothers take a daily multivitamin supplement. While breast milk is considered complete
nutrition for the infant, it is now recognized that supplementing the infant with an initial
injection of vitamin Kat birth and vitamin D and iron by 4 to 6 months optimizes the
nutritional status (Fomon, 1993).
In addition to nutrients, human milk contains a number of immunolog1cally actne
substances that are thought to protect infants from infection. Lactoferrin may slow
bacterial growth by decreasing availability of iron to the infective organism. Lysozymes
may destroy bacterial cell membranes (Department of Health and Human Services, 1988).
The presence of secretory IgA plus colonization and acidification of the infant's
gastrointestinal tract with Lactobacilli may provide additional protection.
Cow's Milk
It is well recognized that unmodified whole cow's milk is an inappropriate feeding
for young infants. Casein accounts for the major fraction of protein in cow's milk with a
casein: whey ratio of 80% casein to 20% whey (Jost et al., 1987). The tough, hard casein
curd is difficult for young infants to digest. Use of whole cow's milk in early infancy may
cause occult bleeding from the gastrointestinal tract and subsequent anemia. In addition,
cow's milk contains lipids, butterfat, that are less digestible than those found in human
milk. Increased fecal fat excretion has been observed with butterfat but is thought to be of
little clinical significance (Fomon, 1993) . Cow's milk has a high renal solute load due to
the high concentration of minerals and protein. The renal solute load may exceed the
excretory capacity of the immature kidney (Department of Health and Human Services,
1988). The amino acid profile of cow's milk varies from that of human milk. Cow's milk

is higher in tyrosine and phenylalanine and lower in taurine and cystine than human milk
(Department of Health and Human Services, 1988).
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Introduction of cow's milk (whole, 2%, and skim) has been a controversial issue in
infant feeding for the past 20 years . It can be assumed that cow's milk \\'as the most likely
alternative breast milk substitute prior to the advent of canned condensed and eYaporated
milks. Use of whole cow's milk is generally not recommended the first year of life
(American Academy of Pediatrics, Committee on Nutrition, 1992) and 1s not used as a
primary infant feeding in developed industrialized nations. Two percent and nonfat milk
are deficient in energy, essential fatty acids, and certain vitamins, and they contain
excessive protein and minerals per calorie for infants less than one year of age. Use of low
fat or skim milk is not recommended for infants and toddlers less than 2 years of age
(Mahan & Escott-Stump, 1996). The macronutrient composition of cow's milk is provided
in Table 1.
Characteristics of Commercial Infant Formulas
A wide variety of commercial infant formulas is heavily marketed and available as
brea-;t-milk alternatives. While there are some standards for infant formula, it should be
recognized that infant formulas are not homogeneous, vary widely in composition, and
should not be considered to be a consistent product (Minchin, 1987). Revisions in formula
composition are ongoing and new products are introduced to the market and old products
withdrawn on a sporadic basis. Modifications of infant formula composition are often
based on optimization of a product to meet the needs of the infant, but are also based on
market demand . Most infant formulas are derived from intact cow's milk proteins. Soybased formulas and specialized products are available to treat children with allergies, inborn
errors of metabolism , and other conditions.
Current infant formulas for healthy term infants are designed to simulate human
milk. Most formulas are derived from nonfat cow's milk, vegetable oils, and added
carbohydrate. Butterfat has largely been replaced with vegetable oils to enhance fat
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absorption (Fomon, 1974) . Carbohydrate is added , in the form of sucrose , com syrup
solids, starch, glucose, lactose, fructose, or a combination (Fomon, 1974) in order to
provide a calorie-to-nitrogen ratio consistent with human milk. Lactose has largely
replaced com syrup solids as the preferred carbohydrate additive in standard infant
formulas. Demineralized whey has been added to provide a casein-to-whey ratio
consistent with that present in human milk. Cow's milk may be diluted to a more
favorable mineral and solute composition, one that parallels that of human milk.
Vitamins are added to meet recommended nutrition requirements of infants.
The unique protein composition of the major cow's-milk-based infant formulas
currently marketed in the United States is reviewed below. Attention is focused on
modifications in protein composition that are likely to affect the BSA composition of
these preparations. The macronutrient composition of cow's-milk-based polymeric and
hydrolyzed infant formulas is provided in Table 1. Formula preparations vary in their
casein-to-whey ratio, degree of thermal processing, and extent of enzymatic hydrolysis.
These factors are likely to affect the BSA content of the formula.
Polvmeric Cow's-Milk-Based Infant Formulas
Standard polymeric infant formulas currently marketed m the United States include
two high-whey products and three high-casein products. Demineralized whey, which
contributes 12% protein and 75% lactose by weight, is added to cow's-milk-based infant
formulas in order to raise the whey protein fraction and increase the non-protein calorie to
nitrogen ratio. Several commercial formulas now contain a protein mix of 60% whey and
40% casein, which closely parallels the casein-to-whey ratio of human milk. These include
Enfamil, SMA (also marketed under pnvate label), specialized formulas designed for
premature infants, and newly modified Similac. Whey increases the proportion of soluble
protein, limits excessive curd formation, and increases the digestibility of the protein. In
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a ddition, the high-whey products have an ammo acid profile that is more consistent with
hat of human milk. A higher whey fraction has also been shown to have the benefit of
ireducing metabolic acidosis in low-birth-weight infants (Jost et al. , 1987) .
The high-whey formulas are, however, likely to contain significantly more BSA , a
s oluble protein , than the more traditional high-casein cow's-milk-based formulas. This
ay be of particular concern in the premature infant with an immature gastrointestinal trac t.
Formulas designed for premature infants contain the highest fractions of whey in their
n utrient mix. The well-known allergenicity and antigenicity of whey proteins , Blactoglobulin , a-lactalbumin, and serum albumin, have been documented (Asselin , Amiot,
Gauthier, Mourad , & Hebert, 1988; Jost et al ., 1987; Pahud , Monti, & Jost, 1985) .
Three polymeric cow's milk products currently marketed in the United States have
a casein: whey ratio of 80% casein to 20% whey. Casein-based formula preparations are
generally well tolerated by the neonate. Incomplete protein digestion , in particular
impacting casein , is considered a normal physiological characteristic of digestion in infancy
( Mason , 1962) and has not been shown to pose significant problems. While casein is
co nsidered to be less digestible than whe y, a variety of processing techniques has been
employed by the formula industry to address the issue of casein curd formation .
Acidification, dilution , boiling, homogenation, modification of mineral content, and
treatment with enzymes are utili zed to decrease curd tension and increase digestibility of
milk protein (Fomon, 1974). Growth in infants on high-casein formulas has no t been
reported to be different from those recei ving whey-based preparations. High-casein
formulations would be expected to contain smaller amounts of BSA than other pol ymenc
fo rmulas and may be a preferable choice given the potential role of BSA in the pathogenesis
of IDDM. While not established, this would be particularly true if the impact of BSA
followed a standard dose response curve.
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Polymeric infant formulas are marketed in several forms. These include spraydried powder, ready-to-serve bottled or canned liquid, and canned liquid concentrate. The
generally held thought is that the three forms of a given product are nutritional equivalents.
However, differences in temperature and duration of thermal processing may impact
protein structure and BSA composition. Moderate heating such as pasteurization or ultra
heat treatment produces little detectable change in caseins; however, the \vhey proteins are
more sensitive to denaturation by heat. Extensive heating results in almost complete loss
of their unique three-dimensional structure, reduces solubility, and decreases antigenicity
(Mclaughlan, Anderson, Widdowson, & Coombs, 1981). The effect of heat treatment on
immunogenicity and allergenicity of milk proteins has been varied (Asselin et al., 1988).
BSA has been shown to be denatured by heat, but at temperatures and for a
duration in excess of manufacturing standards. Extensive heat treatment of BSA denatures
the protein and disrupts conformational epitopes, but the impact on sequential epitopes ,
such as AB BOS, has not been demonstrated. Degree of denaturation, measured by
immuno-diffusion, has been demonstrated to be complete following heat treatment at 90
degrees Celsius for 10 to 30 minutes or after heat treatment at 125 degrees Celsius for 60 to
180 seconds (Jost et al ., 1987). The lower temperature would require extensive heating
and cool-down periods, which would be undesirable in the industnal setting. The ultra
high temperature range presents the danger of lysine blockage in which lysine complexes
with lactose (Jost et al. , 1987) via the Maillard reaction, forming a nutritionall y inferior
derivative. Scorching of milk at these high temperatures and agglutination of proteins may
alter palatability, digestibility, and antigenicity of the proteins.
Hydrolvzed Infant Formulas
Enzymatically hydrolyzed casein and whey formulas have been available for over
40 years for use in infants with defects in protein absorption and allergic reactions to
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cow 's-milk-protein-based infant fonnulas (American Academy of Pediatrics, Committee on
Nutrition, 1989). Protein hydrolysates have been shown to have substantially lov.:er
immunogenicity than the parent proteins. Antibodies specific for the intact parent proteins
show little cross-reactivity with the tryptic hydrolysates (Cordle, Mahmoud, & Moore.
1991 ) . Enzymatic hydrolysis results in destruction of stable structural ep1topes and

cleavage of sequential epitopes (Mahmoud, Malone, & Cordle, 1992; Rugo, Wall, &
Wahn, 1992). Casein-based hydrolysates are characterized by 70% free amino acids and
peptides of up to five to eight amino acid residues (Siemensma et al., 1993). Casein
hydrolysates have been demonstrated to have non-antigenic peptides of less than 1,200
molecular weight and are generally thought to be superior to whey protein hydrolysates for
use in hypoallergenic infant fonnulas (American Academy of Pediatrics, Committee on
Nutrition, 1989). Extensively hydrolyzed casein fonnulas include Pregestimil,
Nutramagen , and Alimentum . These products are considered truly hypoallergenic and do
not contain peptides exceeding a molecular weight of 1,200 (Knights, 1985).
Whey protein hydrolysates range from 40% to 60% free amino acids with peptides
up to 10 to 12 amino acid residues (Siemensma et al ., 1993). In addition, partially
hydrolyzed whey products are available that contain only 10% free amino acids with
peptides up to 15 amino acids in length (Lah! & Braun, 1994; Siemensma et al., 1993).
The cutoff point for antigenicity appears to be peptides of 8 to 10 amino acid residues
(Siemensma et al., 1993). While marketed as potentially better than intact cow's-milkbased fonnulas, some of these partially hydrolyzed products do not meet the American
Academy of Pediatrics standards for hypoallergenic formulas (American Academy of
Pediatncs, Committee on Nutrition, 1989). Antigenicity and allergenicity of cow's milk
hydrolysates have been reported to vary significantly with the degree of hydrolysis
(Cordle , 1994; Oldaeus , Bjorksten, Einarsson, & Kjellman, 1991). Whey hydrolysates
containing a high percentage of larger peptides retain a high capacity to induce positive skrn
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tests , provocative responses , and to bind human IgE antibodies in children known to be
allergic to cow's milk. Where peptides greater than 1,500 and up to 20,000 daltons exist,
considerably allergenic activity remains (Rugo et al. , 1992) .
Theorellcally BSA and the active ABB OS epitope could remain intact in partially
hydrolyzed infant formulas. Of the major proteins present in milk, BSA has been shown
to be one of the most resistant to hydrolysis by trypsin and other proteases (Jost et al. ,
1987) . BSA is strongly disulfide-bonded, shielding the primary structure from enzymatic
cleavage. Antigenic peptide fragments of BSA have been isolated and identified in tryptic ,
chymotryptic, and peptic hydrolysates of BSA (Habeeb & Atassi, 1976; Pahud et al. ,
1985; Wahn, Peters, & Siraganian, 1981). · While SOS-PAGE showed disappearance of
the major whey proteins following only 1 hour of enzymatic hydrolysis, a faint band in the
region of BSA could still be detected following 4 hours of treatment (Pahud et al. , 1985).
Good Start, marketed as Beba HA in Europe , has a protein base of 100% partiall y
hydrol yzed whey. Good Start has been demonstrated to contain a number of unresolved
and non-degraded or partially degraded whey proteins in the range of 5 to 20 kilodalto ns.
Positi ve skin prick tests following admirustration of Good Start were o bserved in 24% of
children with cow's milk hypersensitivity (Oldaeus et al. , 1991). Depending on the extent
of protein hydrolysis and the whey concentratio n of these hydrolyzed formula preparations ,
antigenic epitopes of BSA , including the ABBOS peptide , may still be present.
BSA in Cow's Milk and Cow's-Milk-Based Infant Formula
The reported BSA content of cow's milk varies by four-fold , ranging from 0. 1 to
0 .4 grams per liter (Robin et al. , 1993; Swaisgood, 1982 ; Whitney, 1988). Quantitative
data on the BSA content of cow's-milk-based infant formulas are lacking. Much of the
attention on detection of specific milk proteins in formula has focused on evaluating the
degree of residual antigenicity in extensivel y hydrol yzed formulas designed for use in
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infant with hypersensitivity to cow's milk proteins. Specifically, BSA has not been shown
to the present in Nutramagen or Alimentum by polyacrylamide gel electrophoresis (PAGE)
using silver stain (Cordle, 1994; Oldaeus et al., 1991; Sampson, Bern-Broadbent, Yang, &
Scanlon, 1991). Reports regarding the presence of intact BSA in the partially hydrolyzed
product, Good Start, again using PAGE with silver stain , are mixed (Cordle et al., 1994;
Oldeaus et al., 1991). Serum antibody production to BSA in guinea-pigs has been shown
to be greatly reduced in formula (SMA) provided in liquid concentrate form compared to
antibody prcxiuction following feeding of the corresponding SMA powder (Heppel, Cant,

& K.ilshaw, 1984).
Monte, Johnston, and Roll ( 1994) detected BSA in three of four standard infant
formulas using radial immuncxiiff usion. BSA was not detected in those subjected to ultra
high temperature sterilization or in the one hydrolyzed product tested. Immunodiffusion
methods have previously been reported to be 10,00o-fold less sensitive than ELISA and are
likely to underestimate antigenicity (Leary, 1992). Radial immuncxiiffusion is sensitive
down to 40 mg BSA/Liter, which is about 10% of that found in cow's milk (Strand , 1994)
and may not be sensitive enough to detect BSA in high-casein prcxiucts or to detect residual
BSA in ultra high temperature sterilized or hydrolyzed preparations. Monte and colleagues
( 1994) used centrifuged samples representing the defatted soluble fractions of infant
formulas. Therefore, quantitative data could not be extrapolated back to the original
formula of milk. In addition , the casein-to-whey ratio of polymeric standard infant
formulas has not been addressed.
Research Implications
The extensively hydrolyzed casein-based formula preparations are considered to be
free of BSA and, based on molecular weight of remaining peptides, should also be devoid
of the AB BOS epitope. There are mixed reports in the literature as to whether partially
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hydrolyzed whey formulas contain intact BSA or the ABBOS epitope. Based on reports
of high residual antigenicity and the presence of higher molecular weight peptide
fragments, it appears likely that BSA or the AB BOS peptide may be present. Standard
polymeric infant formulas containing whey certainly contain BSA and the ABBOS epitope
with amounts likely proportional to the whey protein concentration. The impact of various
methods and degrees of heat treatment used in the preparation of infant formulas on the
antigenicity of BSA has not been established. No comprehensive quantitative information
is available describing the BSA content of infant formulas.
Additional knowledge of the BSA content of existing infant formulas is needed in
order to further assess the role of BSA and AB BOS in the pathogenesis of IDDM and to
make sound nutritional recommendations for those infants not exclusively breast-fed.
The present study was undertaken to develop a simple and reliable quantitati ve analysis of
BSA content of cow's milk and cow's-milk-based infant formulas. Both direct and indirect
ELISAs were evaluated as a method for quantitating BSA. A sensitive direct ELISA was
developed to specifically detect and quantitate the amount of BSA present in cow's milk
and infant formula preparations. Use of a polyclonal antibody to BSA allowed for
detection of BSA and antigenic epitopes of BSA. The information obtained provides a
consistent relative quantitative measure of the contribution of cow's milk and cow's-milkbased infant formula to the BSA antigen load in infants' diets.
Thermal and enzymatic processing of infant formula is utilized in the industrial
setting to reduce ailergenicity of these preparations. These processes affect other proteins,
in addition to BSA, resulting in a substantially modified product or protein base having
potential nutritional implications. There are several inherent drawbacks of heat treatment of
infant formula to eliminate BSA . Heat treatment of milk and cow's-milk-based infant
formula has been reported to affect the nutritional quality of these preparations and even if
effective, may not provide the optimal means of destroying or removing BSA and the
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ABBOS epitope from commercial formulas. Heating may cause lysine blockage in which
lysine complexes with lactose in the Maillard reaction. Lysine blockage needs to be
assessed and controlled in order to maintain the nutritional quality of the formula (Jost et
al ., 1987; Kilshaw, Heppell, & Ford, 1982). Lysine is an essential amino acid and is
required in relatively large amounts by the infant for normal growth and development. The
Maillard reaction has been reported to result in a 24% decrease in lysine availability

in

heat-

treated commercial infant formula (Heppel et al. , 1984). Another product formed during
heat treatment is lactulose, a p<X)rly absorbable derivative of lactose. Osmotic activity of
lactulose and fermentation in the intestine can contribute to diarrhea, particularly in infants
recovering from gastroenteritis (Jost et al., 1987). Extensive heat treatment of skim milk
has also been shown to destroy all vi tarn in 812, 60% of the thiamin, 70% of the ascorbic
acid, 30% of the folate with considerable loss of 86, while retaining its capacity to sensitize
guinea-pigs to beta-lactoglobulin and the caseins (Kilshaw et al. , 1982). Extensi ve heat
treatment may also result in scorching and associated flavor alterations. In addition,
enzymatically hydrolyzed infant formulas require fortification with specific amino acids
destroyed in processing and may not be well accepted by the infant due to flavor and
texture alterations. The cost of extensivel y hydrolyzed elemental preparations is up to three
times as much as standard, cow's-milk-based infant formulas.
The objective of the second component of the study was to develop an alternati ve
technology to produce a BSA-free polymeric protein base without extensive heat treatment
or enzymatic hydrolysis. Affinity chromatography was employed to develop an
immunomagnetic capture system to selectively extract BSA from cow's milk and whey
protein isolates that are used in the manufacture of commercial infant formula. Both
monoclonal and polyclonal antibodies were evaluated for capture efficiency. This
methodology could be used in combination with molecular sieving or other alternative
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means of removing or destroying BSA that may be less than 100% effective. An
overview of immunocapture methodology is provided in the following section.

OVERVIEW OFENzyME-LINKED IMMUMOSORBANT ASSAYS
AND IMMUNOAFRNITY CHROMA TOG RA PHY
Enzyme-Linked Immunosorbant Assays
Immunoassays can be performed to estimate the amount of a substance, an
analyte, in an unknown or test specimen. Enzyme-linked immunosorbant assay (ELISA)
technology was introduced in the early 1970s as an alternative to radio immunoassays.
The major difference is that the endpoint is measured by an enzyme-driven colorimetric
reaction rather than radioactivity (Makarananda & Neal, 1992). ELISA is a useful
technique to provide specific and sensitive examination of a substance. Monoclonal or
polyclonal antibodies to the substance can be used to capture and detect the analyte. The
hallmark of ELISA methodology involves an enzyme-labelled detector antibody which,
upon reacting with a substrate, elicits a colored reaction product that is proportional to the
amount of analyte present in the sample. ELISAs have comparable sensitivity to
radioimmunoassays without the limitations of short half-life and problems with disposal
of radioactive materials (Kemeny & Chantler, 1988).
Common uses of immunoassays involve detection and quantitation of antigens ,
scrum antibodies , and a variety of other proteins. Common classifications of ELISA
methodology include the competitive ELISA , direct ELISA, indirect ELISA, and class
capture for immunoglobin subclasses. The focus of the following discussion will be
limited to direct and indirect ELISA techniques for detection and quantitation of antigens .
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Assay Components
Solid Supports
A number of solid supports are available for ELISA. These include plastic,
nitrocellulose, agarose, glass, cellulose, polyacrylamide, dextran, and beads (Carpenter,
:992) . Plastic 96-well microtitre plates formulated from polystyrene or polyvinyl chloride
~re

most commonly used. Microtitre plates are typically coated with antigen or antibody

in

concentrations ranging from 1 to .SO µg /ml diluted in carbonate coatrng buffer (pH 9.6).
Antigens and antibodies are bound via hydrophobic interactions (Carpenter, 1992).
Adsorption is dependent on surface anributes of the plastic, concentration and
characteristics of the antigen, time and temperature (Carpenter, 1992). These factors must

be optimized in each assay system. The limitation of most microtitre plates is the capacity
tJ bind antigen (Kemeny & Chantler, 1988).

Capture Antibodies
The most important requirement for capture antibodies, once bound to the solid
i:hase, is a high capacity to bind relevant antigens (Kemeny & Chantler, 1988). If the
detection antibody is highly specific for the analyte in a sandwich procedure, some lowlevel binding to irrelevant antigens by the primary antibody may be tolerated. Most
polyclonal antibodies bind well to the solid phase (Kemeny & Chantler, 1988).
Monoclonal antibodies are more likely to be problematic, both in terms of their affinity for
the test antigen and stability upon adsorption to the microtitre plate (Butler, 1988).
In most cases it is preferable to use immunoglobin fraction, rather than whole
serum or ascites, for coating wells. Use of immunoglobin fraction prevents competitive
binding and interference by other proteins present in serum or ascites fluid (Kemeny &
Chantler, 1988). Antibody abundance of polyclonal antibodies is essential to the assay.
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Polyclonal antibodies of antiserum having low antibody concentration may requ1re affinity
purification. Howe ver, selection of a polyclonal antibody with high antibody abundance
may be most desirable as it avoids the work of affinity purification and potential problems
of ligand leakage that can occur during purification (Butler, 1988).
Anti bcxiv Conjugates
The quality and efficacy of detector antibodies used for enzyme labeling and
conjugation of the antibody with the enzyme are critical determinants of assay performance
(Kemeny & Chantler, 1988). Each ELISA requires an anllbody conjugated with an
enzyme that can react with a chromagenic substrate (Makarananda & Neal, 1992). The
enzyme , which is attached to an antibody, reacts with a substrate eliciting a colored reaction product. The amount of color is proportional to the concentration of the analyte and
can be monitored visually or via a spectrophotometer depending on the desired sensitivity
needs of the specific assay. A number of multichannel photometers are available for
reading 96-well microtitre plates.
A number off actors may affect the cho ice of enzyme including purity, specifi c
acti vity , sensitivity of substrate detection , ease of co njugation, efficacy, and stability
(Kemeny & Chantler, 1988). The most popular enzymes used for ELISAs are alkaline
phos phatase (AP) , horseradish peroxidase (HRP) , and

~-galactosidase

(Butler, 1994) .

These enzymes have been extensivel y used in ELISA , and product detection systems are
available that are suitable for most uses (Kemen y & Chantler, 1988). These enzymes may
be conjugated with whole pol yclonal antibodies, immunoglobin G (IgG) fraction s, affinity
purified polycional antibodies, and monoclonal antibodies (Carpenter, 1992). Affinity
purified antibodies generally yield the best results with high detectability of anal yte and
lo w background interference (Kemeny & Chantler, 1988).
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Enzyme Substrates
When selecting the substrate, attention should be given to sensitivity, stability,
background absorbance, toxicity , and cost. Since many of these compounds are
potentially carcinogenic , toxicity may be a major concern (Carpenter, 1992). HRP reduces
hydrogen peroxide and oxidizes a second substrate, which collectively prcxiuces the
colored reaction product. The most common substrates used with HRP are aphenylenediamine (OPD), 5-aminosalicylic acid, 2, 2-azincxii-(3-ethylbenz-O-thiazoline-6sulfonate, and 3, 3', 5, 5'-tetramethylbenzidine (TMB) . OPM and TMB have been
reported to be the most sensitive for detection of low levels of enzyme with TMB having
the advantage of being nonmutagenic and noncarcinogenic (Kemeny & Chantler, 1988).
The most common substrates used for photometric measurement of antibodies labeled with
alkaline phosphotase and ~-galactosidase are p-nitrophenyl phosphate (pNPP) and 0nitrophenyl - ~-D-galactopyranoside

(ONGP; Butler, 1994).

General Overview of Selected ELISA Procedures
Direct ELISA
The direct ELISA is often called a sandwich ELISA because the anal yte to be
measured is layered between molecules , which recognize either the same epitope or
different epitopes on the analyte (Butler, 1988) . The two-antibody sandwich ELISA is the
most useful methcxi to detect and quantitate antigen (Harlow & Lane , 1988). The sandwich
ELISA is suited onl y to the measurement of multi valent molecules such as proteins,
antigens , and polysaccharides (Butler, 1988) . This methcxi requires either affinity purified
polyclonal antibodies or two monoclonal antibodies that bind to two different sites on the
antigen (Harlow & Lane, 1988).
In a sandwich ELISA , one antibody, the capture antibody, is bound to the solid
phase. Antigen in the sample is allowed to bind the capture antibody. The anal yte to be
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measured , usually the antigen , is captured by the antibcxiy-coated matrix on the solid
phase. The enzyme-labelled secondary antibcxiy is added , completing the sandwich
(Carpenter, 1992). It is preferable, but not essential , that the capture and detection
antibcxiies are from the same species in order to minimize species cross-reactions (Kemeny
& Chantler, 1988). Sample antigen is detected and quantitated by measuring the amount of

secondary , labelled antibcxiy the binds to the captured antigen (Harlow & Lane, 1988) .
Reacting the enzyme with substrate yields color that is proportional to the amount on
secondary antibcxiy and, therefore, antigen (Makarananda & Neal , 1992). The direct
ELISA procedure for quantitation of immunoglobin or antigen is shown in Figure 5.
Indirect ELISA
With indirect ELISA either antibcxiy or antigen can be can be bound to the solid
phase. T ypically, antigen is bound to the solid phase, which can be used as a target for
antibodies in the test sample (Kemeny & Chantler, 1988). The specific antibodies present
in the sample bind to the antigen-coated solid phase during a second incubation step.
Unbound material is removed by washrng. Bound antibody can be detected by a
secondary enzyme-labelled anti-immunoglobin (Carpenter, 1992 ; Kemeny & Chantler,
1988). Detection of the antibcxiy may be limited by the ability to bind antigen to the solid
phase (Kemeny & Chantler, 1988). After washing, the assay is quantitated by measuring
the amount of antibcxiy bound to the antigen (Harlow & Lane, 1988).
The indirect ELISA can also be used to assess the amount of antigen

in

a sample

bound to the solid phase. The antigen is attached to the solid support during incubation,
and the labelled antibody is allowed to bind (Harlow & Lane , 1988). When the sample
containing antigen is bound to the solid phase, an excess of labelled antibody, to allow full
saturation between antigen and antibody, is required to detect and quantitate the sample
antigen. After washing , the assay is quantitated by measuring the amount of antibody
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bound to the antigen (Harlow & Lane, 1988). In some cases, a primary antibody that is
labeled with an enzyme is commercially available for the specific antigen in question. If
not, a secondary labelled anti-immunoglobin is required. The indirect ELISA procedure is
described in Figure 6.
Ouantitation
Quantitative immunoassays can provide an absolute amount in weight per unit
volume (e.g. , nanograms to micrograms per milliliter) using a precalibrated standard or
a relative comparison of the amount of an analyte by dilution analysis (Hamilton &
Adkinson, 1988). The latter is usually used for antibody determination; however,
problems have been reported to arise due to poor reproducibility of results (Carpenter,
1992). Theoretically a linear relationship should exist between analyte concentration and
optical density. However, since this is likely to be the exception, rather than the rule,
reference standards are employed for extrapolallon of unknown antigen or antibody in the
test sample (Kemeny & Chantler, 1988). A reference standard is used for calibration when
it is desirable to report ELISA data m absolute quantitative amounts. A dose response
curve is generated using the known concentration of the reference standard plotted against
1ts

absorbance. It is important to obtain values for samples falling along the linear portion

of the standard curve. Either homologous or heterologous interpolation can be performed
for translating the response into a dose estimate.
Homologous interpolation utilizes a standard containing a homologous or identical
analyte to that being measured in the test sample. Heterologous interpolation is used when
it may be impossible or too costly to use a homologous reference serum for each analyte.
The analyte is interpolated from a standard curve using a similar, but not identical test
serum (Hamilton & Atkinson, 1988).
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Figure 6. Indirect ELISA. Antigen is added lo the microtilre plate and incubated. Unadsorbed antigen is removed by washing
with PBS-T prior lo addition of antibody. Specific antibody is incubated with the antigen. Unbound material is removed by
washing. Enzyme labelled secondary antibody (species specific anti-IgE) is added and incubated with the bound IgE. The
enzyme chromagenic substrate is added as the final step.
Figure adapted from Kemeny & Chantler (1988) .
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The magnitude of the response provided by the unknown sample (i .e.,
absorbance) can be interpolated from the standard dose response curve. The test sample
must be analyzed with gcxxi parallelism between the dilution curves (Hamilton &
Atkinson, 1988). This is important in order to have an accurate assessment of the
analyte concentration where the interpolated test sample result does not vary as a function
of the serum dilution analyzed. In order to evaluate parallelism, a test sample is measured
in several different dilutions, interpolated from the standard, and corrected for its respective
dilution. Less than 10% interdilutional coefficient of variation of the analyte is considered
to be within reasonable statistical error (Hamilton & Atkinson, 1988). In addition,
variability of the method can further be assessed by testing three dilutions of the reference
antigen to cover the lower, middle, and upper limits of the standard curve in triplicate on
several different assays. Inter- and intra-assay variation can be expressed as the coefficient
of variation ([Standard Deviation X 100]/mean; Kemeny & Chantler, 1988).
Optimization
While ELISAs offer advantages due to their apparent simplicity, careful attention
must be given to development of individual assay systems and optimization of assay
techniques in order to assure gcxxi quality (Kemeny & Chantler, 1988). The optimal
working concentration of labeled antibodies \Viii vary depending on the application and the
assay format. Optimal conditions can be verified only by trial and error (Kemeny &
Chantler, 1988).
Initially, all ELISA reagents alone should be tested for their background
absorbance. The

basic controls on all ELISA plates should include a PBS blank, a negative

sample control, and low and high positive controls. The checkerboard titration is
traditionally used to establish appropriate working dilutions of coating antibody or antigen
and antibody conj ugate. Four dilutions of coating antibody or antigen can be tested in

130

duplicate horizontal rows on a 96-well microtitre plate. Coating proteins are bound
passively during incubation. Non-bound material is removed by washing with phosphate
buffered saline with Tween (PBS-T). Reacted sites are typically blocked with a
nonspecific protein (e.g., BSA, gelatin, or nonfat dry milk; Carpenter, 1992). Test
samples of antigen, which should include a high positive control, a negative control , and
PBS, are added vertically in columns and incubated with the capture antibody or anugen.
Following incubation, unbound material is removed by washing with PBS-T . The
detection antibody conjugate is added in vertical triplicate columns and incubated.
Unbound material is again removed followed by application of the appropriate substrate
(Carpenter, 1992). The optimal antibody or antigen coating concentration is provided by
the least quantity yielding near maximal binding of the analyte. This is used to determine
the impact of varying the concentration of the secondary antibody conjugate (Kemeny &
Chantler, 1988). Typically, higher levels of antibody conjugate increase the background
noise and decrease the measurable analj-te range. Low levels have been demonstrated to
reduce the specific absorbance measured but not the nonspecific binding (Kemeny &
Chantler, 1988). The optimal conjugate dilution is one that yields an absorbance reading
for the PBS blank of less than 0.05, the negauve control value of less than 0.2, and a high
positive of greater than 1.0 (Carpenter, 1992).
The rate at which the assay proceeds is dependent on the concentration of reactants
and is directed by the Law of Mass Action. The concentration of reactants, the capacity of
the solid phase, the concentration of detector, assay speed, incubation temperature , and
detection system can impact the sensitivity of the assay. Attempts to increase the rate of
specific signal detection usually result in an increase in the signal in controls (Kemeny &
Chantler, 1988). For example, increased concentration of labelled detector usually
increases nonspecific binding and, therefore, background noise. The goal of optimization
1s to improve the signal-to-noise ratio. Prolonged incubation times are not desirable and
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have been associated with increased intra-assay variation (Kemeny & Chantler, 1988). The
rate of the reaction is dependent upon temperature. Temperature variations can be
minimized by incubating under controlled conditions.
When immunoassays do not work, the first step is to check primary and secondary
antibodies and detection systems. However, the most common source offailure is in
attaching the antigen to the solid support (Kemeny & Chantler, 1988). Other common
technical problems encountered in ELISA include nonspecific protein binding , crossreactivity and other unwanted interactions, the presence of antibcxlies in sample that
recognize blocking proteins, antibody or antigen excess, temperature variation, and edge
effects (Kemeny & Chantler, 1988). Application of too much antigen or antibody to the
solid phase may result in stacking due to protein-protein interactions and result in
desorption during the assay process (Carpenter, 1992). This problem can be circumvented
by additional washing prior to application of the next layer. Undesirable cross reactivity
with assay components must be removed. Problems with nonspecific and specific
undesirable binding can often be reduced by the addition of BSA, animal sera with or
without Tween 20, or casein hydrolysate to buffers (Kemeny & Chantler, 1988). Serum
albumin, gelatin, casein, nonfat milk, and other proteins have been used to block unreacted
sites on the solid phase following binding of the primary anubody or antigen and can
reduce nonspecific binding. Controlling for nonspecific binding to the plate makes it
possible to use an excess of detection antibody. There are some reports that a so-called
"edge effect" occurs by which coating proteins bind to peripheral wells better than to
interior wells; however, well-to-well variability is likely to be greater than edge effects
(Carpenter, 1992).
The development of each individual ELISA system requires careful attention to
essential steps in order to ensure accurate and reproducible results. The type of assay must
be individually tailored to the particular analyte in question (Kemeny & Chantler, 1988) .
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Mlny aspects of ELISA methodology can prove to be problematic (Carpenter, 1992).
However, if the details of the general ELISA procedures are strictly followed in the
<de•elopment of specific assays coupled \vi th appropriate troubleshooting, reliable and
\Us~f ul

test results can be obtained.
I mm unoaffini ty Chromatography
The basic concept of affinity chromatography is based on a selective interaction

beiween the material to be isolated and a molecule, the ligand, that has been immobilized on
a chromatographic support (Jack, 1992). The ligand is immobilized on the
chromatography support, and the molecule of interest specifically binds to the ligand and
remains bound until the complex is broken with an eluting agent (Scopes, 1992) .
Immunoaffinity chromatography provides the specificity of immunologic reactions
to affinity separations. Immunoaffinity chromatography uses antibodies or antigens as the
affinity ligand whereby separation comes about through immunological reactions (Jack,
1992). Immunoaffinity chromatography is an effective technique for isolation of proteins.

As with any immunological assay, the purity of the anubody and the affinity of the
antibody for the antigen is critical.
The overall process of immunoaffinity chromatography for separation and
extraction of proteins involves immobilization of a specific antibody by chemical bonding
to an inert support matrix. The antibody matrix may be packed into a column, and a
solution containing the protein antigen to be captured is passed over the antibody coated
matrix (Harlow & Lane, 1988). The antigen binding s1 tes located on the arm of the
antibody come in contact with the antigen and capture it. The captured protein is retained,
while unbound material passes through the column. The captured antigen can be recovered
by a variety of elution techniques, which releases the antigen from the solid phase (Scopes,
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1992). Column techniques are designed to allow maximum contact between the material to

be separated and the immobilized ligand (Harlow & Lane, 1988).
Alternatively , batch techniques can be used to isolate proteins. Batch techniques
are used when large amounts of protein antigen need to be captured with minimal effort.
The availability of magnetic beads has greatly enhanced batch techniques wtth ease of
recovery of the ligand bound protein (Wang, Borysiewicz, & Weetman, 1992). The
activated support is incubated with the sample media. Constant stirring is required to
prevent sedimentation of the solid support and loss of ligand efficiency (Blake, 1996).
Application of a magnet for holding the protein ligand complex while removing unreacted
material facilitates the recovery process. The batch technique using paramagnetic beads is
shown in Figure 7 .
For both traditional column and batch techniques, immunoaffinity chromatography
can be divided into three steps: ( 1) preparation of the antibody matrix, (2) binding of the
antigen or protein to the antibody matrix, and (3) elution of the antigen from the matrix is
desired (Harlow & Lane, 1988). Details of some of the more common techniques for
preparing the antibody matrix and binding of the antigen to the antibody matrix are
reviewed below. Since the research presented in the following chapter did not involve
elution of the antigen, a limited discussion of elution techniques 1s provided.
Preparation of the Antibodv Matrix
Characteristics of Common Solid Supports
The desirable characteristic of support matrices used for chromatographic
separations is a large surface area that is mechanically stable with suitable sidechains that
can be easily modified for ligand attachment. The support matrix must be chemically inert
to avoid nonspecific binding (Harlow & Lane, 1988).
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Figure 7. Immunoaffinity chromatography batch technique using magnetic beads.
Magnetic beads with an activated ligand, an antibody, are added to a mixture
containing a number of proteins (x) and the protein (Ag) of interest. The mixture is
incubated allowing the protein of interest to bind to the antibody ligand (#1). The
captured protein can be extracted by applying a magnetic field to the test tube (#2).

A number of supports are available for chromatography. For chromatographic
separations, solid phase supports are usually used in beaded form. Organic supports
include cellulose, dextran, and agarose . Inorganic supports include silica and solid glass
beads. Silica supports can be chemically modified to produce silane groups to which
sidechains (e.g., epoxy and thiol groups) are attached. These sidechains provide
anachment sites for the ligand to be immobilized (Bhatia et al ., 1989) . Silica can also be
modified with a thin coat of hydrophilic polymers, which form both a protective coat and a
spacer arm for ligand attachment (Hermanson, Mallia, & Smith, 1992) . Glass beads can
also be silanized followed by chemical modification of the silanol group for anachment of
reactive side chains (Bhatia et al., 1989). Synthetic supports include polyacrylamide,
methacrylate, and acrylic, which are mechanically strong (Hermanson et al ., 1992).
Composite matrices include polysaccharide-polyacrylamide and magnetic beads.
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Magnetic beads are gaining popularity as ligand suppoms for batch separation
methods as the affinity ligand can easily be recovered with a rrnagnet (Wang et al., 1992).
Beads are good supports for batch purification and immunoas;says using a wide \·ariety of
ligands (Harlow & Lane, 1988). Immunomagnetic beads c1Ja ted with a polystyTene shell
provide a smooth hydrophobic surface that adsorbs molecules; (e.g., anti bodies) or can
bind other bioreactive molecules covalently through surface h;ydroxyl groups (Wang et al.,
1992). Several types of beads can be activated by chemical tr~atment to produce binding

sites for proteins with free amino groups. Ligands can be cc)Ulpled by a variety of
techniques. The disadvantage of the use of magnetic beads ilS the solid phase is that
washing becomes a tedious and time-consuming process (Htlfl!ow & Lane, 1988).
Antibody Ligands
A number of different molecules can serve as affinity' ligands for chromatographic
separation and extraction. The major constraints are that the li[gand binds specifically, and
usually reversibly to the material being isolated and contain grcmps within its chemical
structure that bind the solid support (Harlow & Lane, 1988). I mmunoaffinity
chromatography utilizes antibodies or antigens as the ligand. The discussion here will be
limited to the use of antibodies as the capture ligand.
Either monoclonal antibodies or polyclonal antibodie§ tro the antigen in question are
covalently attached to the solid phase (Harlow & Lane, 1988J.

Monoclonal antibodies can

be made to any number of specific antigenic determinants. Po l:yclonal antibodies react well
with more common antigenic determinants. Polyclonal antibQci!ies usually bind to several
different sites on the antigen with high avidity. This binding pattern, however, makes it
difficult to elute the protein (Harlow & Lane, 1988; Jack, 1992).
The strength and selectivity of the immobilized antibo<dY to the material being
isolated are critical (Pepper, 1992). Polyclonal antibodies used in affinity chromatography
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require purification. Isolation of the IgG fraction can be achieved with either ion exchange
chromatography or salt purification with ammonium or dextran sulfate (Hermanson et al.,
1992) . Further purification by affinity chromatography using the target antigen as the

immobilized ligand may be desirable in some cases. Antibodies with high affinity can yield
quantitative removal in less than 1 hour of incubation. Those with low affinity, even 1f in
high concentration, will never bind all the antigen in solution (Harlow & Lane, 1988).
Attachment of Antibodies to the Solid Phase
A number of methods have been described to attach antibodies to the solid phase.
Antibodies can be immobilized by chemical linkage to reactive sidegroups on the solid
phase or via specialized protein coatings (Bhatia et al., 1989). Direct attachment of
antibodies to the solid phase can be accomplished using a number off unctional side chains
(e.g., thiol, epoxy, carbonyl, and carbonyl diimidazole; Hermanson et al. , 1992) . Direct
attachment of antibodies has been reported to be haphazard. In this case the antibody is
attached by amine groups at any point along the heavy chain and may not be optimally
o riented for antigen capture. For maximum capture efficiency, antibodies should be
attached to the solid phase via the Fe or tail portion , leaving the arms containing the two
antigen receptors free to bind the antigen (Harlow & Lane, 1988). For this reason,
hydrazine has become popular to attach the antibody by the Fe fragment. This can be
achieved following treatment of the antibody carbohydrate moiety with periodate
(Hermanson et al., 1992).
To facilitate optimal binding and orientation of antibodies to the support matrix,
special coatings can be applied to the support matrix. The general methods for coupling
antibodies to the solid phase include use of protein A/G beads, activated beads, and
activated antibodies (Harlow & Lane, 1988). Protein A binds specifically to the Fe , or tail
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portion, of the antibody. The antibody is stabilized to the matrix by cross-linking by a
bif unctional coupling reagent (Harlow & Lane, 1988).
The second methcxi involves use of chemically activated beads containing reactive
groups that are coupled to the antibody (Harlow & Lane, 1988). Several commerciallv
prepared matrices are available that contain secondary reagents that bind specifically to
antibodies. Reagents used to activate beads include carbonyldiimidozole, cyanogen
bromide, and tosyl chloride which bind the solid phase matnx by an -OH group;
gluteraldehyde, which binds by an -NH2 group; and hydroxysuccinate, which binds by
the -COOH moiety (Harlow & Lane, 1988). Antibodies are coupled to the activated beads
through amine groups. Overcoupling can decrease antibody activity and can usually be
avoided by letting the reaction proceed at neutral pH (at of above the pK of the amino
groups; Harlow & Lane, 1988). The major advantage of using activated beads is that the
antibody can be attached covalently ensuring a stable reactive phase (Harlow & Lane,
1988).
Alternately, antibodies can be chemically activated and then attached to the solid
phase (Harlow & Lane, 1988). Purified antibodies may be activated by a number of
bi of unctional reagents where one group binds to the antibody and the other to the solid
phase (Harlow & Lane, 1988). Common reagents for indirect coupling of antibodies to
the solid phase include water-soluble carbodiimides (e.g., l-ethyl-3-(3-dimethylaminopropyl)-carbodiimides, EDAC and EDCI), condensing agents for peptide synthesis
(e.g., N-ethoxycarbonyl-2-etho.xy-1,2-dihydroquinoline, EEDQ), glutaraldehyde, and
periodate (Harlow & Lane, 1988). Antibodies activated by carbodiimides and condensing
agents bind to carboxylic acid. Glutaraldehyde and periodate-activated antibodies bind to
amines (Harlow & Lane, 1988). The primary advantage of antibody activation is that it
allows a choice of a wide range of beads and spacer arms where necessary (Harlow &
Lane, 1988).
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Spacer arms, which extend the immobilized ligand away from the support matn.\,
are utilized to reduce steric hindrance between the immobilized support and the material to
be isolated. Steric hindrance can reduce or prevent specific binding. This can be overcome
by binding a spacer arm to the support matrix prior to attachment of the ligand . The ligand
can be attached by a gluteraldehyde or carbodiimide-mediated reaction (Hermanson et al.,
1992.
Nonspecific interactions can occur between the substance being isolated and either
the support matrix or the spacer arm (Bhatia et al. , 1989). Regardless of the means of
attaching the antibody to the support matrix, once the antibodies are attached, unreacted
side chains should be blocked to avoid both specific and nonspecific binding with
components of the test media (Bhatia et al., 1989).
Attachment of Antigen to the Antibodv Bead Matrix
The two recommended procedures involve binding of the antigen in a constantly
mixing slurry of antibody-activated beads and a sample containing the antigen or by
passing the antigen solution down an antibody-activated bead column (Harlow & Lane ,
1988). The sample is exposed to the antibody bead matrix, and the antigen becomes bound
to the immobilized antibody during incubation (Harlow & Lane, 1988). The remainder of
the unreacted sample is removed by washing (Harlow & Lane, 1988).
Elution
Elution involves desorption of the bound material from the ligand. The forces
holding the antibody-antigen complex intact are the same forces contributing to the
intramolecular structure and stability of the two proteins. Both antibodies and antigens can
easily be denatured by elution buffer (Scopes, 1992). When an antigen is bound to several
different antibodies, as occurs with polyclonal antibodies, the harsh elution conditions
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required to remove the antigen from the solid support can also partially denature the antigen
(Harlow & Lane, 1988). More conservative approaches can be used to elute monoclonal
antibodies due to the limited number and similar characteristics of bonds fanned with the
antigen. Antigen-antibody complexes can be broken by treating with harsh conditions ,
adding a small amount of an agent that resembles the antigen-antibody binding site , or by
treating with an agent that causes an allosteric change in the binding site. The antigen is
released into the eluate and subsequently recovered (Harlow & Lane, 1988).
CONCLUSION
IDDM develops in a relatively small number of individuals who carry specific
genetic characteristics associated with increased disease susceptibility. The interaction of
genetic, immunological, and environmental factors working over the extended diabetic
prodrome appears to be extensively involved in the pathogenesis of the disease. To date ,
the exact mechanism of autoimmunity and its interplay with genetic predisposition and
environmental factors is unknown.
There appear to be a number of potential environmental factors that may trigger and
sustain the autoimmune process that eventually leads to total destruction of the insulinproducing beta-cells of the islets of Langerhans in the pancreas and overt clinical di sease.
If the initial insult triggering the autoimmune response could be identified and subsequentl y
e liminated , a substantial reduction in the incidence of IDDM could be achieved.
Epidemiological evidence points to an important role of diet in the etiology of
IDDM. The complexity of the search for a diabetogenic agent is compounded by the
likelihood of multiple dietary factors and potential interaction with other environmental
detenninants . Studies have failed to look at both the qualitative and quantitative aspects of
infant diet against a background of genetic predisposition and the progression of
autoimmunity to pancreatic beta-cells. While there is still much controversy surrounding

140

infant feeding practices and their relationship to the pathogenesis of IDDM, there is
substantial evidence to suggest that reduced incidence and duration of breast-feeding,
particularly exclusive breast-feeding, and early introduction of cow's milk protein are
contributing factors.
An elaborate scheme involving genetic and immunological factors interacting with
the specific BSA epitope, ABBOS, in the pathogenesis of IDDM has been proposed.
Substantial evidence of an immunological response to BSA, and specifically to the AB BOS
epitope, has been repeatedly and independently documented. There are, however,
conflicting reports linking immunization with BSA to specific genetic and immunological
markers of IDDM. The role of BSA as an antigenic trigger in the pathogenesis of IDDM is
controversial and will require further investigation.
Assessment of the BSA content of cow's milk and commercial infant formula
preparations will provide critical information to assist professionals and public health
agencies in making sound nutritional recommendations to help reduce the incidence of
IDDM in those not exclusively breast fed for the first year of life. The American Academy
of Pediatrics ( 1994) "strong! y encourages" families with a history of I DOM to adopt the
practice of breast-feeding and avoid cow's milk and products containing intact cow's milk
protein dunng the first year of life. Since routine screening to detect the "diabetic genes" is
not practical at this time as a component of public health policy, it may be appropriate for all
infants to avoid BSA . Development of technology to commercially produce an affordable ·
BSA-free breast-milk substitute for use infeeding all infants not exclusively breast-fed may
prophylactically help to reduce the incidence of IDDM.

The results of the research

reported \.vi thin this dissertation provide vital information that infant formula is
heterogeneous in terms of its BSA content. This information can be used to further
evaluate infant feeding practices and the contribution of BSA to the immunopathogenesis of
IDDM.
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CHAPTER III
MErHODS
The dissertation research described below was designed to determine the amount
of BSA present in commercially available infant formulas and to provide a laboratory
model for ex.traction of BSA from cow's milk and whey protein isolates used in the
manufacture of infant formula A sensitive enzyme-linked immunosorbant assay (ELISA )
was developed to detect and quantitate the amount of BSA present in both polymeric and
hydrolyzed infant formulas. The objective of the second component of the research was
to develop a laboratory model to produce mcxiified cow's milk and whey isolates free of
BSA . An immunocapture method, using paramagnetic beads, was developed to
specifically remove BSA and immunologically active epitopes of BSA from cow's milk and
whey isolates. These BSA-free protein sources could be used in the manufacture of infant
formulas, which may in turn decrease the expression of IDDM in genetically susceptible
individuals.
HYPITTHESES
1.

An ELISA can be developed to detect and quantitate the BSA composition of cow's
milk and whole formula samples .

.., The BSA content of cow's milk and polymeric cow 's-milk-based infant formulas varies
directly with the whey protein fraction.
3. Hydrolyzed infant formulas contain antigenic epitopes of BSA that can be detected by
ELISA .
4. BSA can be captured and extracted from cow's milk and whey protein isolates utilizing
a specific anti-BSA immunoaffinity chromatography batch technique.
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MEASURHvtENT OF THE BOVINE SERUM ALBUMIN
CONTENT OF INFANT FORMULAS

Direct and indirect ELISAs were evaluated as methods for detecting and quantitating BSA in cow's milk and cow's-milk-based infant fonnulas . Indirect ELISA is
currently used by the fonnula industry to detect residual antigenicity of hydrolyzed infant
formulas (Cordle, 1994). The two-site, direct ELISA is generally considered to be more
sensitive than indirect methods (Kemeny & Chantler, 1988). A sensitive two-site, direct
ELISA was developed and adopted to quantitate BSA in cow's milk and formula following preliminary evaluation of direct and indirect methods. Preliminary studies are briefly
described below.
Preliminary Studies
Indirect ELISA Methodology
The indirect ELISA was evaluated as a means of detecting and quantitating BSA
antigen (Figure 8) . With indirect ELISA, the antigen, in this case BSA , was bound
passively to the microtitre plate during incubation of the formula sample. Excess sample
was removed by washing. The second layer of the assay consisted of anti-BSA antibody,
added in excess, that was incubated with the bound antigen. Unbound antibody was
removed by washing. Bound antibody, and therefore antigen, was detected using a horseradish peroxidase (HRP) labelled antiimmunoglobin (IgG) . The most senstive substrate
for detection of low levels of HRP enzyme is 3, 3', 5, 5'-tetramethylbenzidine
hydrochloride (TNffi). The color formed is proportional to the amount of labelled antibody and , therefore, antigen (Makarananda & Neal, 1992). Details of the specific ELISA
protocol established to detect and quantitate BSA are outlined in Table 2.
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Table 2
Indirect ELISA Protocol

1.

BSA standards and formula samples diluted in carbonate-bicarbonate coating
buffer (pH 9.6) .
(PBS-Tween 20 used as blank) .
100 µ1 diluted standard or sample added, in triplicate each microtitre plate well .

3.

Plates incubated for 1 hour at 37 degrees Celsius in a humid chamber.

4.

Wells washed 3 times with PBS-0.2% Tween 20 (pH 7.4).

5.

Anti-Bovine Serum Albumin (BSA), developed in rabbit, fractionated antiserum
(Sigma B-7276, lot: 024H8960) diluted 112000 in PBS-Tween 20.

6.

100 µ1 added to microtitre plate wells.

7.

Plates incubated for 1 hour at 37 degrees Celsius in a humid chamber.

8.

Wells washed 3 times with PBS-Tween 20.

9.

Anti-rabbit IgG (horseradish)-peroxidase (Kirkegaard & Perry, 074-1506
Peroxidase-Labelled Affinity Purified Antibody to rabbit IgG (H + L) produced
in goat) diluted 1/2000 in PBS-Tween 20.

10.

100 µladded to microtitre plate wells.

11 .

Plates incubated for 1 hour at 37 degrees Celsius in a humid chamber.

12.

100 µ1 TMB substrate added to microti tre plate wells.

13 .

100 µ12 M H 2 S04 added to each microtitre plate well to stop reaction at 30 minutes .

14.

Absorbance read at 450 nm using the Bio-Rad EIA Mac Reader 2.0.

(Adapted from Bono, Fisher, Abuodeh, Legendre, & Scalarone, 1995).
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The initial indirect ELISAs were performed using an enzyme-labelled anti-BSA as
the detector antibody. The availability of the enzyme-labelled anti-BSA eliminated the need
fo r the secondary antibody conjugate. Unfortunately, the anti-BSA HRP-labelled antibody
used in the first set of experiements gave no response to substrate. It was cone! uded that
the HRP label was not bound to the antibody.
In the second set of experiments, anti-BSA antibody was used in conjunction with
a secondary HRP-lalelled anti-immunoglobin conjugate, as described in Table 2. This
ELISA system responded well in the presence of substrate with anti-BSA antibody
demonstrating avidity for the BSA antigen. Several trial runs were performed using
various concentrations of primary and secondary antibody with serial dilutions of BSA and
positi ve control formula samples on several independent occasions. Problems were
encountered with high background interference. It was concluded that the low signal-tonoise ratio could be anributed to inability of the BSA antigen in the test sample to bind to
the microtitre plate, a known limitation of indirect ELISA (Kemeny & Chanter, 1988) . In
addition, specific and nonspecific binding could result from interaction of either the primary
or secondary antibody and the unreacted sites on the microtitre plate. The target antigen , in
this case BSA, is the most common agent used to block unreacted sites and prevent
nonspecific binding in ELISA . For these reasons, the indirect ELISA was aborted, at this
point, in exchange for the more sensitive, d1rect, two-site ELISA .
Direct ELISA Methodologv
The second approach utilized the direct, two-site ELISA (Figure 9). Anti-BSA
antibody was passively bound to the microtitre plate and served as the capture antibody.
Samples containing BSA antigen were incubated with the capture antibody. Bound BSA
was subsequently detected and quantitated using a second HRP-labelled anti-BSA antibody
that binds to a different region of BSA than the capture antibody. With the direct approach,
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BSA is "sandwiched" between two layers of antibodies. Table 3 provides a detailed
description of the final direct ELISA protocol fordetection and quantification of BSA in
cow's milk and infant formula . Several optimization strategies were employed to arrive at
this final direct ELISA protocol and are briefly reviewed below.
Optimization of the Direct ELISA
Determining Working Antibody Concentrations
The first step was to measure the background absorbance of each ELISA reagent.
The ELISA reagents included the primary anti-BSA antibody in coating buffer, the
secondary anti-BSA HRP-labelled detector antibody in PBS-Tween, BSA standards in
PBS, a negative sample (soy formula), a positive sample, TMB substrate, and a PBS
blank. Baseline absorbance of individual ELISA components was unremarkable.
Optimal working conditions for each antibody were determined using checkerboard
titration. Figure 10 shows the sheme for optimization of the primary capture and secondary
detector antibodies. A working concentration of 111,500 for the capture antibody and
116,000 for the detector antibody was selected. Together, these concentrations provided an
ELISA system with the maximum signal for the BSA standards to background absorbance
of the PBS-Tween and soy blanks. Consistent with optimization guidelines of Kemeny
and Chantler ( 1988) and Carpenter ( 1992) , these dilutions yielded a high positive control
o f approximately 1 aborbance unit (0.978) and a negative sample absorbance of less than
0 .2 (0. 15).
The preliminary titration studies confirmed the efficacy of the direct ELISA as a
means of quantitating BSA in cow's milk and infant formula A graded absorbance reading
was obtained for serial dilutions of BSA. BSA could be recovered from the spiked soy
formula. At this point, the direct ELISA was adopted for further experiments.
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Table 3
Direct (Two-Site) ELISA Protocol
1.

Anti-Bovine Serum Albumin (BSA), developed in rabbit, fractionated antiserum
(Sigma B-7276, lot: 024H8960) diluted 111500 in carbonate bicarbonate coating
buffer (pH 9.6) .

..,

100 µ1 diluted antitxxiy preparation added to each well of 96-\.vell microlltre plate
(Coming, disposable non-sterile polystyrene assay plates, 25880-96).

3.

Plates incubated in a humid chamber at room temperature for 2 hours or overnight
at 5 degrees Celsius.

4.

Wells washed 3 times with PBS-Tween 20 (0.2%).

5.

BSA standards and samples diluted in PBS-Tween 20 (0.2%).
(PBS-Tween used alone in selected wells to blank absorbance on EIA Reader.)

6.

100 µ1 standard or samples added to each microtitre plate well, in triplicate.

7.

Microtitre plates incubated at room temperature for 1 hour in a humid chamber.

8.

Wells washed 3 times with PBS-Tween 20 (0.2%).

9.

Anti-Bovine Albumin-Peroxidase, developed in sheep, (horseradish)-peroxidase
labelled (The Binding Site, PP204, batch 5939) diluted 116000 in PBS-Tween 20.

10.

100 µ1 diluted antitxxiy conjugate added to each microtitre plate well.

11.

Microtitre plates incubated for 1 hour at room temperature.

12 .

Wells washed 3 times with PBS-Tween 20, last wash no Tween.

13 .

100 µ1 TMB substrate added to each microtitre plate well
( Pierce, 34022, 3,3',5,5' tetramethylbenzidine (TMB) substrate for HRP, 1-step
Turbo TMB-ELISA, 0034022) .

14.

100 µ12 M H 2 S04 added to each microtitre plate well to stop reaction at 30 minutes.

15.

Absorbance read at 450 nm using the Bio-Rad EIA Mac Reader 2.0.
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Figure 10. Checkerboard titration for antibody dilution optimization. The primary
antibody was tested in duplicate rows in concentrations ranging from 111,500 to 1112,000.
The secondary antibody conjugate was tested in columns in dilutions of 113,000 and
l/6000 over each dilution of the primary antibody. Dilutions of 119000 and 1112,000 of
secondary antibody conjugate were tested on a second plate. Three BSA dilutions of 1, 10,
and 100 nanograms of BSA per 100 µ1; a PBS-Tween and soy blank; and soy formula
spiked with to nanograms of BSA were used as samples and controls.

Assessment of Blocking Agents
It is common in ELISA to block unreacted sites on the microtitre plate following
binding of the capture antibody. Since BSA itself is the most common blocking agent used
in ELISA, and likely present in other common blocking agents (e.g., powdered milk and
gelatin derived from beef), alternative blocking agents were evaluated.

l.50

To optimize the signal-to-noise ratio, 3 % gelatin extracted from pork, was
incubated 1 hour at 38 degrees Celsius with the previously bound antibody on the solid
phase. Unbound material was removed using three washes of PBS-Tween. The direct
ELISA protocol was subsequently follm\:ed from step 5 (Table 3). The background was
found to be much higher when gelatin was used to block unreacted sites on the solid phase.
The gelatin was found to be an unsuitable blocking agent due to nonspecific binding of the
detector antibody. This could possibly be explained by the stickiness of the gelatin
attributed to high bloom.
Casein and salmine at concentrations of 1, 3, and 5% and Tween 20 at 0.2 and
0.4% diluted in PBS were evaluated as alternative blocking agents. The blocking effect of
salmine was greater than that of casein. The Tween exhibited the greatest blocking effect,
which was similar at both concentrations.
It was postulated that the formula sample could be diluted in PBS-Tween, avoiding
the blocking step all together. To test this hypothesis , identical plates were run with
(a) 100 µl PBS-Tween 20 (0.2%) added to the antibody matrix and incubated for l hour at
37 degrees Celsius prior to addition of a positive formula sample diluted in PBS and (b)
direct addition of the positive formula sample diluted in PBS-Tween 20 (0.2 %). The latter
proved to be as effective and eliminated the time and effort of a separate blocking step.
Comparison of Effectiveness of the Direct ELISA
in Whole Samples Versus the Soluble Fraction
Preliminary studies were performed using the soluble fraction of cow's milk and
select formula samples. Results were compared to whole formula samples to determine if
the ELISA could be performed using whole formula samples. Since BSA is a whey
protein, it should be isolated to the soluble fraction . Formula samples were centrifuged at
5 ,000 RPMs for 90 minutes at 4 degrees Celsius and the soluble fraction extracted for
assay. Initial assays performed using the soluble fraction did not yield superior results
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relative to whole formula samples. The laner method was preferred due to relative ease of
assay and quanl!tation of the actual BSA load provided to the infant from the formula being
evaluated.

Estimation of Recoverv of BSA
In order to determine if BSA could be effectively captured from whole formula
samples by the refined ELISA system , whole formula samples, two high-whey , two h1ghcasein, and a negative soy control were spiked with 10 nanograms of BSA. Recovery of
BSA was estimated by subtracting the amount of BSA in the nonspiked sample from the
amount of BSA detected in the spiked sample. The capture efficiency confirmed the direct
ELISA protocol for quantitating the BSA antigen load in cow's milk and infant formula.
Samples
Preliminary evaluation of direct and indirect ELISA methodology was conducted
using BSA samples. BSA samples were diluted in the appropriate ELISA buffer. BSA
samples were diluted in carbonate-bicarbonate coating buffer for assessment of indirect
ELISA methodology. All other BSA standards and samples were diluted in phosphatebuffered-saline (PBS) with Tween 20 (Polyoxy-ethylenesorbitan Monolaurate, Sigma
P-7949, Lot 15H09291).

The BSA content of cow's milk (2%), 12 polymeric infant formulas (Table 4) ,
and 4 hydrolyzed infant formulas was measured (Table 5) . Ready to serve, concentrated
liquid, and powdered infant formulas were selected where available. Formula samples
\Vere prepared according to manufacturers' directions. Powdered formula samples were
weighed and reconstituted with the appropriate amount of deionized water. Whole formula
samples were chosen for analysis , which is consistent with that currently used in the

-..,
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industrial setting in quality control evaluations for residual antigenicity of hypoallergen.ic
formula preparations.
Cow's milk and infant formulas were tested in serial dilutions from each of three
batches. Samples were diluted in phosphate buffered saline (PBS) with Tv,:een 20 (Butler,
1988). Sample dilutions were as follows: full strength, 11100, 11500, 111,000, 115,000,
1110,000, and 1150,000. Individual sample dilutions were tested in triplicate.
Controls
BSA standards were weighed in triplicate and diluted in PBS-Tween 20. BSA
standards ranged from 0 .08 ng/100 µ1to50ng / 100 µ1. Each of the three sets of BSA
standards was run in triplicate on three microtitre plates by direct ELISA . The standard
curve was determined by plotting the actual absorbance measured by the EIA Mac Reader

2.0 against the known BSA concentration. Construction of the BSA standard curve
provided an absolute precalibrated standard as a reference for homologous interpolation
and a quantitative evaluation of the BSA content of samples (Kemeny & Chantler, 1988).
The BSA concentration of unknowns was interpolated from the BSA standard curve based
on the absorbance of the formula sample. In addition, BSA standards for high, middle,
and low positive controls were performed on each plate in order to assess the interassay
coefficient of variation.
A follow-up study was performed to determine whether our direct ELISA system
detected the presence of the ABBOS epitope. Synthetic AB BOS peptide was obtained from
Hans-Michael Dosch, M.D., Hospital for Sick Kids, Toronto, Canada. The direct and
indirect ELISA procedure was performed using the AB BOS peptide as the antigen in place
of BSA. Using both direct and indirect ELISA provided a means of individually assessing
the avidity of the capture and detector antibcx:ly for the AB BOS epitope.
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Table 4
Polymeric Infant Formulas

Product type

Lot number

Manufacturer

High-casein, powder
Similac Fe Powder

95120T3-05, 01505 RB, &
88674 RB

Ross Laboratories

High-casein, ready-to-serve
Similac Fe Ready-to-Serve

88248 RD, 93515 RR
L5Sl91506

Ross Laboratories

Preemie, ready-to-serve
Similac Special Care

96183 RD, 90305 RD
01236X8-11

Ross Laboratories

Preemie, powder
Similac Neocare

95136 RB, 03897 RB
95136 RB

Ross Laboratories

Preemie, ready-to-serve
Similac Neocare

09176 RD, 92373 RD
91355 RD

Ross Laboratories

High-whey, powder
Enfamil Fe Powder

BAJ04, BAJ06
BAJ18

Mead Johnson Nutritional
Brystol-Meyers

Preemie, ready-to-serve
Enfamil Premature 24

MAJ12, MFD08
tv1LD11

Mead Johnson Nutntional
Brystol-Meyers

High-whey, powder
SMA Powder

E20CTA , A 1lCTD
J24ATA

Wyeth-Ayerst Laboratories

Preemie, ready-to-serve
SMA Preemie

Al2LL7
808CC9

Wyeth-Ayerst Laboratories

High-casein, liquid
concentrate
Gerber liquid Concentrate

ACJ17, AFD06
AGD08

Brystol-Meyers

High-casein, powder
Gerber Powder

BKJOOP, BGJ02M
BGJ21M

Brystol-Meyers

High-casein, powder
Bonamil

V23A TK, S 16A TC
V23ATA

Wyeth-Ayerst Laboratories
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Table 5
Hvdrolvzed Infant Formulas

Product type

Lot number

Manufacturer

Hydrolyzed whey, powder
Carnation Good Start

5114EWGS976L
5023EWGS688L
5053EWGS9190

Carnation, Nestle Co.

Casein hydrolysate, powder
Pregestimil

BLD07
BGJ14M
BHJ15M

Ross Laboratories

Casein hydrolysate,
ready to serve
Alimentum

06417 RE
05290 RE
02869 RC

Ross Laboratories

Casein hydrolysate, powder
Nutramagen

BMJ21M
BGJ20M
BHJ22M

Mead Johnson Nutritional
Brystol-Meyers

Electrophoresis
Formulas testing negative for BSA by ELISA were evaluated by electrophoresis to
confirm the absence of BSA from the sample. Defatted formula samples, skim milk, and
BSA standards were prepared for analysis by mixing 100 µI sample, 100 µ110 mM Tris
Buffer, 350 µI 10% SOS, 350 µI deionized water, and 50 µI 2-mercaptoethanol. Prepared
samples and controls were brought to a boil for 5 minutes and vortexed to separate proteins
in order to facilitate their migration on the polyacrymide gel. Proteins from the powdered
hydrolyzed formulas migrated well in the polyacrylamide gel; however, the initial runs
performed on the polymeric ready-to-serve and liquid concentrate preparations did not
migrate into the polyacrylamide gel. This observation was hypothesized to be due to
agglutination of the proteins during heat sterilization of the formula. To enhance separation
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of the agglutinated proteins , the Tris buffer was increased to a 100-mM concentration ; 4(X)

µl of 10% SOS was added, and the samples were boiled for 10 minutes . Following
preparation, formula samples and controls were analyzed by the PhastSystem, PhastGel
Electrophoresis System (Pharmacia UCB Biotechnology). BSA has a molecular weight of
66 kilodaltons, which can be easily detected by electrophoresis.
INIMUNOCAPTURE AND EXTRACTION OF BOVINE SERUM
ALBUMIN FROM COW'S MILK AND WHEY ISOLA TES
Affinity chromatography, using magnetic beads with an immobilized antibody
against BSA, was utilized to selectively extract BSA from cow's milk and whey isolates.
Immobilization of antibodies to hydroxyl groups on silica surfaces with heterobif unctional
crosslinkers has previously been reported (Bhatia et al ., 1989). Bhatia's methodology has
been modified in Dr. Weimer's laboratory at Utah State University by Michael Blake for
immunocapture, detection, and quantification of bacterial spores infood products and
environmental samples, patent pending (Blake, 1996). Blake's methodology was applied
and adapted for immunocapture and extraction of BSA from cow's milk and whey protein
isolates. The experiments outlined below provide proof of concept of a laboratory model
demonstrating that BSA, and antigenic epitopes of BSA, can be captured and extracted
from cow's milk and whey protein isolates.
Purification of Polyclonal Antibodies
Two sets of polyclonal antibodies ( 1) Polyclonal Rabbit Anti-Serum to BSA
(Chappel 55269; lot# 39879) containing 61.8 mg/ml total protein and 6 mg/ml antibody
and (2) Polyclonal Rabbit Anti-Bovine Serum Albumin, Delipidized Whole Antiserum
(Sigma Bio Sciences B-1520; lot# 055H481 l) containing 60.4 mg/ml total protein and
3 .0 mg/ml specific antibody were purified using Pierce ImmunoPure (A/G) IgG
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Purification Kit (No. 44902) according to the standard protocol (Table 6). The IgG
fraction of purified antibodies was subsequently determined by measuring the absorbance
at 280 nm . Punfied antibody samples were blanked against ImmunoPure IgG Elution
Buffer. At 280 nanometers an absorbance of 1.35 corresponds to an IgG protein
concentration of 1 mg/ml (Harlow & Lane, 1988). The protein concentration of selected
aliquots of purified antibody measured 1.66 mg IgG/200 µ1 and 2.9 mg IgG/200 µ1 sample
sets 1 and 2, respectively.
Washing and Desalting of Antibodies
Purified polyclonal and monoclonal antibodies were washed to remove excess salts
and stored in appropriate buffer solutions depending on the intended used of the antibodies.
General procedures for washing and desalting antibodies are outlined in Table 7.
Antibodies to be used for standard ELISA were washed in phosphate buffered saline (PBS)
(pH 7.2) and stored at -20 degrees Celsius. Antibodies to be attached to paramagnetic
beads and used in immunocapture and BSA extraction experiments were washed in 0.1 M
sodium phosphate (pH 7.0) and stored at 5 degrees Celsius for use within 48 hours .
Monoclonal antibodies to BSA, Mouse, lgG lK, Ig Fraction (American Qualex
MMO 250 P, lot# 60658G) containing an anubody concentration 4.11 mg/ml (0.5 mg) in
PBS were also prepared for ELISA and immunocapture BSA extraction experiments. Five
microliters of the monoclonal antibody preparation was aliquotted for running standard
ELISA and stored at -20 degrees Celsius. The remaining 116.65 µ1 of monoclonal
antibody was washed in 0. 1 M sodium phosphate (pH 7.0) according to the general
procedures for washing and desalting antibodies outlined in Table 7. In variation to the
above procedure, each wash consisted of a 20-minute centrifuge cycle at 2500 RPMs
(Blake, 1996). Washed and desalted monoclonal antibodies to be attached to paramagnetic
beads \Vere stored at 5 degrees Celsius for use within 48 hours.
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Table 6
Standard Protocol for the Isolation and Purification of IgG

1.

Protein A/G column opened. Top stopper removed first and storage solution
poured off column.
Protein A/G column equilibrated with 10 ml of the ImmunoPure IgG Binding
Buffer.

3.

Diluted sample applied to the column and allowed to flow completely into the gel.
(Affinity PAK Columns stop flowing automatically when the liquid reaches the top
disc.)

4.

Protein A/G column washed with 20 ml of the ImmunoPure IgG Binding Buffer.

5.

Bound IgG eluted with 10 ml of the ImmunoPure IgG Elution Buffer. To obtain
the most concentrated sample, ten 1.0 ml fractions were collected. Elution of
bound proteins was monitored by absorbance at 280 nm.

6.

Column regenerated by flushing and storing with 10 ml 0.02% sodium azide.

(Instructions ImmunoPure [A/Gj IgG Purification Kit ; Pierce, 1995)

Attachment of Antibodies to Paramagnetic Beads
Tosylactivated, super paramagnetic, 2.8 µm, polystyrene beads (Dynabeads M-280;
Dynal 142.03) were used as the solid phase for immunocapture and biomagnetic extraction
of BSA from cow's milk and whey protein isolates. A polythreonine cross-linker (60 nm,
MW (vis] 12, 100) was covalent! y coupled to the tosylacti vated groups of the bead via the
terminal amine (Hermanson et al., 1992). This configuration, as shown in Figure 11,
provided an extended cross-linker to minimize steric hindrance between the BSA molecule
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Table 7
General Procedures for Washing and Desaltmg Antibodies

1.

..,

Antibodies washed with PBS (pH 7 .2) or NaP0 4 (pH 7 .0) .
Filtered concentrator used for centrifuging and washing antibodies .
(Centricon 30 concentrator 4208, MDB093 or Filtron 30K Macrosep 00030C36).

3.

Antibodies placed in top of tube (above filter).

4.

To wash, top of tube filled with PBS or NaP04 . Sample centrifuged 30 to 60
minutes at 50C)() RPMs (centrifuged with filter perpendicular to centrifuge pull).
Wash in bottom of centrifuge filter tube discarded, antibody (above filter) saved.
Washing repeated 5 times.

5.

After final wash, wash discarded, centrifuge concentrator tube recapped, placed
upside-down in centrifuge, and spun at 1000-2000 rpms for 1 minute to collect
antibody. Antibody aiiquotted and stored for future use.

(Adapted from Blake, 1996)

to be captured and the bead. In addition, the long flexible arm allowed the antibody to
establish the correct binding orientation with the BSA antigen (Blake, 1996). Tris buffer,
m particular the amine group, served to block the remaining tosylactivated sites. Adenine
dihydrazide (ADH) was linked to the carboxyl terminal of the bound polythreonine using
an ethylene diarnine carbodiimide mediated reaction (Hermanson et al., 1992).
The ADH functions to convert the hydroxyl end of the polythreonine to an activated amine.
Either monoclonal or polyclonal anti-BSA antibodies were attached to the carboxyl, ADHaclivated end of the polythreonme spacer via the carbohydrate moiety of the Fe or tail of
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Polythreonine spacer

lmmunomagnetic Bead

Figure 11. Immunomagnetic capture of BSA antigen using a polythreonine spacer.
(Adapted from Blake, 1996)

the antibody during incubation. This methodology provided an immunomagnetic capture
medium that allowed for extraction of BSA from cow's milk and whey protein isolates.
Paramagnetic beads were prepared in two batches according to the bead washing
and preparation procedures (Table 8). Batch one, l ml of beads, was washed and prepared
for coating with purified Polyclonal Rabbit Anti-serum to BSA (Cappel). Batch 2,
1250 µI of beads, was prepared accordingly; l ml of beads was prepared for coating with
purified Polyclonal Rabbit Anti-Bovine Serum Albumin (Sigma) and 250 µI of beads was
prepared for coating with monoclonal antibodies to BSA (American Qualex). The two sets
of purified polyclonal antibodies and one set of monoclonal antibodies were prepared for
coating of the prepared beads as outlined in Table 9. Sodium meta-periodate was used to

160

oxidize the carbohydrate moiety of the antibody and later removed by washing (Hermanson
eta!., 1992).
Each set of oxidized antibody preparation was combined with an equal volume of
activated beads in a 1.5-ml microcentrifuge tube and incubated overnight on a parastaltic
pump at room temperature. Coated beads were washed three times with sodium phosphate
(ph 7.0) by gentle hand motion, approximately 3 minutes per wash (Blake, 1996) .
Subsequent assays revealed that four additional washes were required to remove unbound
antibody from the bead suspension. Beads were resuspended in the original volume of
PBS-Tween 20 to block unactivated sites on the bead surface. One set of control beads
was prepared with polythreonine (Steps 1- 9, Table 8), without the addition of antibody,
and stored in PBS-Tween 20. Sodium azide was added to each set of beads at a final
concentration of 0.02% to prevent bacterial growth. Beads were stored at 5 degrees
Celsius.
Enzyme-Linked Immunosorbant Assay (ELISA)
The two-site, direct ELISA described in the preceding section was utilized to
quantitate BSA for establishing BSA standards; baseline BSA concentrations of skim milk,
acid whey, and sweet whey; and for analysis of residual BSA in samples treated with
polyclonal and monoclonal anti-BSA activated antibody-coated paramagnetic beads.
An overview of the direct ELISA procedures has previously been provided, Table 3.
BSA standards were weighed in triplicate and diluted in PBS-Tween 20. BSA
standards ranged from 0.08ng/ 100 µl to 50 ng/100 µl. Each of the three sets of BSA
standards was run in triplicate on three microtitre plates by direct ELISA. The standard
curve was determined by plotting the actual absorbance measured by the EIA Mac Reader
2.0 against the known BSA concentration. Construction of the BSA standard curve
provided an absolute precalibrated standard as a reference for homologous
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Table 8
Washing and Preparation of Beads

I.

Beads resuspended by pipetting and vortexing for l minute (avoid foaming) .
Desired volume of paramagnetic beads pipetted into 1.5 ml microcentrif uge tube .

3.

Beads sequestered in magnetic chamber, 3 minutes.
(MPG 3-in-1 MPS, Magnetic Particle Separator, MPS0301, lot 112895, Cpg Inc. )

4.
. 5.
6.

Sodium phosphate pipetted off.
Beads resuspended in half volume 0.05 M borate buffer (pH 9.5) .

Equal volume of polythreonine added to bead suspension:
(polythreonine protein concentration 400 µg /ml 0.05 M borate buffer)
polythreonine weighed,
polythreonine dissolved in appropriate volume deionized water,
borate buffer (0.5 M stock solution) added for final concentration
of 0.05 M.

7.

Beads incubated 24 hours at 37 degrees Celsius on parastaltic pump.

8.

Beads sequestered in magnetic chamber. Borate supernatant pipetted off and
discarded.

9.

Beads washed in 0.2 M Tris Buffer (pH 8.5) (three times) :
-Tris Buffer added to beads in microcentrifuge tube to bring to original volume ,
-beads placed on parastaltic pump at room temperature for 10 minutes
(washed by gentle rolling motion),
-beads sequestered in magnetic chamber, supernatant removed and discarded,
-fourth wash done running on parastaltic pump for 30 minutes.
(table continues)
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10.

Beads washed twice with 0.1 M 2-[N-Morpholino]ethanesulfonic acid (MES)
(pH 4.75) :
-MES added to beads in microcentrif uge tube to bring to original volume,
-beads washed by gentle hand washing, no parastaltic pump,
-beads sequestered, supernatant removed and discarded.

11 .

Adipic Acid Dihydrazide (ADH), 0.5 M (pH 4.75) in 0. 1 MMES added to beads
to bring to original volume:
-ADH weighed into 1.5 ml microcentrif uge tube,
-appropriate volume 0. 1 MMES added to yield 0.5 M ADH,
-added to beads.

12.

ADH and beads added to 1-ethyl-3 (3-dimethylarninopropyl) carbomide (EDAC):
-EDAC weighed to 1.5 ml microcentrifuge tube,
-goal 0.03 gms/ml,
-ADH and bead suspension added to EDAC.

13 .

Beads incubated 3 hours at room temperature on parastaltic pump.

14.

Beads washed by gentle hand motion as follows:
-two washes sterile water at original volume,
-two washes in 1 M NaCl at angina] volume,
-three washes sterile water at original volume,
-two washes 0. 1 M sodium phosphate (pH 7.0) at original volume .

15.

Beads sequestered in magnetic chamber, supernatant pipetted off and discarded.

16.

Beads resuspended in half volume sodium phosphate (pH 7 .0) .

(Adapted from Blake, 1996)
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Table9
Preparation of Antibodies

1.

Volume of purified antibody measured using pipette.

"'

Sodium phosphate (pH 7.0) added to bring to 1 ml.

3.

Antibody concentration measured by absorbance at 280 nm ( 1.35 = 1 mg/ml lgG) .

4.

Sodium phosphate (pH 7.0) added to bring antibody concentration to 1 mg/ml.

5.

Antibody preparation added to sodium-m-periodate:
(5 mg sodium-m-periodate/ml antibody)
-weight sodium-m-periodate to 1.5 ml microcentrifuge tube,
-add antibody.

6.

Antibody preparation incubated 30 minutes in the dark. Tube wrapped in foil.

7.

Antibodies washed six times with 0.1 M sodium phosphate (pH 7 .0) in order to
remove sodium-m-periodate:
-antibody transferred by pipette to filtered concentrator centrifuge tube
( Centricon 30 concentrator 4208, MDB093) ;
-antibodies placed in top of tube (above filter);
-to wash , top of tube filled with sodium phosphate, sample centrifuged 30
minutes at

5CX)()

RPMs , wash in bottom of centrifuge filter tube di scarded ,

antibody (above filter) saved ; washing repeated 6 times ;
-after final wash , waste discarded , centrifuge tube recapped, placed upsidedown in centrifuge, and spun until centrifuge comes up to 2()(X) RPMs .
8.

Antibodies brought to half original volume with sodium phosphate (pH 7.0).

(Blake, 1996)
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interpolation and a quantitative evaluation of the BSA content of samples (Kemeny &
Chantler, 1988). Baseline BSA concentration of Skim Milk (Meadow Gold Nonfat Skim
Milk ; Vitamin A and D , 49-7, August 18; Meadow Gold Dairies Inc., Columbus, Ohio)
was determined by the direct ELISA . Acid Whey (Utah State University, Dairies ;
delactosed whey) and Sweet Whey (Utah State University, Dairies ; from cheddar cheese )
were reconstituted in deionized water to a 10% solution. Whey isolates were adjusted to
a pH of 7.0 using 1 Mand 0.1 M sodium hydroxide. Baseline BSA concentration of the
whey isolates was determined by direct ELISA .
Preliminary Immunocapture Experiments
Preliminary antibody capture BSA extraction experiments are summarized in
Appendix B. Several studies were performed on independent ocsasions using 5, 10, and
20 µl of polyclonal anti-BSA antibody acti vated paramagnetic beads added to milk samples

ranging from 100 to 500 microliters. Samples and beads were incubated at room
temperature on a rotating parastaltic pump for 1 hour. Beads were sequestered in a
magnetic chamber. Samples were removed and saved for evaluation of residual BSA
content by the direct ELISA .
ELISA evaluation of the residual BSA content of the treated milk samples did not
sho w a measurable reduction in the BSA content of the samples following treatment with
pol yclonal anti-BSA antibod y acti vated paramagnetic beads. It was hypothesized that
these observations could be explained by a large excess of BSA in the milk sample relative
to the capacity of the immunocapture system to bind BSA . However, these observations
raised several additional questions. Was antibody present on activated beads? Was
unbound antibody present in the bead suspension that could bind BSA and remain in the
treated sample after the beads were sequestered? Could BSA be captured from the milk
sample ? What was the capture efficiency of BSA in skim milk, acid whey, and sweet
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whey using polyclonaJ and monoclonal antibody-activated beads? In order to answer these
questions, additional assays were developed to quantitate the amount of antibody attached
to the activated paramagnetic beads and the amount of BSA captured by the antibody
activated beads. This methodology is described below.
Initial follow-up studies revealed that antibody was attached to the activated beads.
Some antibody was detected in the bead suspension that was not bound to paramagnetic
beads, but the amount present was not felt to have a significant in pact relative to the total
amount of BSA present in the treated sample. The unbound antibody could be removed
with additional washes. BSA could be captured by the antibody-activated beads; however,
a large excess of BSA remained in the treated sample. Subsequent studies focused on
determining the capture efficiency of polyclonal and monoclonal antibody-activated beads
in skim milk, acid whey, and sweet whey. This information could be utilized to determine
the efficiency of the system and evaluate the feasibility of its application to the industrial
setting.
Quantitation of Antibody Attached to Paramagnetic Beads
In order to provide a means to compare antibody attached to beads and efficiency
of BSA capture between polyclonal , monoclonal, and control polythreonine-activated
paramagnetic beads, bead concentrations were measured spectophometrically. Refraction
was measured at 590 nanometers for each set of beads. Bead concentrations were
equilibrated using PBS-Tween 20.
The antibody attached to the activated paramagnetic beads was quantitated using an
antibody excess ELISA (Figure 12). The detailed modified ELISA methodology, using the
bead as the solid support, is described in Table 10. Three sets each of polyclonal anti-BSA
activated paramagnetic beads and monoclonal anti-BSA activated paramagnetic beads were
assayed in serial triplicate dilutions. Polyclonal antibodies were quantitated using
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Horseradish Conjugated Goat Anti-Rabbit IgG (Sigma Bio Sciences, A-6154, lot
026H8896) as the capture antibody. Monoclonal antibodies were quantitated using Ant1Mouse IgG Peroxidase Conjugate (Sigma Bio Sciences, A-4416, lot 082H8892) for
capture. Polythreonine beads devoid of antibody served as the control.
A standard curve for each set of species specific capture antibodies was developed
in tnplicate using serial dilutions of the HRP-labeled antibody. Diluted anti-IgG-HRP
standards were placed in triplicate ( 10 µl) in microtitre plate wells. Ninety microliters of
TMB substrate were added to each well. Standards were incubated for 30 minutes at room
temperature. The reaction was stopped with 2 M sulfuric acid. Microtitre plates were read
at 450 nanometers on Bio-Rad EIA Mac Reader 2.0. Each of the three sets of anti-IgG
standards was run in triplicate on three microtitre plates. Construction of a standard curve
for each anti-BSA HRP-labelled antibody was developed based on the signal elicited when
the TMB substrate was added to use as a reference standard for quantitating antibody
content of beads. Absorbance of the sample, taken from the bead supernatant, was plotted
against the species-specific IgG standard. The amount of antibodies present on beads is
reported in nanograrns of IgG. Values reported assume a one-to-one molar capture
efficiency between the antibody on the bead and the anti-rabbit or anti-mouse IgG and
represent relative, semiquantitative findings .
Antibody Capture BSA Extraction
Antibody capture BSA extraction experiments were repeated three times for
each set of polyclonal and the monoclonal anti-BSA antibody activated paramagnetic beads
and controls in order to provide a means to calculate and optimize the ratio of beads to skim
milk and whey isolates necessary for BSA extraction. Capture efficiency of each set of
monoclonal and polyclonal anti-BSA activated paramagnetic beads was compared. In
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Figure 12. Antibody excess ELISA for quantitation of anti body attached to activated
paramagnetic beads.

addition, capture efficiency was compared between the media of skim milk, acid whey , and
sweet whey for the monoclonal and polyclonal antibody-activated beads.
Samples of skim milk, acid \\'hey, and sweet whey were aliquotted to 1.5-ml
microcentnf uge tubes. Activated beads were resuspended by rotating on a parastaltic pump
for 5 to IO minutes and then mixed with a pipette. Ten microliters of polyclonal or
monoclonal anti-BSA antibody activated paramagnetic beads was added to a 500-µl sample
for treatment. Control samples were treated with matching amounts of polythreonine
treated beads devoid of antibody. Samples and beads were incubated at room temperature
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TablelO
ELISA Procedures for Quantitation of Antibodv on Activated Paramagnetic Beads

1.

10 µ1 active and control beads suspended in 500 µ1 of PBS-Tween.

Serial dilutions made in 1.5-ml microcentnfuge tubes
(full-strength, 1110, 11100, 111000).
3.

Beads sequestered in magnetic chamber and resuspended in 350 µ1 species specific
anti-IgG-HRP in a 115000 dilution in PBS-Tween 20.

4.

Beads incubated on parastaltic pump for 1 hour at room temperature.

5.

Beads sequestered in magnetic chamber and washed three times in PBS-Tween
(gentle hand washing) .

6.

Beads sequestered and resuspended in 350 µ1 TMB substrate.

7.

Beads incubated at room temperature for 30 minutes in TMB on parastaltic pump.

8.

Beads sequestered, 100 µl supernatant (reacted TMB) added to microtitre plate
wells in triplicate.

9.

100 µ12 M H2 S04 added to each well to stop reaction.

10.

Absorbance read at 450 nm using the Bio-Rad EIA Mac Reader 2.0.

on a rotating parastaltic pump for 1 hour. Beads were sequestered in a magnetic chamber.
Treatment and control samples were removed and saved for evaluation of residual BSA
content by the direct ELISA . The beads were washed once with equal volume to sample of
PBS-Tween. Beads were sequestered. Wash was pipetted off and saved for analysis of
residual BSA. Beads were resuspended in equal volume to samples of PBS-Tween 20 and
saved for quant1tation of captured BSA.
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A trial run of molecular sieving was performed to determine whether the bulk of the
BSA could be removed from the sample, followed by use of the immunocapture to remove
residual BSA . Skim milk was filtered in two Centricon tubes using a 50-kilodalton and
100-kilodalton separation device. Samples were centrifuged at 3000 RPMs for 3.5 hours.
The filtrate less than 50 and greater than 100 kilodaltons was assayed by direct ELISA to
determine residual BSA content. Since the bulk of the BSA, but not all BSA, could be
removed by molecular seiving, it was proposed that coupling the immunocapture to
molecular sieving to remove the relatively small amount of BSA remaining in the sample
may be advantageous in order to overcome the limitations of the immunocapture system
and strengthen its potential application to the industrial setting.
In order to determine if BSA could be removed totally from a sample and assess
capture efficiency of activated beads at substantially lower baseline BSA concentrations,
known samples of BSA (25 ng/.500 µ1 in PBS-Tween) were treated with 10 µI of the
Polyclonal Rabbit Anti-Bovine Serum Albumin (Sigma) activated paramagnetic beads and
polythreonine control. The experiment was performed in triplicate according to the above
procedures.
Quantitation of Captured BSA on Beads
Quantitation of BSA captured by polyclonal and monoclonal anti-BSA antibodyactivated paramagnetic beads was achieved using a direct ELISA, with the immunomagnetic bead serving as the solid support, Figure 13. This procedure was developed and
selected due to its relative ease and minimal potential loss of BSA, which might otherwise
occur during elution precedures. The antibody attached to the activ~ted bead served as the
capture andtibody. Anti-Bovine Albumin-Peroxidase (horseradish-peroxidase labelled;
developed in sheep; The Binding Site, PP204, batch 5939) diluted 115,000 in PBS-Tween
20 was used as the detector antibody. The specific steps in the direct ELISA are the same
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Figure 13 . Direct ELISA for quantitation of captured BSA on bead. The immunomagnetic
beads functions as the solid support in the ELISA. The antibody attached to the activated
bead serves as the primary capture antibody. Following incubation of the antibody
activated beads with the treatment sample, the beads are sequestered and washed with PBSTween. Captured BSA is detected by the addition of the secondary anti-BSA HRPconj ugate. Following incubation, the beads are sequestered and washed with PBS-Tween.
Substrate is added to the microcentrif uge tube. The supematent, carrying the
enzyme/substrate reaction product is removed and added to a microtitre plate for anal ysis on
the EIA MAC reader 2.0.

as those previously described in Table 10 for quant1tation of the amount of antibod y
attached to the paramagnetic beads. Once BSA is bound to the bead , the secondary
antibody conjugate can be added "sandwiching" the BSA between the two antibodies .
A standard curve was developed for the anti -BSA-HRP as previously described for the
species specific anu-IgG standards. The amount of BSA present on beads is reported in
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nanograms and assumes a one-to-one molar capture efficiency between the antibody on the
bead and anti-BSA-HRP conjugate and represents relative, semiquantitative findings .
The capture efficiency of each set of polyclonal and monoclonal antibody activated
beads was determined after treatment of sample media (i.e., skim milk, acid whey, and
sweet whey) . The molar to molar capture efficiency was calculated using the following
equation.
Capture Efficency = ng BSA captured bv 10 ul beads I 66,000 kD
ng IgG bound to 10 µl beads I 160,000 kD
This calculation assumes a one-to-one molar capture efficiency between the anti-BSA
antibody attached to the activated beads and the species-specific detector antibody conjugate
used to quantitate the amount of antibody attached to the beads. In addition, a one-to-one
capture efficiency is assumed between the antibody present on the activated beads, BSA,
and the secondary anti-BSA HRP-labelled antibody used to quantitate the captured BSA.
Given this limitation, results represent relative semiquantitative data.
Data Analysis and Report
The standard curves for BSA, anti-mouse IgG-HRP, anti-rabbit IgG-HRP, and
anti-BSA IgG-HRP were developed using known concentrations of the standard plotted
against absorbance of the standard. The Kruskal-Wallis nonparametric test, which is
designed to compare two or more groups of cases on one variable, was used to
determine variability between plates and sets of known standards. The plate and set
variation of each standard is reported as the chi-square value, Q value, and degrees of
freedom. Linear regression analysis was performed to determine the line of best fit for all
standards based on a 95% confidence interval. The R-Square, standard error,

.E value,

and significance of .E are reported with the each standard curve. The equation for the
regression line was used to interpret the respective sample concentration as indicated above.
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The unknown sample concentrations of BSA, IgG, and captured BSA were interpolated
from their respective standard cur\'e based on the absorbance of the sample. Sample
concentrations are reported along with the standard deviation. The coefficient of variation
for the ELISA was determined for the BSA quantitated in formula samples.
Three high, medium, and low standards were included on each plate used to quantitate
the BSA concentration of infant formulas in order to assess the reproducibiity of the assay.
The interassay coefficient of variation and standard deviation is reported along with the mean
of the BSA standards. The BSA content of infant formulas is also reported with both the
standard deviation and coefficient of variation. The coefficient of variation, in this case,
reflects both intra-assay and interdilutional variation.
The Kruskal-Wallis nonparametric test was used to determine the variance in
amount of antibody bound to activated paramagnetic beads and in capture efficiency
between monoclonal and polyclonal antibodies within and between sample media (milk,
acid whey, sweet whey, and the known 25-ng BSA sample). In addition, the KruskalWallis test was used to assess the significance of BSA extraction from the 2.5-ng BSA
standard. Standards and sample unknowns are reported along with the chi-square value,

g value, and degrees of freedom . All statistical analysis was performed using SPSS
Advanced PowerMac Version 6.1. l.
SUMMARY OF METHODS
Measurement of the BSA content of infant formulas by ELISA provides a
quantitative assessment of BSA and antigenic epitopes of BSA present in infant
formulas. A summary of individual ex:penments performed in the preliminary stages
to evaluate ELISA techniques and quantitation of BSA in cow's milk and formula is
provided in Appendix: A. Appendix B summarizes experiments for antibody capture
and BSA extraction from cow's milk and whey protein isolates. This includes prelimi-
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nary experiments as well as experiments leading to proof of concept that BSA can be
extracted from cow's milk and whey protein isolates. A list of reagents and solutions
used in the experiments outlined above is provided in Appendix C.
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CHAPTER IV
RESULTS

MEASUREMENT OF BOVINE SERUM ALBUMIN
CONTENT OF INFANT FORMULAS
Evaluation of Indirect and Direct ELISA Methodology

Preliminary evaluation of the indirect ELISA for quantitating BSA content of
known samples of BSA resulted in poor coating of the plate with BSA and high
background interference due to difficulty finding a suitable blocking agent. As a result,
efforts were directed toward development of the two-site, direct ELISA. The development
of the direct ELISA is described in detail in the preceding chapter. The direct ELISA was
utilized for quantitation of the BSA content of infant formulas.
Several blocking agents were evaluated for use in the direct ELISA since BSA the
traditional blocking agent could not be used. Blocking with gelatin at 1% and3 % resulted
in an extremely high background on the control blank. The blank was visibly in excess of
the positive BSA sample on the indirect ELISA . The mean background absorbance for
casein was 0 .210 ( 1%), 0.249 (3 %), and 0.290 (5%). Salmine exhibited a mean
absorbance of 0.235 ( 1%) , 0.229 (3 % ), and 0. 197 (5%).

PBS-Tween 20 at 0 .2% and

0.4% exhibited a mean absorbance of 0. 170 and 0. 176, respectivel y. PBS-Tween 20
(0.2%) exhibited a lower background than casein, salmine, or gelatin, but the blocking
effect did not reach the level of statistical significance(£> 0.05). The blocking effect of
PBS-Tween 20 (0.4%) was essentially equivocal to the 0.4% PBS-Tween 20. PBSTween 20 (0.2%) was chosen as the blocking agent for the direct ELISA .
The recovery of BSA for the direct ELISA system was determined by spiking two
high-whe y, two hit gh-casein, and a negative soy control with 10 nanograms of BSA . The
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percent recovery of BSA was 100 and 96% for the two high-whey formulas , 99 and 63 %
for the two high-casein preparations, and 82% for the spiked soy control. The capture
efficiency did not differ significantly between sample formula media (Q > 0.5). The
overall average percent recovery was 88% (± 15.7) .
BSA Content of Infant Formula
The BSA standard curve for the quantitative, two-site direct ELISA for quantitation
of the BSA content of infant formulas is shown in Figure 14. Data reflect BSA standards
from three independent sample sets of BSA across dilutions; each was performed in
triplicate on three separate microtitre plates. There were no significant differences
collectively or within dilutions between the three independent sample sets or between plates
(Q. > 0.05). The interassay coefficient of variation (CV) was determined for BSA standards

of 50, 10, and 5 nanograms per 100 µl performed on each assay plate. The mean
absorbance values were 0.660 (standard deviation= 0. 13 ; CV= 19), 0.550 (Standard
Deviation= 0. 10; CV= 18), and 0.410 (standard deviation= 0.07; CV= 17). All baseline
and residual sample BSA content was interpolated from the BSA standard curve.
The mean BSA content of 20% milk and infant formulas is reported in Table 11.
BSA was detected and quantitated in all polymeric powdered infant formulas and 2% milk.
BSA was not detected by the ELISA in any of the ready- to-serve or concentrated liquid
formulas , including those that are counterparts to the powdered formulas containing BSA .
All elemental, partially hydrolyzed formulas tested negative for BSA regardless of form .
There were no statistically significant differences between powdered high-whey (60%)
formulas from different manufacturers (Q > 0.05). No statistically significant differences
were observed between brands of high-casein formulas (Q. > 0.05) . In order to
demonstrate reproducibility of the test, the test was repeated in one high-whey formula,
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Figure 14. BSA standard for infant formula The equation for the regression line is:
Y = 55.971886 (absorbance) + (-0.605137); standard error= 1.69; .E = 929;
significance of .E = 0.0000. The mean absorbance of each BSA standard coordinate is:
2.5 ng/100 µl = 0.042 (±0.011), 5 ng/100 µl = 0. 13 (±0.022), LO ng/100 µJ = 0.218
(±0.022), and 25 ng/100 µJ = 0.439 (±0.035).

SMA powder. The mean BSA content of SMA run 1was37 mg/100 ml compared to
SMA run 2 of 45 mg/100 ml, which was not significantly different (Q > 0.05) . Since
polyclonal antibodies were used for capture and detection of BSA in these preparations,
both BSA and antigenic epitopes of BSA should be able to be detected, if present. Anti-

BSA antibodies used for capture and detection of BSA failed to recognize the AB BOS
epitope in levels that might have been present in the test samples. The bulk of the antibody
response from the polyclonal antibodies did not appear to be directed toward the AB BOS
peptide.
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Table 11
BSA Content of Polymeric and Hydrolyzed Infant Formulas

Product type

Manufacturer

BSA mg/ l OOml

Std. deviation

CV

2%milk

Meadow Gold

52

(± 4)

7.7

High-casein, powder
Similac Fe Powder

Ross Laboratories

13

(± 2)

7.5

High-casein, ready-to-serve
Similac Fe Ready-to-Serve

Ross Laboratories

none detected

Preemie, ready-to-serve
Similac Special Care

Ross Laboratories

none detected

Preemie, powder
Similac Neocare

Ross Laboratories

0.6

(± 0.075)

12.5

Preemie, ready-to-serve
Similac Neocare

Ross Laboratories

none detected

High-whey, powder
Enfamil Fe Powder

Mead Johnson
Nutritional
Brystol-Meyers

41

( ± 6)

14.6

Preemie, ready-to-serve
Enfamil Premature 24

Mead Johnson
Nutritional
Brystol-Meyers

none detected

High-whey, powder
SMA Powder

Wyeth-Ayerst
Laboratories

37
45

( ± 5)
( ± 10)

13 .5
22.2

Preemie, ready-to-serve
SMA Preemie

Wyeth-Ayerst
Laboratories

none detected

High-casein, liquid
concentrate
Gerber Liquid Concentrate

Brystol-Meyers

none detected

High-casein, powder
Gerber Powder

B rystol-Meyers

13

(± 2)

15.4

High-casein, powder
Bonamil

Wyeth-Ayerst
Laboratories

13

(± 2)

15.4

(table continues)
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Product type

Manufacturer

Hydrolyzed whey, powder
Carnation Good Start

Carnation, Nestle Co. none detected

Casein hydrolysate, powder
Pregestimil

Ross Laboratories

none detected

Casein hydro! ysate,
ready-to-serve
Alimentum

Ross Laboratories

none detected

Casein hydro! ysate, powder
Nutramagen

Mead Johnson
Nutritional
B rystol-Meyers

none detected

BSAmg/ lOOml

Std. deviation

CV

CV =coefficient of variation

PhastGel electrophoresis was used to evaluate formulas testing negative for BSA by
the two-site, direct ELISA. All hydrolyzed formulas, regardless of form, ran no detectable
protein bands and were negative for BSA. This further confirmed that the hydrolyzed
formulas were devoid of BSA. No BSA band was detected for the ready-to-serve and
concentrated liquid formulas on SOS-PAGE.
A correlation was run to determine the relationship between the whey protein
fraction of the formula and the BSA concentration. Results are summarized in Figure 15.
The BSA content was highly correlated with the whey protein concentration in powdered
polymeric infant formulas and 2% milk (correlation coefficient= 0.8445; Q = 0.008).
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R = 0.84; P = 0.008
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Figure 15. Comparison of BSA content to whey protein fraction. Formula: ( 1) highcasein JX)Wder, Bonamil; (2) high-casein JX)Wder, Similac ; (3) high-whey powder,
Enfamil; (4) high-whey JX)Wder. SMA ; (5) high-casein powder, Gerber ; and (6) 2 % milk
(correlation coefficient= 0 .85 ; Q = 0 .008) .

IMMUNOCAPTURE AND EXTRACTION OF BOVINE SERUM
ALBUMIN FROM COW'S MJLK AND WHEY ISOLATES
Baseline and Residual BSA Content of Cow's Milk and Whey Iso lates

The BSA standard curve for the quantitative , two-site direct ELISA for baseline
BSA content of cow's milk, whey isolates, and residual BSA content of samples treated
by immunomagnetic capture is shown

in

Figure 16. Data reflect BSA standards from three

independent sample sets of BSA across dilutions; each performed in tnplicate on three
separate m1crotitre plates. There were no significant differences collectively or within
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Figure 16. BSA standard curve for quantitation of BSA in milk, whey, and
treated samples. The equation for the regression line is:
Y = 73 .571532 (absorbance) + (-0.153229); standard error= 2.25; F = 508;
significance of .E = 0.0000. The mean absorbance of each BSA standard coordinate rs :
2.5 ng/100 µ1=0 .031 (±0.019), 5 ng/100 µ1=0 .074 (±0.028), 10 ng/100 µ1=0.158
(±0.029), and 25 ng/ 100 µJ = 0.323 (±0.033).

dilutions between the three independent sample sets or between plates (Q > 0.05). All
baseline and residual sample BSA content was interpolated from the BSA standard curve.
The mean baseline BSA concentration of skim milk measured 28mg/ 100 ml
(± 0. 8). Solutions of 10% delactosed acid whey and 10% sweet whey measured
17mg/100 ml(± 0.2) and 12 mg/ 100 ml (± 0. 1) , respectively.
Preliminary immunocapture BSA extraction experiments using 5, 10, and '.?.O µ1
of polyclonal ancibody activated paramagnetic beads incubated with 100 to 500 µ] of skim
milk demonstrated that the antibody-activated beads were able to capture BSA from the
skim milk. However, no significant reduction in the amount of BSA in the milk sample
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was observed. BSA remaining in the treated sample was well in excess ( 10,000-fold) of
that captured by the beads.

Anti-BSA Antibody Present on Activated Paramagnetic Beads
In order to quantitate the amount of antibody present on each set of antibodyactivated beads by ELISA, a standard curve for each species-specific labelled capture
antibody was developed. Anti-mouse IgG-HRP standards were used to quantitate the
amount of antibody present on the monoclonal antibody activated paramagnetic beads,
Figure 17. Data reflect anti-mouse IgG standards from three independent sample sets
of antibody across dilutions; each was performed in triplicate on three separate microtitre
plates. There were no significant differences collectively within dilutions or between
plates (Q > 0.05) . The difference between set standards reached the level of significance
for 0.03813 ng IgG/100 µI sample (chi-square= 7.2; Q. = 0.0273; 2 d.f.) , the 0 .07625 ng
IgG/100 µI sample (chi-square= 7.2; Q. = 0 .0273; 2 d.f.), the 0.1525 ng IgG/ 100 µI
(chi-square= 7.2 ; Q. = .0273 ; 2 d.f.), and the 0.305 ng/100 µI sample (chi-square= 6.49;
Q. = 0.039; 2 d.f.). The amount of monoclonal antibody attached to the beads was

interpolated from the anti-mouse IgG-HRP standard. Polythreonine-treated beads devoid
of anti body served as the control.
Anti-rabbit IgG-HRP standards were used to quantitate the amount of antibody
present on each set of polyclonal antibody activated paramagnetic beads, Figure 18. Data
renect anti-rabbit IgG standards from three independent sample sets of antibody across
dilutions ; each was performed in triplicate on three separate microtitre plates. There were
no significant differenCes collectively within dilutions between the three independent
sample sets or between plates (Q. > 0.05). The amount of polyclonal antibody on activated
beads was interpolated from the anti-rabbit IgG-HRP standard. Pol ythreonine-treated
beads devoid of antibody served as the control.
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Figure 17. Anti-mouse IgG-HRP standard for quantitation of monoclonal antibody on
beads. The equation for the regression line is: Y = 0.674769 (absorbance) + 0.0000 l;
standard error= 0.02968; E = 2167; significance of E = 0.0000. The mean absorbance at
each IgG coordinate is: 0.03813 ng IgG/ 100 µI= 0 .059 (±0.009),
0.07625 ng IgG/100 µI= 0.117 (±0.016), 0. 1525 ng IgG/100 µI= 0.232 (0.023) ,
0.305 ng IgG/100 µI= 0.453 (±0.047), and 0 .610 ng IgG/100 µI= 0.891 (±0.084).

The amount of antibody bound to each set of paramagnetic beads is reported in
Table 12. Values are expressed in nanograms of IgG present on 10 µI of activated beads.
Reported values assume a one to one capture efficiency between the anti-mouse or antirabbit IgG and the antibody present on the bead and provide relative, semiquantitati ve
data. The amount of antibody attached to the activated beads varied significantly between
monoclonal antibody activated beads and both sets of polyclonal antibody-activated beads
(chi-square= 7.2;

Q

= 0.0273; 2 d.f.) . Polyclonal (Sigma) antibody-activated beads

contained 17 ng lgG/ 10 µI beads, which was significantly more bound antibody than
either the monoclonal antibody-activated beads with 3.9 ng IgG (chi-square= 3 .86 ;
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Figure 18: . Anti-rabbit IgG-HRP standard for quantitation of polyclonal antibody on beads.
The equation for the regression line is: Y = 0.55376 (absorbance) + ( -0.006459); standard
error= 0.01782; .E = 4584; significance of .E = 0.0000. The mean absorbance at each IgG
coordinate is: 0.0331 ng IgG/100 µJ = 0.059 (±0.015), 0.0662 ng IgG/100 µJ = 0.122
(±0.005) , 0.1325 ng IgG/100 µJ = 0.270 (0.026), 0.265 ng IgG/ 100 µJ = 0 .511 (±0.035),
and 0.530 ng IgG/100 µJ = 0.950 (±0.043).

Q

= 0.0495; l d.f.) or polyclonal (Cappel) antibody activated beads with 8.1 ng IgG

(chi-square= 3.86; I2 = 0.0495; 1 d.f.). The polyclonal (Cappel) ant1body-act1vated
beads contained s1gnificantlymore bound antibody than the monoclonal antibodyactivated beads (chi-square= 3.86;

Q

= 0.0495 ; l d.f.) . Control polythreonine beads

tested negative for anti bodies.

BSA Captured by Activated Paramagnetic Beads
In order to quantitate the amount of BSA captured by the antibody-activated beads
by the modified ELISA procedures, a standard curve of the capture anti-BSA-HRP
antibody was developed. Anti-BSA-HRP standards are shown in Figure 19.
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Figure 19. Anti-BSA-HRP antibody standard for quantttation of captured BSA by beads .
The equation for the regression line is: Y =0.223718 (absorbance) + (-0.005117) ; standard
error: 0.009 ; E 1446; significance of E 0.0000. The mean absorbance at each IgG
coordinate 1s: 0.0375 ng IgG/100 µl 0. 116 (±0.012). 0.047 ng IgG/100 µl = 0.240
(±0.016), 0.095 ng IgG/100 µl = 0.478 (0.044), and 0. 19 ng IgG/100 µl = 0.848
(± 0.06 4) .

=

=

=

Data reOect anti-BSA-HRP standards from three independent sample sets of antibody across dliuuons; each was performed

in

tnplicate on three separate microtitre plates.

There were no significant differences collectively within dilutions between the three
independent sample sets or between plates (£> 0.05) . BSA captured by antibody-activated
and control polythreonine paramagnetic beads was interpolated from the anti-BSA-HRP
standard curve.
BSA captured by each set of paramagnetic beads is reported in Table 12. Values
are expressed in nanograms of BSA captured by 10 µl of activated beads. Reported values
assume a one-to-one capture efficiency between the anti-BSA-HRP and the BSA captured

Table 12
Immunocapture anJ Extraction of BSA Data Summary

Captwed BSA ng/ 10 ul beads

Beals

ng lgG/ 10 ul beads

Molar-lo-molar captwe efficiency

Milk

Al:idwhey

Sweet whey

Milk

Acid whey

Sweet whey

Monoclonal

3.9 (±l.62)

0.94 (±0.19)

1.46 (±0.38)

1.47 (±0.39)

59% (±12)

91 % (±24)

91% (±24)

Polyclonal
(Sigma)

17.0 (±0.749)

1.34 (±0.51)

2.20 (±11)

l.66 (±0.27)

19% (±7)

31%(±15)

24% (±3)

Polyclonal
(Chappel)

8.1 (±0.899)

0 04 (±0.015)

Control0.00
negligible
poly threonine

negligible

11% (±4)

negligible

negligible

negligible

negligible

Molar to Molar Capture Efficiency = ng BSA captured by l 0 µJ beads/ 66,000 kD
ng IgG bound to 10 µl beads/ 160,000kD

00
VI
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by the bead and provide relative, semiquantitative data. BSA captured by the control
polythreonine beads devoid of antibody was negligible.
Capture efficiency is reported in a one-to-one molar ratio based on a molecular
weight of IgG of 160,000 kilodaltons and a molecular weight of BSA of 66,000
kilodaltons (Table 12). The capture efficiency of the monoclonal and polyclonal antibody
activated beads did not differ significantly between sample media of milk, acid whey, or
sweet whey (Q > 0.05).
Capture efficiency in milk varied significantly between monoclonal and both sets
of polyclonal antibody-activated paramagnetic beads (chi-square= 5.96; significance=
0.05; 2 d.f.) . The monoclonal antibody activated beads exhibited the highest capture
efficiency of 59% compared to 19% (chi-square= 3.86; Q = 0.0495; 1 d.f.) and 11 %
(chi-square= 3.86; Q = 0.0495; 1 d.f.) for the polyclonal (Sigma) and polyclonal
(Cappel) antibody-activated beads, respectively. Capture efficiency between the two
sets of polyclonal antibody-activated beads did not differ significantly (Q = 0.05).
Capture efficiency of the monoclonal antibody-activated beads (91 %) was significantly
greater in both acid whey and sweet whey compared to the polyclonal (Sigma) antibodyactivated beads. Capture efficiency of polyclonal antibody-activated beads was 31 %
(chi-square= 3.86; Q

= 0.0495; 2 d.f.) and 24% (chi-square= 3.86; Q = 0.0495;

2 d.f.) for acid and sweet whey, respectively.
Molecular Sieving
The initial molecular seiving experiments performed on the milk sample resulted
in incomplete removal of BSA. BSA was not detected in the less than 50,000 molecular
weight effluent, but was detected in excess of 1 mg/ 100 ml from the greater than
100,000 molecular weight effluent.
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BSA Extraction
Treatment of a known sample of 25 ng of BSA in 500 µI of PBS-Tween 20
with 10 µI of polyclonal (Sigma) antibody-activated beads resulted in a high capture
efficiency. Compared to skim milk containing 138,640 ng BSA/500 µI treated with
10 µI beads where the capture efficiency averaged 19%, treatment of on! y 25 ng
BSA/500 µI sample resulted in an average capture efficiency of 35% (±3) , which was
significantly greater (chi-square= 3.86; Q = 0.0495; 1 d.f.). The residual BSA content
of the treated sample measured 7.7 ng/500 µI (± 1.7) and represents a 70% reduction in
the BSA content of the treated sample (chi-square= 4.35; significance= 0.0369 ;
1 d.f.) . No BSA was detected in treated samples that were diluted beyond full strength.
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CHAPTER V
DISCUSSION
MEASUREMENT OF BOVINE SERUM ALBUMIN
CONTENT OF INFANT FORMULAS
Enzyme-Linked Immunosorbant Assay (ELISA)
Enzyme-linked immunosorbant assays (ELISAs) have been utilized to measure
antigenicity of milk proteins found in infant formulas and residual antigenicity following
extensive acid and enzymatic hydrolysis, as well as heat treatment. The ELISA has been
reported to be an effective means of quantitating immunologically active antigen at
concentrations as low as 10 ng/ml or 30 PPM (Cordle et al., 1994). The critical element
used to determine the interaction between the preformed antibody and the whole protein
or antigenic epitope of the protein antigen resides in the quality of the antiserum.
Immunoassay results are affected by the proportion of epitopes (residual epitopes) and
intact protein recognized by the antiserum and functional avidity of the specific antibodies
for the antigenic regions (Leary, 1992). Since the ELISA measures antigenicity, it should
detect fragmented antigen, antigenic epitopes, as well as intact protein (Cordle et al.,
1994; Lah! & Braun, 1994; Mahmoud et al., 1992). Differences in residual antigenicity
may not be strictly quantitative. However, ELISA is the system of choice for determining residual antigenicity because of its inherent sensitivity (Leary, 1992) and was used
in this study to detect and quantitate the BSA content of cow's milk and infant formulas .
Preliminary evaluation of the indirect ELISA for quantitating the BSA content of
known samples of BSA resulted in poor coating of the plate with BSA and high
background interference due to difficulty finding a suitable blocking agent. As a result,
a sensitive two-site, direct ELISA was developed and utilized for assessment of the BSA
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content of infant formulas . PBS-Tween 20 (0.2 % ) was a more effective blocking agent
than casein, salmine, and gelatin. The sensitivity was high wilh detection of antigen at
concentrations as low as 1 ng/100 µ1, which 1s consistent with that reported by Cordle and
colleagues ( 1994). Polyclonal antibodies to BSA were used to capture and quant1tate BSA
in cow's milk and infant formulas. Polyclonal antibodies, directed towards various anttgen
binding sites, should recognize antigenic epitopes of BSA as well as the native protein .
The antibody response of our polyclonal capture and detector antibodies to the AB BOS
peptide was negligible. It would appear that the bulk of the polyclonal antibodies were
not directed against the AB BOS epitope.
BSA Standards
The BSA standard was developed by diluting BSA in phosphate-buffered saline.
Use of isolated BSA in buffer avoided potential interference due to the presence
of large quantities of carbohydrates, insoluble lipid, large molecular weight vitamins,
minerals, and emulsifiers (Knights, 1985). However, these factors remained an issue in
whole formula samples. In order to determine the impact of these background factors ,
cow's milk and formula samples were spiked with a known concentration (5 and 10 ng)
of BSA. Preliminary experiments showed a mean recovery of 88% of the total amount of
BSA present in the sample. Therefore , the values reported in Table 11 of the BSA content
of cow's milk and polymeric infant formulas may underestimate the absolute amount of
BSA by approximately 10%.
BSA Content of Cow's Milk
The BSA content of 2% cow's milk measured by the direct ELISA was

52 mg/ 100 ml (0.5 g/L). There are multiple other reports of the BSA content of cow's
milk in the literature with values ranging from 10 to 40 mg/100 ml (0. 1to0.4 grams of
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BSA per liter of milk ; Robin et al., 1993; Swaisgood, 1982; Whitney, 1988). The
variability in the BSA content of milk likely reflects assay techniques and the known
heterogeneity of the BSA molecule . BSA exhibits several properties that contribute to the heterogeneity, including pol~mer formation, related sulfur linkages , and
microheterogeneity (Whitney, 1988). This may impact detection of BSA in a sample by
different methodologies. It is unlikely that this amount of variability in the BSA content
between pooled samples of cow's milk could be explained by differences

in

breed, feed,

or season.
BSA Content of Powdered Polymeric Infant Formula
BSA was detected and quantitated in all polymeric powdered infant formulas
(Table 11). The high-whey formulas, 40% casein and 60% whey, contained 37 to 44
milligrams of BSA per 100-ml sample. The high-casein preparations, 80% casein and 20%
whey, contained 12 to 13 milligrams of BSA per 100-ml sample. The BSA content of the
powdered polymeric infant formulas and 2% milk was highly correlated with the whey
protein concentration (correlation coefficient= 0.84; Q = 0.008) . Given that BSA is
present

in

the whey fraction of dairy products, this finding was expected and lends support

to the ELISA methodology as a means of quantitating BSA in whole formula samples and
milk.
BSA Content of Hydrolyzed Infant Formulas
All elemental and partially hydrolyzed formulas tested negative for BSA using
ELISA . The extensively hydrolyzed preparations Nutramagen, Alimentum, and
Pregestimil, derived from intact casein, would be unlikely to test positive for any intact
protein based on manufacturers reported molecular weight limits and degree of extensive
enzymatic hydrolysis . These formulas contain approximately 70% free amino acids with
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remaining peptides of less than eight amino acids. In contrast, the second generation whey
hydrolysates (e.g., Good Start HA) contain from 40% to 60% free amino acids with
remaining peptides up to 12 amino acid residues (Lah! & Braum, 1994). Based on these
charactenstics, none of these formulas would be expected to contain BSA or the 17
amino acid ABBOS epitope.
Polyacrylamide gel electrophoresis is an indication of intact parent protein (Cordle,
1994) and was utilized to confirm the results of the ELISA. No detectable protein bands
were observed for any of the three extensively hydrolyzed products that we evaluated.
This is consistent with earlier reports of SOS-PAGE analysis employing the more
sensitive silver stain. Consistent with our findings, a high degree of degraded cow's milk
protein with no visible protein bands was observed from the casein-based hydrolysates
Nutramagen and Alimentum (Cordle, 1994; Oldaeus et al., 1991; Sampson et al. , 1991) .
The presence of immunologically active whey following immunization of animals with
these highly hydrol yzed infant formulas (Alimentum, Nutramagen, and Pregestimil ) has
previous Iy been reported to be almost negligible (Cordle et al. , 1994) although specific
reactivity to BSA was not addressed. Follow-up ultrafiltration of tryptic hydrolysates
has been proven to be effective in removing the BSA (Lahl & Braum, 1994). Lack of
oral sensitization with extensivel y hydrol yzed whey suggests successful elimination of
existing epitopes of the native protein (Pahud et al. , 1985). The combination of enzymatic
hydrolysis , thermal-processing, and particle separation has been reported to lead to marked
reduction in the allergenici ty of these proteins (Siemensma et al. , 1993 ). Our results ,
taken together with these reports focusing exclusively on the allergenicity of infant
formulas , suggest that the extensivel y hydrolyzed infant formulas are devoid of BSA
and , most likely, antigenic epitopes of BSA.
While enzymatic hydrolysis of whey protein antigens has been reported to
significantly reduce antigenicity, serum albumm appears to be resistant to enzymatic

192

hydrolysis (Figure 20; Jost et al., 1987). Polyvalent peptide fragments of BSA have
been isolated and identified following hydrolysis with trypsin, chymotrypsin, and pepsm
(Alling , MeiJer, & van Berstein, 1997; Habeeb & Atassi, 1976; Wahn et al. , 1981). BSA
has been detected in trypsin-hydrolyzed whey and whey protein concentrates on SDSPAGE (66 kilodaltons; Jost et al., 1987; Pahud et al., 1985). Resistance of BSA to
enzymatic hydrolysis by trypsin and other proteases has been attributed to shielding of its
sensitive sites by a strongly disulfide-bonded primary structure (disulfide loops; Jost et al.,
1987) . In addition, those fragments compnsing the last third of BSA are reported to
account for all the antigenic reactivity of the native protein (Habeeb & Atassi, 1976).
This is consistent with the position of the ABBOS epitope.
Despite our observation that BSA was not detected by ELISA in any of the
elemental or partially hydrolyzed products, some concern exists that BSA and/or antigenic
epitopes of BSA may remain intact in the hydrolyzed formulas, particularly the partially
hydrolyzed product Good Start HA . We found no detectable BSA in Good Start HA
powdered formula on ELISA or with the

Pha~tGel

electrophoresis using Coomassi-blue

stain. However, reports in the literature are varied regarding the presence of BSA and
other milk proteins in this partially hydrolyzed product, as well as, residual antigenicity.
Good Start HA has previously been reported to show a number of unresolved
proteins and non-degraded and partially degraded whey proteins in the range of 5 to 20
kilodaltons (Oldaeus et al., 1991). Identifiable fractions of peptides of greater than 4000
daltons have been detected by silver nitrate stained SDS-polyacrylamide gel
electrophoresis (Sampson et al ., 1991). A weak protein-stained band corresponding to
BSA (69,000) has also been reported, but was not determined specifically to be BSA
(Oldaeus et al., 1991). However, most recently Cordle and colleagues (1994) reported
the more sensitive silver-stained polyacrylamide gel electrophoresis of Good Start to be
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Figure 20. Resistance of bovine serum albumin to enzymatic hydrolysis. Decrease in BSA
antigen following tryptic hydrolysis of demineralized whey by double immunodiffusion.
Adapted from Jost et al., 1987.

highly positive for BSA. The conflicting reports regarding the presence of the BSA antigen
may potentially be explained by revisions in thermoprocessing and enzymatic hydrol ysis of
the product.
Good Start has been shown to cause allergic reactions in 24% of cow's-milksensitive infants (Oldaeus et al ., 1991 ; Oldaeus , Bradley, Bjorksten, & Kjellman , 1992).
Good Start has been reported to exhibit whey protein levels by ELISA at 700 times the
amount detectable in the extensively hydrolyzed products Alimentum and Nutramagen
(Sampson et al ., 1991). In addition, the polymeric products Enfamil and Similac, in
comparison to Good Start, have been shown to contain immunologically active whey
proportional to their respecti ve whey protein concentration independent of hydrolysis.
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Despite reduction in antigenicity of the whey protein fraction of Good Start compared to
these polymeric formulas, immunogenicity, as measured by indirect (inhibition) ELISA,
has been reported to be very high (Cordle et al ., 1994). While we did not detect intact BSA
in Good Start, these findings suggest that antigenic epitopes of BSA, in particular the
ABBOS epitope, may
still be present. Development of an ELISA system using antibody specific to the AB BOS
epitope would provide additional insight into this question.
BSA Content of Liquid Concentrate and Ready-to-Serve
Formula Preparations
BSA was not detected by the ELISA in any of the ready-to-serve or concentrated
liquid formulas, including those that are counterparts to the powdered formulas containing BSA . This is consistent wtth the findings by Monte and colleagues ( 1994), who also
'

failed to detect BSA in any of six liquid formulas tested, using radial immunodiff usion.
These polymeric concentrated liquid and ready-to-serve formulas are sterilized under heattreatment, which may denature proteins reducing or eliminating immunogenicity. Serum
antibody production to BSA m guinea-pigs has previously been shown to be greatly
reduced in SMA Gold Cap liquid concentrate compared to the corresponding spray-dried
powder (Heppel, 1984). In addition, extensive heating and shelf storage may result m
agglutination, coagulation, and precipitation of BSA and other proteins, masking binding
sites and preventing interaction of the BSA antigen with the antibodies . Similarly,
disruption of antigenic determinants may make the BSA undetectable by radial
immunodiffusion (Monte et al., 1994). While BSA was not detected, the proposed
antigenic trigger of autoimmunity in IDDM, the ABBOS epitope, may still be intact.
No detectable band was observed m the region of BSA on follow-up
polyacrylamide gel electrophoresis (PAGE) using Coomassi stain for polymeric liquid

195

concentrate and ready-to-serve infant formulas tested. This is consistent with findings
reported by Monte and colleagues ( 1994), who demonstrated that liquid formulas testing
negative for BSA via radial immunodiffusion demonstrated protein migration on an
antibody-free agarose gel and appeared to be BSA free. Fox ( 1982) has previously
reported considerably altered protein migrauon with failure to resolve the proteins of
milk or sodium caseinate following heat treatment at 140 degrees Celsius for 10 minutes
on PAGE (Fox, 1982). However, these temperatures are in excess of thermal processing
of sterilized milk. Our initial runs of formula samples on SOS-PAGE revealed heavy
protein aggregation with failure of the sample to migrate into the gel. An increase in the
concentration of SOS and an increase in boiling time were required to allow migration of
proteins from the heat-treated formula samples into the gel.
While BSA is markedly resistant to hydrolysis, it appears to be sensitive to heatinduced denaturation. BSA is heavily disulfide bonded (cysteine, cystine) and is easily
denatured by heat. Heating whey proteins has been demonstrated to result in disruption
of hydrogen and ionic bonds. The destabilized structure generally unfolds. BSA
precipitates after heat treatment at 40 to 50 degrees Celsius due to hydrophobicity-directed
unfolding (Brown, 1988). Serum albumin can be reduced below detectable limits of
immunodiff usion analysis by heating at 80 to 90 degrees Celsius for up to 30 minutes or
125 degrees Celsius for 3 minutes (Jost et al., 1987). However, the whey had previously
been subjected to enzymatic hydrolysis, and it is possible that this situation would not
parallel that seen in sterilized canned formula preparations. Table 13 provides a summary
of various degrees and duration of heat treatment and the degree of residual antigenicity of
BSA. Extensive heat treatment of whey proteins, including BSA, has been reported to
result in almost complete loss of their unique three-dimensional structure, reduces
solubility, and decreases antigenicity as measured by passive cutaneous anaphalaxis (PCA)
testing (Mclaughlan et al., 1981).
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Table 13
Heat-Induced Destruction of BSA Antigens in Trvpsin-Hvdrolvzed Demineralized Whev

Treatment

BSA(l/d.f.)

Demmeralized whey

32

Trypsin hydrolyzed whey (240 min)

32.

Hydrolysate:
Heated at 80 degrees Celsius
3 min
5min
10 min
30min

32.
32.
16

8

Heated at 90 degrees Celsius
3min
5min
10 min
30min

32
4
0
0

Heated at 125 degrees Celsius
30 sec
60 sec
180 sec

32
16
0

Note. Units of BSA l/df is the reciprocal of the dilution factor for the double
immunodiffusion. No residual antigen activity is observed after 10 minutes at 90 degrees
Celsius or 180 seconds at 125 degrees Celsius (Jost et al. , 1987).

Aside from denaturing whey proteins , heating milk may result in coagulation, a
decrease in the pH, Maillard browning, and interaction with caseins. Protein-protein
interactions are enhanced by heating. Aggregation and precipitation due to intermolecular
disulfide binding can occur (Robin et al., 1993). Precipitation with K-casein by
sulfhydryl-disulfide interaction has been observed following heat treatment at 90 degrees
Celsius for 5 minutes (Fox, 1982) . A drop in pH to as low as 5.5 to 6.0 due to produc-

197

tion of organic acids and formic acid from lactose may further promote changes in the
BSA molecule. Hydrogen ion and ionized calcium \vork together to promote heat-induced
coagulation (Fox, 1982). These interactions have been observed in sterilized milk. In
addition, there is some evidence to suggest that proteolysis occurs in ultra-high-temperature
(UHT)-treated milk and to a lesser extent in products sterilized by the indirect method of
autoclaving. Proteases of microbial origin survive Ul-IT treatment (Harwalkar, 1982).
Heat-induced changes in caseins treated at high temperatures for long periods of time
( 120 degrees Celsius for 5 hours) include proteolysis of 10 to 20% of caseins.
Protein denaturation secondary to heat treatment has been demonstrated to
result in loss of conformational epitopes of intact protein (Siemensma et al., 1993) .
Bottled sterilized milks that are highly heat treated have been reported to be less
sensitizing than the spray-dried powders (McLaughlan et al., 1981). Evaporated milk,
commonly used as the breast-milk substitute prior to the upsurge of the infant formula
industry, is extensively heat treated at high temperature ( 110- 115 degrees Celsius for
15-20 minutes) where virtually all whey proteins are denatured. Evaporated milk shows
significantly decreased oral sensitization in guinea-pigs compared with cow's milk and
SMA gold cap liquid concentrate. Oral sensitization has been shown to be inversel y
related to the degree of heat used in the preparation of the final milk-based product
(McLaughlan et al., 1981).
Strand ( 1994) has suggested that pnmary prevention of insulin-dependent diabetes
could be achieved by simply increasing the temperature used to process mtlk from 60
to 72 degrees Celsius (pasteurization) to at least 85 degrees Celsius. Serum albumin
is heat labile and the rate of denaturation increases exponentially with increasing temperature. Based on milk processing temperatures, BSA-free commercially available milk
products include those canned at greater than 100 degrees Celsius and include infant
formula, those ultrapasteurized at 138 degrees Celsius , and UI--IT- processed at 149
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degrees Celsius. The absence of BSA in these preparations has been confirmed by radial
1mmunodiffusion (Strand, 1994). In addition, BSA could be destroved
. and ,therefore

.

eliminated in any milk product simply by bringing the product to a boil (> 85 degrees
Celsius) . However, radial-immuno-diffusion is sensitive down to 40 mg BSA/L which is
about 10% of that found in cow's milk. Although Strand (1994) reports that heat treatment
has been shown to eliminate allergeniclly and antigenicity associated with BSA according to
the work of Ratner, Dwaretzky, Oguri, and Ascheim ( 1958), currently available
. comparatively highly sensitive techniques for assessing residual antigenicity give
conflicting reports.

It would appear that heat treatment of mtlk denatures whey proteins and would,
therefore , destroy conformational epitopes. Enzymatic hydrolysis is required to
destroy sequential epitopes (Siemensma et al. , 1993). It has not been established that
heat treatment destroys the AB BOS epitope which appears to be the culprit in the
pathogenesis of IDDM. Al ting and colleagues ( 1997) have recently shown that heat
treatment of BSA to denature the protein followed by simulated gastrointestinal
conditions in infants results in reduced proteolysis. Increased aggregation and
insolubilization due to heat treatment may decrease potential enzymatic cleavage sites
and have been demonstrated to leave significant amounts of the AB BOS epitope intact
(A lling et al., 1997). While heating has been shown to significantly reduce antigenicity,
theoretically heating to denature the protein will destroy only the conformational
antigenic epitopes, leaving sequential epitopes intact. More sensitive indicators may be
warranted to further confirm whether heat modification destroys the primary sequence
of amino acids in BSA, including the ABBOS epitope and is protective against BSA
triggered disease.
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Conclusion BSA Content of Infant Formulas
Taken together these findings point to the heterogeneous nature of cow's-milkbased infant formula, specifically in terms of its BSA content. Powdered polymeric
cow's-milk-based infant formula contains BSA in amounts proportional to the whey
protein concentralion. The first generation, extensively hydrolyzed casein-based
formulas are devoid of BSA and almost certainly, antigenic epitopes of BSA. The
partially hydrolyzed product also appeared to be free of intact BSA; however, \Ve
cannot say with certainty that the ABBOS epitope was not present. The commerciall y
sterile liquid concentrate and ready-tcrserve infant formulas also appear to be free of
immunologically active BSA . Again the question as to whether the ABBOS epitope is
present and masked due to protein aggregation or absent due to hydrol ysis is
unresol ved. Use of a monoclonal antibody specific for the ABBOS epitope could
resolve these questions with certainty.
Epidemiological evidence suggests that milk consumption follows a "dose
response" pattern in the pathogenesis of IDDM. A significant positive correlation has
been reported between milk consumption and incidence of IDDM (Cerrato, 1993 ; DahlJorgensen et al. , 1991 ; Scott, 1990). Case-control studies , to date, examining
the contribution of BSA in the pathogenesis or !DOM have failed to decipher individual
formula characteristics. The wide variety of commercially available cow's-milk-based
infant formula preparations on the market, as well as homemade preparations den ved
from whole cow's milk or commercially sterilized canned milk products , further
complicates the issue. In addition, the possibility exists for BSA to cross into the
mammary gland and, therefore, be present even in human milk (Paul & Peterson, 1993).
However, Monte and colleagues ( 1994) did not detect BSA in pooled human
milk. The potential presence of a small amount of BSA even in breast milk, while unlikel y,
could pose a confounding problem that should not be ignored (Rennie , 1992).
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While several studies have specifically looked at the issue of formula feeding in
comparison to breast-feeding and the incidence of IDDM, none have attempted to address
the issue of the heterogeneous nature of breast milk substitutes revealed in the present
study. For instance, an infant receiving 75% breast milk and 25% of its nutrition from
a high-whey formula would receive more BSA than an infant receiving 25% breast milk
and as much as 75% supplementation with a high-casein preparation. An infant receiving
100% of its nutrition from a hydrolyzed product, even the partially hydrolyzed standard
infant formula, Good Start HA, would have a negligible BSA intake similar to the breastfed infant. Given the observed heterogeneous nature of breast milk substitutes, it is not
surprising that case-control studies attempting to establish a link between breast-feeding
practices and early introduction of cow's milk proteins have been able only to demonstrate
a weak, though consistent, relationship between infant feeding practices and the incidence
of IDDM (Gerstein, 1994; Norris & Scott, 1996). If BSA is indeed a trigger of IDDM,
the trend toward a decrease in the casein and an increase in the whey content of infant
formula may be a contributing factor in the incidence of IDDM independent of breastfeeding.
Infant feeding practices, in particular introduction of cow's-milk-based infant
formulas as breast-milk substitutes, need to be reevaluated for their potential contribution to the pathogenesis of IDDM in genetically predisposed individuals. A large multicenter, international prospective cohort study of 3,()(X) families, to be followed over a
10-year period, where cow's milk proteins are withheld for the first 9 months of !ife,
has been initiated (Alberti, 1993). While exclusive breast-feeding certainly remains the
preferred method offeeding infants the first 6 months of life, many new mothers have
difficulty initiating and maintaining breast-feeding. It is estimated that approximately 50%
of newborns and 80% of infants at 6 months of age are currently receiving cow's-milkbased infant formula containing intact protein (Ross Laboratories, 1996). While numerous

201

groups have been actively working to promote breast-feeding worldwide, fonnu.a feeeding
remains a commonly practiced alternative. The American Academy of Pediatrics( 19914)
"strongly encourages" that families with a strong history of !DOM, particularly fa
sibling has diabetes, adopt the practice of breast-feeding and avoid commercially ivail!able
cow's milk and products containing intact cow's milk protein dunng the first yea- of llife.
Since routine screening to detect the"diabetic gene" is not practical at this ume ard is rnot
a component of public health policy, it may be appropriate for all infants not exc1us1v1ely
breast-fed to receive BSA free fonnulas. Prophylactic use of BSA-free infant feeding~ may
reduce the incidence of IDDM, improve life-expectancy and quality to life for thoSe at : risk of
developing IDDM, and reduce overall health care cost related to the long-tenn medical!
management of IDDM and the advanced complications of its chronic disease prcx:ess. If
standard polymeric fonnulas are used, it may be prudent to choose a fonnula witll a hiigher
proportion of casein to whey.
IMMUNOCAPTURE AND EXTRACTION OF BOVINE SERUM
ALBUMIN FROM COW'S MILK AND WHEY ISOLATES
Preliminary Studies
The mean baseline BSA concentration of skim milk measured 28mg/ 100 rnl
(± 0.8). Solutions of 10% delactosed acid whey and 10% sweet whey measured

17 mg/lOOml (± 0.2) and 12 mg/lOO ml (± 0.1), respectively. Preliminary imrnunocapture BSA extraction experiments using 5, 10, and 20 µI of polyclonal antibcxiy'activated paramagnetic beads incubated with 100 to 500 µI of skim milk demonstr«tted
that the antibcxiy-activated beads were able to capture BSA from the skim milk. How~ver ,
no significant reduction in the amount of BSA in the milk sample was observed. IBSA
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remaining in the treated sample was well in excess ( 10,CXX:)-fold) of that captured by the
beads.
The immunocapture methodology employed for extraction of BSA from cow's
milk has previously been reported by Blake ( 1996). The strengths of this method relative
to use for extraction of BSA from cow's milk include: (a) use of small 2.8 µm
paramagnetic beads, which are easily dispersed in the sample and permit greater bead-area
to be used; (b) use of a long flexible polythreonine spacer that was attached to the tosylactivated groups on the bead surface, allowing correct orientation of the antibody to the
BSA antigen; (c) avoidance of steric hindrance between the BSA antigen and the bead; and
(d) proven effectiveness of antigen (spore) capture in cow's milk, formula, and a variety of
media, indicating that the sample media did not influence antigen binding. However, since
this methodology has previously been used to detect and capture small amounts of spores
down to 8 x lo3 cfu/ml (Blake, 1996), it would seem most likely, in our application , that
the system did not provide sufficient antibody to fully extract BSA from the milk sample.
While Blake confirmed the presence of antibody on beads using ELISA, no quantification
of the amount of antibody attached to the beads was reported.
Anti-BSA Antibody Present on Activated Paramagnetic Beads
The amount of antibody bound to each set of paramagnetic beads is reported in
Table 12. Values are expressed in nanograms of IgG present on 10 µI of activated beads.
Reported values assume a one-to-one capture efficiency between the anti-mouse or antirabbit IgG and the antibody present on the bead and provide relative, semiquantitative
data. Polyclonal (Sigma) antibody activated beads contained 17 ng IgG/10 µI beads,
polyclonal (Cappel) antibody activated beads 8.1 ng IgG, and the monoclonal antibodyactivated beads 3.9 ng IgG. Control polythreonine beads tested negative for antibody.
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The differences in the amount of each set of antibody attached to the beads were significant
in all cases at the Q< 0.5 level. While these findings were statistically significant, the
practical significance points to the need to know how much antibody is present on the bead.
Since each set of antibody might be expected to act differently in binding to the beads via
the polythreonine cross linker, it is important to quantify the amount of antibody on beads
in order to be able to calculate capture efficiency of the antibody-acuvated beads when
presented with antigen.
Capture Efficiency of Activated Paramagnetic Beads
Against BSA Antigen
BSA captured by each set of antibody-activated paramagnetic beads is reported in
Table 12. Values are expressed in nanograms of BSA captured by 10 µ1 of activated
beads. Reported values assume a one-to-one capture efficiency between the anti-BSAHRP and the BSA captured by the bead and provide relative, semiquantitative data.
BSA captured by the control po!ythreonine beads devoid of antibody was negligible and
confirms that nonspecific binding between the bead and the antigen did not occur.
Capture efficiency is reported in a one-to-one molar ratio based on a molecular
weight of IgG of 160,000 kilodaltons and a molecular weight of BSA of 66,000
kilodaltons (Table 12). The capture efficiency for BSA by the monoclonal
and polyclonal antibody-activated beads did not differ significantly between treatment of
samples of milk, acid whey, or sweet whey (Q > 0.05). These findings are consistent
with those reported by Blake ( 1996) demonstrating that antibody-activated paramagnetic
beads can effectively capture spores in a variety of media and that the media do not impact
antigen binding.
While the sample media did not affect antigen binding, significant differences
were observed between the capture efficiency of monoclonal and polyclonal antibody-
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activated paramagnetic beads in milk, acid whey, and S\.veet whey (Q < 0.05). The
monoclonal antibody-activated beads exhibited the highest capture efficiency in all
three media. It is likely that each set of antibodies would vary in their avidity for the
antigen, in this case BSA. The specificity and sensitivity of any ELISA is highly
dependent upon the efficiency with which the solid phase antibody can bind the sample
antigen (Kemeny & Chantler, 1988). In a commercial application of this immunocapture
technology, monoclonal antibodies could be produced with consistency and in quantity
to BSA, or specifically, to the ABBOS epitope. Monoclonal antibodies provide the
advantage of ensuring continuity of reagents, which normally poses a considerable
source of error in ELISA (Kemeny & Chantler, 1988).
BSA Extraction
The primary focus at the outset of this study was to provide proof of concept
that BSA could be extracted from cow's milk and whey protein isolates and, therefore,
significantly be reduced or eliminated from the test samples. Despite a respectable capture
efficiency of BSA by antibody-activated paramagnetic beads, it is apparent, given the
amount of antibody present on the beads, that the BSA in the sample media greatly
overrides the limitations of the system. It would be impractical from a cost standpoint
if not physically impossible to add enough beads to the full-strength cow's milk or
whey isolates to totally remove BSA from the sample. While BSA 1s considered a
minor whey protein, there are still substantial quantities of the BSA antigen present in
cow's milk and whey isolates. In order for the immunocapture methodology to be
commercially practical, it would need to be coupled to another method of removing
individual proteins from the sample media. Molecular sieving could be used to remove
gross amounts of BSA from cow's milk or whey isolates followed by the immunocapture m order to remove residual BSA.
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In order to determine whether antibodies were effective in capturing BSA
when BSA was present in small amounts, such as that which might remain after
completion of molecular sieving, a known sample of 25 ng of BSA

in

500 µI of PBS-

Tween 20 was treated with 10 µI of polyclonal (Sigma) antibody-activated beads. The
capture efficiency exceeded that in skim milk containing 138,640 ng in 500 µI. The
residual BSA content of the treated sample measured 7.7 ng/500 µI and represents a
significant 70% reduction in the BSA content of the treated sample (chi-square= 4.36 ;
d.f. = 1; g = 0.0369). Given that the immunocapture was effective in removing small
residual amounts of BSA, the immunocapture together with molecular sieving could be
effective in reducing the BSA content of cow's milk from 138,640 ng/500 µI to
7.7 ng/500 µl. This represents a 99.99% decrease in the BSA content of cow's milk.
Addition of a greater quantity of beads to the sample and an increase in the incubation
time allowed for binding would likely increase the efficacy of the BSA extraction. As the
absolute zero point is approached, the standard direct (two-site) would require amplification to discriminate diminutive nanograrn differences in BSA content.
Conclusion Immunocapture and Extraction of Bovine Serum
Albumin from Cow's Milk and Whey Isolates
The research presented here provides proof of concept that BSA can be extracted
from cow's milk and whey protein isolates using immunocapture methodology. Both
monoclonal and polyclonal antibody-activated paramagnetic beads were effective in
capturing BSA from the sample media. Given the significant amount of BSA present in
cow's milk and whey protein isolates and the large quantities of antibody-activated
paramagnetic beads that would be required to totally remove these quantities of BSA, it
\vould appear that coupling of the immunocapture methodology with another means of
extracting individual proteins from sample media may be warranted. A trial run of
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molecular sieving proved less than 100% effective in extracting BSA . We were able to
demonstrate that the immunocapture methodology was effective in capturing and
extracting BSA when only small amounts (25 ng) were present in the sample. Use of
glass or ceramic beads with greater potential for recycling would increase the practicality
of the immunocapture technology outside the laboratory setting. Immunocapture
methodology would appear to be most effective in capturing and removing proteins when
only small amounts are present in the sample or to clean up a sample when other means
of extracting individual proteins are less than optimal ( 100%).
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CHAPTER VI
CONCLUSION

IDDM is one of the most prevalent and costly severe diseases of childhood in
North America and Europe. Despite advances in medical management, disease morbidity and mortality remain high. IDDM develops in a relatively small number of individuals who carry specific genetic characteristics associated with increased disease
susceptibility. A chronic progressive autoimmune process leads to destruction of the
insulin-producing pancreatic beta-cells and ultimately to clirucal IDDM. The interaction
of genetic, immunological, and environmental factors working over the extended
diabetic prodrome appears to be intricately involved in the pathogenesis of the disease.
There appear to be a number of potential environmental factors that could
trigger and sustain the autoimmune process that eventually leads to IDDM, most notably
viruses. There is also agreement that an epidemiological role of diet in the etiology of
IDDM exists. If the initial insult triggering the autoimmune response could be identified
and subsequently elimi.nated, a substantial reduction in the incidence of IDDM could be
achieved.
The interrelationship between breast-feeding and the timing of introduction of
breast-milk substitutes, cow's milk, and solid foods into the infant's diet has been
e:xtensi vely studied. To date, studies have failed to look at both the qualitative and
quantitative aspects of infant diet against a background of genetic predisposition and the
progression of autoimmunity to pancreatic beta-cells. While there is still much controversy surrounding infant feeding practices and their relationship to the pathogenesis of
IDDM, there is substantial evidence to suggest that reduced incidence and duration of
breast- feeding, particularly exclusive breast-[eeding, and early introduction of cow's
milk protein are contributing factors .
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An elaborate scheme involving genetic and immunological factors interacting
with the specific BSA epitope, ABBOS, m the pathogenesis of IDDM has been proposed.
Immunization w!lh BSA and the AB BOS epitope prior to establishment of normal selftolerance in the infant precipitates a cross-reactive immunological response \V1th the betacell protein p69 via molecular mimicry. The chronic autoimmune process proceeds until
beta-cell destruction is complete and manifestation of clinical IDDM becomes apparent.
Substantial evidence of an immunological response to BSA, and specifically the AB BOS
· epitope, has been repeatedly and independently documented. However, there are
conflicting reports linking immunization with BSA to specific genetic and immunological
markers of IDDM. The role of BSA as an antigenic trigger in the pathogenesis of IDDM
is controversial and requires further investigation.
The research presented here points to the heterogeneous nature of cow's-milk-based
infant formula, specifically in terms of its BSA content. Powdered pol ymeric cow's-milkbased infant formulas contain BSA in amounts proportional to the whey protein
concentration. The first generation, extensively hydrolyzed casein-based formulas are
devoid of BSA and, almost certainly, antigenic epitopes of BSA . The partially hydrol yzed
whey product also appeared to be free of intact BSA ; however, we cannot say with
certainty that the ABBOS epitope was not present. The commercially sterile liquid
concentrate and ready-to-serve infant formulas also appear to be free of immunologically
active BSA . Additional research will be required to answer the question as to whether the
AB BOS epitope is present and masked due to protein aggregation or absent due to
hydrolysis. Development of an ELISA system using a monoclonal antibody specific for
the ABBOS epitope could be one alternative approach used to resolve these questions with
certainty.
Studies to date attempting to establish a link between early exposure to cow's
milk proteins, in particular the BSA antigen, have failed to take into consideration
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whether or not BSA is indeed present in infant formulas and to what degree . Given
the results obtained from this study, which clearly demonstrate that the BSA composition
of breast-milk substitutes varies widely, it 1s not surprising that case-control studies
anemptmg to establish a link between breast-feeding practices and early mtroduction of
cow's milk proteins have been able only to demonstrate a weak, though consistent,
relationship between infant feeding practices and the incidence of IDDM. If BSA is
indeed a trigger of IDDM, the trend toward a decrease in the casein and an increase
in the whey content of infant formula may be a contributing factor in disease pathogenesis independent of breast-feeding. Given the knowledge of formula composition
gained in this study, it may now be feasible to look at diabetes incidence rates from
Center for Disease Control (CDC) or the Supplemental Program for Women, Infants,
and Children (WIC) databases and determine method of infant feeding, including the
specific formula used. Information gained from such a study could provide relative
quantitative information on the BSA load received by the infant. Comparative studies of
infant feeding practices and disease incidence could help to resolve the cow's milk/BSA
controversy.
Breast milk, formula, or cow's milk is the primary source of an infant's nutritional
intake the first year of life. It is estimated that approximately 50% of newborns and 80%
of infants at 6 months of age are currently receiving cow's-milk-based infant formula
containing intact protein (Ross Laboratories, 1996). While numerous groups have been
actively working to promote breast-feeding worldwide, formula-feeding remains a
commonly practiced alternative. While exclusive breast-feeding certainly remains the
preferred method of feeding infants the first 6 months, approximately 50% of newborns
are initiated on infant formula at birth. It can be assumed that most infants who are not
breast-fed or who are breast-fed for only a short duration will receive cow's-milk-based
infant formula.
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Infant feeding practices, in particular introduction of cow's-milk-based infant
fonnulas as breast-milk substitutes, need to be reevaluated for their potential contribution to the pathogenesis of IDDM in genetically predisposed individuals. Evidence of an
immune defect that can be triggered by cow's milk or BSA has raised concerns regarding the safety and advisability offeeding intact cow's milk protein to infants (Gerstein,
1994) . Since gut closure is variable over the first year of life when many new foods are
introduced, caution may need to be exercised during this vulnerable period (Paul &
Peterson, 1993). Introduction of artificial cow's-milk-based breast-milk substitutes and
introduction of solid foods should be avoided for a minimum of the first 3 months of
!ife. The Amencan Academy of Pediatrics recommends breast-feeding for all infants the
first 6 to 12 months. In addition, several recommendations have specifically been put
foiward to address dietary risk factors associated with IDDM (American Academy of
Pediatrics, Work Group on Cow's Milk Protein and Diabetes, 1994). In families with a
strong history of IDDM, particularly if the sibling has diabetes, breast-feeding and
avoidance of commercially available cow's milk and products containing intact cow's
milk protein during the first year of life are strongly encouraged. The substitution of
soy-based fonnulas for milk-based fonnulas is not advised for either general or high-risk
infant feeding practices because of animal studies linking the ingestion of soy protein intake
to the development of diabetes (American Academy of Pediatrics, Work Group on Cow's
Milk Protein and Diabetes, 1994). While the substitution of elemental formulas may
eliminate potentially hannful large proteins and has been recommended for use in those
with identified genetic predisposition, the American Academy of Pediatrics, Work Group
on Cow's Milk Protein and Diabetes (1994) does not endorse this feeding option as
prophylaxis for IDDM given the lack of scientific studies in humans confirming
the benefits. Appropriate solid foods should be introduced between 4 to 6 months of age
(American Academy of Pediatrics, 1992). Prophylactic use of BSA-free infant feeding may
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reduce the incidence of IDDM, improve life-expectancy and quality of hfe for those at risk
of developing IDDM, and reduce overall health care cost related to the long-tenn medical
management of IDDM and the advanced complications of its chronic disease process. If
standard polymeric formulas are used, it may be prudent to choose a formula with a higher
proportion of casein to whey in order to minimize the BSA load to the infant.
Manufacturers of infant fonnulas should be encouraged to develop processing
procedures to destroy BSA and its ABBOS subunit. Based on our findings, several
commercial infant formulas appear to be devoid of BSA . With the exception of the
extensively hydrolyzed preparations, which can cost up to three times the amount of
standard fonnulas, we cannot say with certainly that the ABBOS epitope is not present.
The research presented here provides an alternative means by which BSA can be
selectively extracted from cow's milk and whey protein isolates using immunocapture
methodology. We were able to demonstrate that the immunocapture methodology was
effective in capturing and extracting BSA when only small amounts were present in the
sample. Immunocapture methodology would appear to be most effective in capturing and
removing proteins when only small amounts are present in the sample or a follow-up
process when other means of removing BSA (e.g., molecular sieving, enzymatic
hydrolysis, and thennal processing) are less than optimal . Commercial availability of
an affordable BSA-free infant feeding may prophylactically help to reduce the incidence
of IDDM and would be relatively harmless.
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APPENDIX A
MEASUREMENT OF THE BOVINE SERUM ALBUMIN
CONTENT OF INFANT FORMULA
Assessment of Indirect ELISA Methodology.
Evaluation of BSA standards.
Evaluation of anti-BSA antibodies.
Reevaluation of anti-BSA antibodies, first HRP-labeled detection antibodv inacti\ e.
Assessment of blocking agents.
Optimization of antibody concentration using checkerboard titration.
Optimize blocking and washing procedures.
Evaluate differences between whole formula samples or soluble fraction for
quantitation of BSA.
Rule out indirect ELISA for quantitation of BSA in samples.
Assessment of direct (two-Site) ELISA Methodology.
Evaluation of BSA standards.
Evaluation of anti-BSA antibodies.
Obtain primary and secondary anti-BSA antibody, HRP-labeled secondary
antibody.
Assessment of blocking agents.
Optimization of antibody concentration using checkerboard titration.
Optimize blocking and washing procedures.
Evaluate differences between whole formula samples or soluble fraction for
quantitation of BSA.
Adopt direct ELISA for quantitation of BSA in cow's milk and formula samples.
Develop BSA Standards.
Weigh BSA independently three times and dilute in appropriate buffer.
Evaluate linearity.
Redo standards with a greater number of dilutions in linear response range.
Complete BSA standard for each plate.
Complete collective set of BSA standards , 3 plates, 3 replicates, from each of
3 sets of BSA standards.
Preliminary statistical analysis .
Quantitation of BSA in cow's milk and infant formula using direct ELISA.
Assay repeated for each of 15 formulas and cow's milk.
Statistical Analysis.
Interpolation of BSA content of formulas from BSA standard curve.
SDS-PAGE PhastGel of those formulas testing negative for BSA.
Centnfuge samples to remove fat and obtain soluble fraction of protein.
Prepare reagents.
Optimize heating temperature and times, reagent concentration, and protein.
Run 10 formulas testing negative for BSA by ELISA .
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APPENDIX B
Hv1MUNOCAPTURE AND EXTRACTION OF BOVINE SERUM ALBUMIN
FROM COW'S MILK AND WHEY PROTEIN ISOLA TES
SUMMARY OF EXPERIMENTS
Preparation and Anti bodies and Beads.
Punfication of polyclonal rabbit anti-serum to BSA (Chappel).
Activation of paramagnetic beads.
Attachment of polyclonal antibodies to beads.
Direct ELISA performed to test activity of set lpolyclonal rabbit
anti-serum to BSA .
Direct ELISA repeated on set lpolyclonal rabbit anti-serum to BSA.
Purification of polyclonal rabbit anti-bovine serum albumin, delipidized whole
antiserum (Sigma).
Direct ELISA performed to test activity of set 2 Polyclonal Rabbit Anti-Bovine
Serum Albumin (Sigma).
Preparation of monoclonal antibodies to BSA, Mouse, IgG lK, lg Fraction for
ELISA and attachment to beads( American Qualex).
Direct ELISA performed to test activity of Monoclonal antibodies to BSA .
Activation of second batch of paramagnetic beads to beads (Sigma).
Attachment of Monoclonal antibodies against BSA to beads (American Qualex) .
ELISA performed to test blocking agents, Tween 20, salmine, and casein.
Preparation of BSA standards.
Preparation of polythreonine beads devoid of antibody to use as true control.
Preliminary Capture Experiments.
500 ul of skim milk treated with 5, 10, and 20 ul polyclonal anti-BSA active beads.
Direct ELISA performed on milk, wash, and beads.
500 ul skim milk treated with 5, 10, and 20 ul polyclonal anti-BSA activated beads.
Direct ELISA performed on milk, wash, and beads.
Experiment performed three times.
150 ul skim milk treated with 5, 10, and 20 ul polyclonal anti-BSA activated
beads, 10 ul "inactive" anti-BSA activated beads as control.
Direct ELISA performed on milk, wash, and beads.
lOOul skim milk treated with 5, 10, and 20 ul polyclonal anti-BSA activated beads,
10 ul "inactive" anti-BSA activated beads as control.
Direct ELISA performed on milk, wash, and beads.
500 ul skim milk diluted 1/ 10, 11100, 111,000, and 1110,000 treated with 10 ul
active polyclonal and "inactive" control beads.
Direct ELISA performed on beads, milk, and wash.
Direct ELISA performed on supernatant of beads to determine if free antibody
existed in bead preparation.
ELISA for detection of antibody on polyclonal anti-BSA activated beads, "inactive"
beads, and polythreonine treated control beads.
150 ul skim milk treated with 5, 10, and 20 ul polyclonal anti-BSA
activated beads, and 5, 10, and 20 ul "inactive" anti-BSA activated beads
as control.
Direct ELISA perfonned on milk, wash, and beads.
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Proof of Concept Antibody Capture BSA Extraction.
Direct ELISA to quant1tate baseline BSA concentration of skim milk and whey
isolates.
Quanlitation of polyclonal anti-BSA antibody on set 1 and 2 of activated beads and
control polythreonine beads.
Experiments performed three times.
Development of anti-rabbit-lgG-HRP standard curYes.
Experiments performed three times.
Antibody capture BSA extraction in skim milk using set 2 polyclonal antibody
activated and polythreonine control beads.
Quantitation of BSA captured by beads.
Experiments performed three llmes.
Development of anti-BSA-HRP standard curves.
Experiments performed three times.
Antibody capture BSA extraction in skim milk using set 1 polyclonal antibody
activated and polythreonine control beads.
Quantitation of BSA captured by beads.
Experiments performed three times.
Quantitation of monoclonal anti-BSA antibody on activated beads and control
polythreonine beads.
Experiments performed three times.
Development of anti-mouse-IgG-HRP standard curves.
Experiments performed three times.
Antibody capture BSA extraction in skim milk using monoclonal antibody and
polythreonine control beads.
Quantitation of BSA captured by beads.
Experiments performed three times.
Antibody capture BSA extraction in acid whey using set 2 polyclonal antibody
activated and polythreonine control beads.
Quantitation of BSA captured by beads.
Experiments performed three times.
Antibody capture BSA extraction in sweet whey using set 2 polyclonal antibody
activated and polythreonine control beads.
Quantitation of BSA captured by beads.
Experiments performed three times .
Antibody capture BSA extraction in acid whey using monoclonal antibody activated
and polythreonine control beads.
Quantitation of BSA captured by beads.
Experiments performed three times.
Antibody capture BSA extraction in sweet whey using monoclonal antibody
acti vated and polythreonine control beads.
Quantitation of BSA captured by beads.
Experiments performed three times .
Molecular sieving of whey protein isolates.
Direct ELISA to assess residual BSA .
Antibody capture BSA extraction in 25 ng BSA/500 ul PBS-Tusing pol yclonal
antibody activated and polythreonine control beads.
Quantitation of BSA captured by beads.
Experiments performed three times.
Statistical anal ysis.
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APPENDIX C
REAGENTS AND SOLUTIONS
Carbinate-b1carbonate coating buffer (pH 9.6)
0.159 g Na co
2
3
0 .293 g NaHC0
3
100 ml disltilled water
Phosphate Buffered Saline (PBS) (pH 7.4)
16.0 g NaCl
0.4 g KH 2 P04
5.8 g Na2HP04-7H20
0.4 g KC!
2000 ml distilled water
PBS-Tween 20 (0.2% Tween)
1500 ml PBS
3 .0 ml Tween 20
(Tween 20 Sigma, Polyoxyethylene-sorbitan monoluarate,
P-7949: Lot: 15H09291)
5 M Stock Solution Sulfuric Acid
50 ml H2S04 (98%)
50 ml distilled water
Stop Solution, 1 M Sulfuric Acid
10 ml stock solution
40 ml distilled water
Sodium Phosphate (0.1 M NaP04) (pH 7.0):
Sodium Phosphate , Dibasic (MW 268.07) (pH 6.0)
0. 1M26.8 g
1000 ml distilled water
Titrated with: Sodium Phosphate, Monobasic (MW 120.0) (pH 11.0)
0.1M12.0 g
1OOOml distilled water
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Borate Buffer (0.05 M Borate Buffer) (pH 9.5) :
3.09 g H2803 (MW 61.83)
1000 ml distilled water
Ma!linckroft 2549-500: B 1320
Tris Buffer (0.2 M Tris Buffer) (pH 8.5):
2.42 g Trisma Base C4Hl 1N03 (Tris[hydroxymethyl]amino methane) FW 121. l
l 00 ml distilled water
(adjust pH)
Sigma, T -6791: Lot: 95H5731
MES (0.1 M) (pH 4.75):
2. 132 g MES

C6H13N04S-H20
(2-[N-Morpholino ]ethane-sul fonic acid, mono hydrate)

100 ml distilled water
Sigma, M-5287: Lot: 114H57281
Adi pie Acid Dihydrazide (ADH):
C6H14N402
FW 174.2
Sigma, A-0638: Lot: 60H5008
EDAC:

C8H17N3-HCI
FW 191.7
( l-ethyl-3(3-dimethylaminopropyl) carbomide, hydrochloride)
Sigma, E-1769: Lot: 85H01521
Sodium m-Periodate:
Nal04
FW 213.9
Sigma, S-1878: Lot: 95H0766
Poly-L-Threonine:
MW (vis) 12, 100
Sigma, P-8077: Lot: 24H5536
2-mercaptoethanol:
C2H605
FW 78.13
Sigma, M-3148: Lot: 53H074115
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10% SOS (Sodiumdodecylsulfate) :
C 12H2504SN9
FW 288.4
2.884 g Laurel Sulfate
100 ml water
Sigma, L-3771: Lot: 55H06061
Tris Buffer:
10 mM Trisma + 1mM EDT A
100 ml distilled water
0.1211 g Trisma Base
0.029225 g EDT A (Ethylenediamine-tetra acetic acid)
Cl0Hl4N208Na2-2H20
Sigma, ED2SS: Lot: 55Hl360
100 mM Tris+ 10 mM EDTA
Trisma
1.211 g
EDTA
0.29225
lOOml
distilled water

FW 372.2

Destaining Solution:
(30% methanol + 10% acetic acid)
2 Liters:
6CO ml methanol
200 ml acetic acid
1200 ml distilled water
Preserving Solution:
(5% glycerol+ 10% acetic acid)
500ml:
25 ml glycerol
50 ml acetic acid
425 ml distilled water

20% Acetic Acid:
1000 ml :

200 ml acetic acid
800 ml distilled water

Fast Commassi Staining:
(0.1 % PhastGel R Blue in 30% methanol and 10% acetic acid)
100 ml:
· 50 ml stain stock
50 ml 20% acetic acid
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